

**UNITED STATES BANKRUPTCY COURT  
SOUTHERN DISTRICT OF NEW YORK**

---

|                                     |   |                         |
|-------------------------------------|---|-------------------------|
| In re:                              | : | Chapter 11              |
|                                     | : |                         |
| PURDUE PHARMA L.P., <i>et al.</i> , | : | Case No. 19-23649 (RDD) |
|                                     | : |                         |
| Debtors. <sup>1</sup>               | : | (Jointly Administered)  |
|                                     | : |                         |

---

**FIRST MONTHLY FEE STATEMENT OF KPMG LLP FOR COMPENSATION  
FOR SERVICES RENDERED AND REIMBURSEMENT OF EXPENSES  
INCURRED AS TAX CONSULTANT FOR THE DEBTORS  
AND THE OFFICIAL COMMITTEE OF UNSECURED CREDITORS  
FOR THE PERIOD FROM DECEMBER 23, 2019 THROUGH JANUARY 31, 2020**

|  |   |
|--|---|
| Name of Applicant:   | KPMG LLP  |
| Authorized to Provide Professional Services to:                              | The Debtors and the Official Committee of Unsecured Creditors |
| Date of Retention:   | February 24, 2020, <i>nunc pro tunc</i> to December 23, 2019  |
| Period for Which Compensation and Reimbursement is Sought:                   | December 23, 2019 through January 31, 2020                    |
| Amount of Compensation Sought as Actual, Reasonable, and Necessary:          | \$ 580,539.30   |
| Less 20% Holdback:   | \$ (116,107.86)   |
| Amount of Expense Reimbursement Sought as Actual, Reasonable, and Necessary: | \$ 614.93   |
| Total Fees and Expenses Due:   | \$ 465,046.37   |

---

<sup>1</sup> The Debtors in these cases, along with the last four digits of each Debtor's registration number in the applicable jurisdiction, are as follows: Purdue Pharma L.P. (7484), Purdue Pharma Inc. (7486), Purdue Transdermal Technologies L.P. (1868), Purdue Pharma Manufacturing L.P. (3821), Purdue Pharmaceuticals L.P. (0034), Imbrium Therapeutics L.P. (8810), Adlon Therapeutics L.P. (6745), Greenfield BioVentures L.P. (6150), Seven Seas Hill Corp. (4591), Ophir Green Corp. (4594), Purdue Pharma of Puerto Rico (3925), Avrio Health L.P. (4140), Purdue Pharmaceutical Products L.P. (3902), Purdue Neuroscience Company (4712), Nayatt Cove Lifescience Inc. (7805), Button Land L.P. (7502), Rhodes Associates L.P. (N/A), Paul Land Inc. (7425), Quidnick Land L.P. (7584), Rhodes Pharmaceuticals L.P. (6166), Rhodes Technologies (7143), UDF L.P. (0495), SVC Pharma L.P. (5717) and SVC Pharma Inc. (4014). The Debtors' corporate headquarters is located at One Stamford Forum, 201 Tresser Boulevard, Stamford, CT 06901.

Dated: March 2, 2020

/s/ Howard Steinberg

Howard Steinberg

KPMG LLP

1350 Avenue of the Americas

New York, New York 10019

(212) 872-6562

EXHIBIT A

Purdue Pharma L.P.

Case No. 19-23649

Summary Of Hours and Discounted Fees Incurred By Professional

December 23, 2019 through January 31, 2020

| Professional Person | Position & Department                    | Country of Origin | Total Billed Hours | Hourly Billing Rate | Total Compensation |
|---------------------|--|-------------------|--------------------|---------------------|--------------------|
| Andy Farinich       | Senior Associate - International Tax     | US                | 65.4               | \$ 534              | \$ 34,923.60       |
| Anja Poesl          | Senior Manager - German Intl Tax         | US                | 5.8                | \$ 750              | \$ 4,350.00        |
| Arik Eytan          | Partner - Tax                            | Israel            | 1.8                | \$ 555              | \$ 999.00          |
| Aroen Rambhadjan    | Partner - Tax                            | Netherlands       | 1.8                | \$ 985              | \$ 1,773.00        |
| Arpit Desai         | Senior Manager - Tax                     | UK                | 4.0                | \$ 750              | \$ 3,000.00        |
| Arpit Kakar         | Senior Associate - Tax                   | India             | 2.8                | \$ 640              | \$ 1,792.00        |
| Ashley Armfield     | Senior Associate - M&A Tax               | US                | 138.2              | \$ 534              | \$ 73,798.80       |
| Carlotta Bertu      | Senior Associate - Tax                   | Italy             | 0.6                | \$ 640              | \$ 384.00          |
| Casey Nunez         | Senior Manager - M&A Tax                 | US                | 32.7               | \$ 744              | \$ 24,328.80       |
| Christian Schmid    | Partner - Int'l Tax                      | Germany           | 5.5                | \$ 985              | \$ 5,417.50        |
| Christin Witt       | Manager - German Intl' Tax               | US                | 0.4                | \$ 650              | \$ 260.00          |
| Danielle Moloughney | Associate - Tax                          | Canada            | 1.6                | \$ 172              | \$ 275.20          |
| Dawn Krishnamurthy  | Manager - M&A Tax                        | US                | 150.7              | \$ 695              | \$ 104,736.50      |
| Devon Rowles        | Associate - M&A Tax                      | US                | 125.0              | \$ 350              | \$ 43,750.00       |
| Dong-Ju Shin        | Senior Manager - Global Tax              | South Korea       | 0.5                | \$ 750              | \$ 375.00          |
| Douglas Holland     | Principal - Washington National Tax      | US                | 1.1                | \$ 985              | \$ 1,083.50        |
| Frank Caratzola     | Senior Associate - Intl' Tax             | US                | 20.7               | \$ 534              | \$ 11,053.80       |
| Gavin Little        | Managing Director - Tax                  | UK                | 2.3                | \$ 985              | \$ 2,265.50        |
| Gregory Bell        | Partner - Tax                            | Canada            | 1.5                | \$ 743              | \$ 1,114.50        |
| Howard Steinberg    | Partner - M&A Tax                        | US                | 27.4               | \$ 856              | \$ 23,454.40       |
| Isaac Hirsch        | Managing Director - Int'l Tax            | US                | 79.1               | \$ 819              | \$ 64,782.90       |
| Jess Commisso       | Associate - M&A Tax                      | US                | 170.1              | \$ 350              | \$ 59,535.00       |
| Jonas Lau           | Senior Manager - Tax                     | Canada            | 5.5                | \$ 614              | \$ 3,377.00        |
| Karen Erickson      | Senior Manager - Tax                     | US                | 5.6                | \$ 690              | \$ 3,864.00        |
| Karl Tong           | Manager - Tax                            | China             | 0.3                | \$ 594              | \$ 178.20          |
| Kees Van Meel       | Principal - Int'l Tax                    | US                | 0.5                | \$ 757              | \$ 378.50          |
| Kyung-Min Kim       | Senior Manager - Tax                     | South Korea       | 1.0                | \$ 750              | \$ 750.00          |
| Lorenzo Bellavite   | Partner - Tax                            | Italy             | 0.5                | \$ 985              | \$ 492.50          |
| Lukas van der Veen  | Manager - Tax                            | Netherlands       | 7.2                | \$ 730              | \$ 5,256.00        |
| Madeleine Latham    | Associate - Tax                          | UK                | 4.4                | \$ 380              | \$ 1,672.00        |
| Maggie Scully       | Associate - M&A Tax                      | US                | 3.1                | \$ 350              | \$ 1,085.00        |
| Mark Hoffenberg     | Principal - Washington National Tax      | US                | 6.3                | \$ 980              | \$ 6,174.00        |
| Michael Land        | Senior Associate - M&A Tax               | US                | 111.7              | \$ 534              | \$ 59,647.80       |
| Monica Plangman     | Associate Director - Bankruptcy          | US                | 3.6                | \$ 264              | \$ 950.40          |
| Naman Gupta         | Senior Associate - Tax                   | India             | 3.1                | \$ 640              | \$ 1,984.00        |
| Nick Morgan         | Associate - M&A Tax                      | US                | 12.9               | \$ 350              | \$ 4,515.00        |
| Nidhi Jain          | Senior Associate - Tax                   | India             | 3.5                | \$ 640              | \$ 2,240.00        |
| Oron Zeevi          | Senior Manager - Tax                     | Israel            | 5.5                | \$ 450              | \$ 2,475.00        |
| Paul Kunkel         | Senior Manager - Washington National Tax | US                | 1.4                | \$ 744              | \$ 1,041.60        |
| Pete DiMatteo       | Manager - Int'l Tax                      | US                | 93.4               | \$ 650              | \$ 60,710.00       |
| Philipp Reer        | Partner - German Intl Tax                | US                | 4.5                | \$ 765              | \$ 3,442.50        |
| Renay Gosen         | Associate - M&A Tax                      | US                | 3.2                | \$ 350              | \$ 1,120.00        |
| Sam Tyler           | Partner - Tax                            | Canada            | 3.2                | \$ 743              | \$ 2,377.60        |
| Sonia Stricker      | Associate - Tax                          | Germany           | 28.3               | \$ 380              | \$ 10,754.00       |

EXHIBIT A

Purdue Pharma L.P.

Case No. 19-23649

Summary Of Hours and Discounted Fees Incurred By Professional  
December 23, 2019 through January 31, 2020

| Professional Person   | Position & Department               | Country of Origin | Total Billed Hours | Hourly Billing Rate | Total Compensation              |
|---|-------------------------------------|-------------------|--------------------|---------------------|---------------------------------|
| Thomas Giordano   | Associate - Int'l Tax               | US                | 148.3              | \$ 350              | \$ 51,905.00                    |
| Thomas Heubach  | Senior Manager - Tax                | Germany           | 23.5               | \$ 750              | \$ 17,625.00                    |
| Tracy Stone   | Principal - Washington National Tax | US                | 1.3                | \$ 906              | \$ 1,177.80                     |
| Wendy Shaffer   | Manager - Bankruptcy                | US                | 33.7               | \$ 202              | \$ 6,807.40                     |
| Less 50% Rate Reduction related to Non-Working Travel Time    |                                     |                   |                    |                     | \$ (2,457.00)                   |
| <b>Subtotal of Hours and Discounted Fees</b>                  |                                     |                   | <b>1,354.5</b>     |                     | <b>\$ 712,996.30</b>            |
| Less KPMG Voluntary Reduction (See Exhibit C1)                |                                     |                   |                    |                     | \$ (130,000.00)                 |
| Less KPMG Voluntary Reduction (See Exhibit C2)                |                                     |                   |                    |                     | \$ (2,457.00) <sup>(1)</sup>    |
| <b>Total Discounted Fees</b>                                  |                                     |                   |                    |                     | <b>\$ 580,539.30</b>            |
| Total Out of Pocket Expenses                                  |                                     |                   |                    |                     | \$ 989.04                       |
| Voluntary Reduction in Expenses                               |                                     |                   |                    |                     | \$ (374.11)                     |
| <b>Total Out of Pocket Expenses After Voluntary Reduction</b> |                                     |                   |                    |                     | <b>\$ 614.93</b> <sup>(2)</sup> |
| <b>Total Fees and Out of Pocket Expenses</b>                  |                                     |                   |                    |                     | <b>\$ 581,154.23</b>            |
| Less Holdback Adjustment (20%)                                |                                     |                   |                    |                     | \$ (116,107.86)                 |
| <b>Net Requested Fees &amp; Out of Pocket Expenses</b>        |                                     |                   |                    |                     | <b>\$ 465,046.37</b>            |
| <b>Blended Hourly Rate</b>                                    |                                     |                   |                    | <b>\$ 428.60</b>    |                                 |

<sup>(1)</sup> KPMG is taking a voluntary reduction of non-working travel time.

<sup>(2)</sup> See Exhibit D and D1 for an explanation of the expenses and the voluntary reduction.

**EXHIBIT B**

**Purdue Pharma L.P.**

**Case No. 19-23649**

Summary of Hours and Discounted Fees Incurred by Category  
December 23, 2019 through January 31, 2020

| <b>Category</b>                     | <b>Exhibit</b> | <b>Total<br/>Billed Hours</b> | <b>Total Fees<br/>Requested</b> |
|-------------------------------------|----------------|-------------------------------|---------------------------------|
| Bankruptcy Tax Consulting Services  | C1             | 1,311.1                       | \$ 572,712.00                   |
| Non -Working Travel Time            | C2             | 6.0                           | \$ -                            |
| Retention Services                  | C3             | 3.6                           | \$ 950.40                       |
| Fee Application Prepration Services | C4             | 33.8                          | \$ 6,876.90                     |
| <b>Total</b>                        |                | <b>1,354.5</b>                | <b>\$ 580,539.30</b>            |

**EXHIBIT C1**

**Purdue Pharma L.P.**

**Case No. 19-23649**

Bankruptcy Tax Consulting Services  
December 23, 2019 through January 31, 2020

| <b>Name</b>      | <b>Date</b> | <b>Description</b>  | <b>Hours</b> | <b>Rate</b> | <b>Amount</b> |
|------------------|-------------|---|--------------|-------------|---------------|
| Isaac Hirsch     | 12/26/19    | Call with I. Hirsch - partial attendance, M. Hoffenberg and H. Steinberg (all KPMG) to discuss Pharma project work plan and services to be provided by KPMG member firms.   | 0.5          | \$ 819      | \$ 409.50     |
| Howard Steinberg | 12/26/19    | Call with I. Hirsch - partial attendance, M. Hoffenberg and H. Steinberg (all KPMG) to discuss Pharma project work plan and services to be provided by KPMG member firms.   | 0.8          | \$ 856      | \$ 684.80     |
| Mark Hoffenberg  | 12/26/19    | Call with I. Hirsch - partial attendance, M. Hoffenberg and H. Steinberg (all KPMG) to discuss Pharma project work plan and services to be provided by KPMG member firms.   | 0.8          | \$ 980      | \$ 784.00     |
| Isaac Hirsch     | 12/29/19    | Performed International Tax Managing Director review and concurrently comment on initial draft of KPMG Purdue workplan  | 1.0          | \$ 819      | \$ 819.00     |
| Devon Rowles     | 12/30/19    | Updates to the information request list (IRL) with more detail regarding required data to complete a request pursuant to receiving all documents for deliverables   | 1.1          | \$ 350      | \$ 385.00     |
| Devon Rowles     | 12/30/19    | Began tracking designated portion of revenue, for numerous Mundipharma entities, in financial statements for years 2016, 2017, 2018 pursuant to prioritizing jurisdictions for future tax analysis.   | 1.7          | \$ 350      | \$ 595.00     |
| Michael Land     | 12/30/19    | (1.8) Preparation of initial workplan related to Purdue Pharma tax consulting; (0.4) review of virtual data room information (provided by client) as of 12/30/19 related to potential tax information of the independent associated companies | 2.2          | \$ 534      | \$ 1,174.80   |
| Devon Rowles     | 12/30/19    | Drafting the US information request list pursuant to reviewing and concurrently organizing documents necessary to complete deliverables.  | 2.3          | \$ 350      | \$ 805.00     |
| Devon Rowles     | 12/30/19    | Recording revenues for the various jurisdictions, for KPMG member firms we have already engaged, in order to prioritize those jurisdictions for the engagement.   | 2.9          | \$ 350      | \$ 1,015.00   |
| Michael Land     | 12/30/19    | Review of initial summary of gross revenue on an entity-by-entity basis to determine high priority jurisdictions  | 2.9          | \$ 534      | \$ 1,548.60   |
| Jess Commisso    | 12/30/19    | Review of assigned portion of numerous Mundipharma entities' financial statements to create a revenue breakdown pursuant to prioritizing jurisdictions for engagement of additional KPMG member firms.  | 3.9          | \$ 350      | \$ 1,365.00   |
| Casey Nunez      | 12/31/19    | Performed senior manager review of master workplan draft as requested by client.  | 0.6          | \$ 744      | \$ 446.40     |
| Jess Commisso    | 12/31/19    | Continue, from earlier in the day, to review assigned portion of numerous Mundipharma entities' financial statements to create a revenue breakdown pursuant to prioritizing jurisdictions for engagement of additional KPMG member firms.     | 0.7          | \$ 350      | \$ 245.00     |

**EXHIBIT C1**

**Purdue Pharma L.P.**

**Case No. 19-23649**

Bankruptcy Tax Consulting Services  
December 23, 2019 through January 31, 2020

| <b>Name</b>        | <b>Date</b> | <b>Description</b>  | <b>Hours</b> | <b>Rate</b> | <b>Amount</b> |
|--------------------|-------------|---|--------------|-------------|---------------|
| Jess Commisso      | 12/31/19    | Updating virtual data room (VDR) tracker / revenue breakdown with regards to additional documentation received as of 12/31 to update our Mundipharma jurisdiction revenue breakdown - pursuant to determining priority jurisdictions for assistance by KPMG member firms. | 1.9          | \$ 350      | \$ 665.00     |
| Devon Rowles       | 12/31/19    | Continued (from 12/30) to track designated portion of revenue for numerous Mundipharma entities in financial statements for years 2016, 2017, 2018 pursuant to prioritizing jurisdictions for future tax analysis.  | 3.3          | \$ 350      | \$ 1,155.00   |
| Jess Commisso      | 12/31/19    | Continued (from 12/30) to review assigned portion of numerous Mundipharma entities' financial statements to create a revenue breakdown pursuant to prioritizing jurisdictions for engagement of additional KPMG member firms.   | 3.9          | \$ 350      | \$ 1,365.00   |
| Dawn Krishnamurthy | 01/02/20    | 0.1 Manager review of draft email to KPMG member firms requesting their high priority tax information requests; 0.3 Review of Purdue Term Sheet filed on docket for purpose of gaining insight regarding potential tax issues related to proposed transactions.           | 0.4          | \$ 695      | \$ 278.00     |
| Ashley Armfield    | 01/02/20    | Review of latest version of Purdue Information Request List and concurrently providing comments to M. Land (KPMG).  | 0.6          | \$ 534      | \$ 320.40     |
| Pete DiMatteo      | 01/02/20    | Review draft information request list from an international tax perspective   | 0.7          | \$ 650      | \$ 455.00     |
| Casey Nunez        | 01/02/20    | Conference call with H. Steinberg, I. Hirsch, C. Nunez, D. Krishnamurthy, M. Land, and P. DiMatteo (all KPMG) to discuss initial information request listing and work plan for purposes of determining project strategy and preliminary modeling                          | 0.8          | \$ 744      | \$ 595.20     |
| Dawn Krishnamurthy | 01/02/20    | Conference call with H. Steinberg, I. Hirsch, C. Nunez, D. Krishnamurthy, M. Land, and P. DiMatteo (all KPMG) to discuss initial information request listing and work plan for purposes of determining project strategy and preliminary modeling                          | 0.8          | \$ 695      | \$ 556.00     |
| Howard Steinberg   | 01/02/20    | Conference call with H. Steinberg, I. Hirsch, C. Nunez, D. Krishnamurthy, M. Land, and P. DiMatteo (all KPMG) to discuss initial information request listing and work plan for purposes of determining project strategy and preliminary modeling                          | 0.8          | \$ 856      | \$ 684.80     |
| Isaac Hirsch       | 01/02/20    | Conference call with H. Steinberg, I. Hirsch, C. Nunez, D. Krishnamurthy, M. Land, and P. DiMatteo (all KPMG) to discuss initial information request listing and work plan for purposes of determining project strategy and preliminary modeling                          | 0.8          | \$ 819      | \$ 655.20     |

**EXHIBIT C1**

**Purdue Pharma L.P.**

**Case No. 19-23649**

Bankruptcy Tax Consulting Services  
December 23, 2019 through January 31, 2020

| <b>Name</b>   | <b>Date</b> | <b>Description</b>  | <b>Hours</b> | <b>Rate</b> | <b>Amount</b> |
|---------------|-------------|---|--------------|-------------|---------------|
| Michael Land  | 01/02/20    | Conference call with H. Steinberg, I. Hirsch, C. Nunez, D. Krishnamurthy, M. Land, and P. DiMatteo (all KPMG) to discuss initial information request listing and work plan for purposes of determining project strategy and preliminary modeling  | 0.8          | \$ 534      | \$ 427.20     |
| Pete DiMatteo | 01/02/20    | Conference call with H. Steinberg, I. Hirsch, C. Nunez, D. Krishnamurthy, M. Land, and P. DiMatteo (all KPMG) to discuss initial information request listing and work plan for purposes of determining project strategy and preliminary modeling  | 0.8          | \$ 650      | \$ 520.00     |
| Isaac Hirsch  | 01/02/20    | Meeting with P. DiMatteo and I. Hirsch (both KPMG) to review and concurrently discuss information request listing for purposes of determining strategy for preparing preliminary modeling   | 1.0          | \$ 819      | \$ 819.00     |
| Pete DiMatteo | 01/02/20    | Meeting with P. DiMatteo and I. Hirsch (both KPMG) to review and concurrently discuss information request listing for purposes of determining strategy for preparing preliminary modeling   | 1.0          | \$ 650      | \$ 650.00     |
| Casey Nunez   | 01/02/20    | (0.8) Senior manager revisions to updated version of workplan as requested by clients; (0.7) performed senior manager review of updated information request list; (0.4) communication via email to KPMG foreign member firms regarding work plan / information request list.                        | 1.9          | \$ 744      | \$ 1,413.60   |
| Michael Land  | 01/02/20    | (1.1) Review and concurrently update workplan related to US documents needed to gain insight regarding the independent associated companies' tax profile; (0.8) review of virtual data room documents, as of 1/2/2020, related to potential tax information of the independent associated companies | 1.9          | \$ 534      | \$ 1,014.60   |
| Isaac Hirsch  | 01/02/20    | Review Norton Rose analysis of high level tax consequences of straw man settlement and concurrently brainstorm with regards to the structure of the KPMG cash tax cost model  | 2.2          | \$ 819      | \$ 1,801.80   |
| Michael Land  | 01/02/20    | (1.2) Preparation of initial information request list related to US documents needed to gain insight regarding the independent associated companies' tax profile; (1.2) Updated initial information request list with regards to manager comments received as of 1/2/2020.                          | 2.4          | \$ 534      | \$ 1,281.60   |
| Michael Land  | 01/02/20    | Review and concurrently update independent associated company summary file to determine priority of jurisdictions   | 3.1          | \$ 534      | \$ 1,655.40   |



**EXHIBIT C1**

**Purdue Pharma L.P.**

**Case No. 19-23649**

Bankruptcy Tax Consulting Services  
December 23, 2019 through January 31, 2020

| <b>Name</b>        | <b>Date</b> | <b>Description</b>  | <b>Hours</b> | <b>Rate</b> | <b>Amount</b> |
|--------------------|-------------|---|--------------|-------------|---------------|
| Isaac Hirsch       | 01/02/20    | (1.2) Performed International Tax Managing Director review and concurrently comment on updated draft KPMG workplan / information request list provided by C. Nunez; (0.6) email communication with C. Nunez (KPMG) regarding comments related to draft KPMG workplan / information request list; (1.9) review documentation in virtual data room (provided by client) for purposes of analyzing potential cash tax cost of straw man settlement agreement | 3.7          | \$ 819      | \$ 3,030.30   |
| Karl Tong          | 01/03/20    | Preparation of detailed workplan (0.2) in connection with the bankruptcy and restructuring tax services in China; creation of initial information request list (0.1)  | 0.3          | \$ 594      | \$ 178.20     |
| Pete DiMatteo      | 01/03/20    | Prepare template to be utilized for purposes of creating organization charts depicting relevant entities to assist with transaction structuring.  | 0.5          | \$ 650      | \$ 325.00     |
| Jess Commisso      | 01/03/20    | Prepared for upcoming call with project team (on same day) by consolidating project team notes (from previous meetings) to identify items requiring follow-up / tasks to be discussed in upcoming meeting.  | 0.5          | \$ 350      | \$ 175.00     |
| Ashley Armfield    | 01/03/20    | Call with H. Steinberg, P. DiMatteo, M. Hoffenberg, I. Hirsch, C. Nunez, M. Land, A. Armfield and D. Krishnamurthy (all KPMG) to discuss latest version of workplan and updates that need to be made as of 1/3/2020.  | 0.6          | \$ 534      | \$ 320.40     |
| Casey Nunez        | 01/03/20    | Call with H. Steinberg, P. DiMatteo, M. Hoffenberg, I. Hirsch, C. Nunez, M. Land, A. Armfield and D. Krishnamurthy (all KPMG) to discuss latest version of workplan and updates that need to be made as of 1/3/2020.  | 0.6          | \$ 744      | \$ 446.40     |
| Dawn Krishnamurthy | 01/03/20    | Call with H. Steinberg, P. DiMatteo, M. Hoffenberg, I. Hirsch, C. Nunez, M. Land, A. Armfield and D. Krishnamurthy (all KPMG) to discuss latest version of workplan and updates that need to be made as of 1/3/2020.  | 0.6          | \$ 695      | \$ 417.00     |
| Howard Steinberg   | 01/03/20    | Call with H. Steinberg, P. DiMatteo, M. Hoffenberg, I. Hirsch, C. Nunez, M. Land, A. Armfield and D. Krishnamurthy (all KPMG) to discuss latest version of workplan and updates that need to be made as of 1/3/2020.  | 0.6          | \$ 856      | \$ 513.60     |
| Isaac Hirsch       | 01/03/20    | Call with H. Steinberg, P. DiMatteo, M. Hoffenberg, I. Hirsch, C. Nunez, M. Land, A. Armfield and D. Krishnamurthy (all KPMG) to discuss latest version of workplan and updates that need to be made as of 1/3/2020.  | 0.6          | \$ 819      | \$ 491.40     |
| Mark Hoffenberg    | 01/03/20    | Call with H. Steinberg, P. DiMatteo, M. Hoffenberg, I. Hirsch, C. Nunez, M. Land, A. Armfield and D. Krishnamurthy (all KPMG) to discuss latest version of workplan and updates that need to be made as of 1/3/2020.  | 0.6          | \$ 980      | \$ 588.00     |

**EXHIBIT C1**

**Purdue Pharma L.P.**

**Case No. 19-23649**

Bankruptcy Tax Consulting Services  
December 23, 2019 through January 31, 2020

| <b>Name</b>      | <b>Date</b> | <b>Description</b>  | <b>Hours</b> | <b>Rate</b> | <b>Amount</b> |
|------------------|-------------|---|--------------|-------------|---------------|
| Michael Land     | 01/03/20    | Call with H. Steinberg, P. DiMatteo, M. Hoffenberg, I. Hirsch, C. Nunez, M. Land, A. Armfield and D. Krishnamurthy (all KPMG) to discuss latest version of workplan and updates that need to be made as of 1/3/2020.  | 0.6          | \$ 534      | \$ 320.40     |
| Pete DiMatteo    | 01/03/20    | Call with H. Steinberg, P. DiMatteo, M. Hoffenberg, I. Hirsch, C. Nunez, M. Land, A. Armfield and D. Krishnamurthy (all KPMG) to discuss latest version of workplan and updates that need to be made as of 1/3/2020.  | 0.6          | \$ 650      | \$ 390.00     |
| Paul Kunkel      | 01/03/20    | Reviewed document "9/15/19 "Notice of Filing of Term Sheet With Ad Hoc Committee "in order to get a sense of the transactions that have been proposed to settle the bankruptcy case.  | 0.6          | \$ 744      | \$ 446.40     |
| Casey Nunez      | 01/03/20    | Conference call with H. Steinberg, M. Hoffenberg, T. Stone, I. Hirsch, C. Nunez, P. DiMatteo, P. Kunkel, M. Land, D. Rowles, J. Commisso (all KPMG) to discuss preliminary workplan and initial request list with a focus on trust documents and information necessary for purposes of determining project strategy and preliminary modeling. | 0.8          | \$ 744      | \$ 595.20     |
| Devon Rowles     | 01/03/20    | Conference call with H. Steinberg, M. Hoffenberg, T. Stone, I. Hirsch, C. Nunez, P. DiMatteo, P. Kunkel, M. Land, D. Rowles, J. Commisso (all KPMG) to discuss preliminary workplan and initial request list with a focus on trust documents and information necessary for purposes of determining project strategy and preliminary modeling. | 0.8          | \$ 350      | \$ 280.00     |
| Howard Steinberg | 01/03/20    | Conference call with H. Steinberg, M. Hoffenberg, T. Stone, I. Hirsch, C. Nunez, P. DiMatteo, P. Kunkel, M. Land, D. Rowles, J. Commisso (all KPMG) to discuss preliminary workplan and initial request list with a focus on trust documents and information necessary for purposes of determining project strategy and preliminary modeling. | 0.8          | \$ 856      | \$ 684.80     |
| Isaac Hirsch     | 01/03/20    | Conference call with H. Steinberg, M. Hoffenberg, T. Stone, I. Hirsch, C. Nunez, P. DiMatteo, P. Kunkel, M. Land, D. Rowles, J. Commisso (all KPMG) to discuss preliminary workplan and initial request list with a focus on trust documents and information necessary for purposes of determining project strategy and preliminary modeling. | 0.8          | \$ 819      | \$ 655.20     |
| Jess Commisso    | 01/03/20    | Conference call with H. Steinberg, M. Hoffenberg, T. Stone, I. Hirsch, C. Nunez, P. DiMatteo, P. Kunkel, M. Land, D. Rowles, J. Commisso (all KPMG) to discuss preliminary workplan and initial request list with a focus on trust documents and information necessary for purposes of determining project strategy and preliminary modeling. | 0.8          | \$ 350      | \$ 280.00     |

**EXHIBIT C1**

**Purdue Pharma L.P.**

**Case No. 19-23649**

Bankruptcy Tax Consulting Services  
December 23, 2019 through January 31, 2020

| <b>Name</b>     | <b>Date</b> | <b>Description</b>  | <b>Hours</b> | <b>Rate</b> | <b>Amount</b> |
|-----------------|-------------|---|--------------|-------------|---------------|
| Mark Hoffenberg | 01/03/20    | Conference call with H. Steinberg, M. Hoffenberg, T. Stone, I. Hirsch, C. Nunez, P. DiMatteo, P. Kunkel, M. Land, D. Rowles, J. Commisso (all KPMG) to discuss preliminary workplan and initial request list with a focus on trust documents and information necessary for purposes of determining project strategy and preliminary modeling. | 0.8          | \$ 980      | \$ 784.00     |
| Michael Land    | 01/03/20    | Conference call with H. Steinberg, M. Hoffenberg, T. Stone, I. Hirsch, C. Nunez, P. DiMatteo, P. Kunkel, M. Land, D. Rowles, J. Commisso (all KPMG) to discuss preliminary workplan and initial request list with a focus on trust documents and information necessary for purposes of determining project strategy and preliminary modeling. | 0.8          | \$ 534      | \$ 427.20     |
| Paul Kunkel     | 01/03/20    | Conference call with H. Steinberg, M. Hoffenberg, T. Stone, I. Hirsch, C. Nunez, P. DiMatteo, P. Kunkel, M. Land, D. Rowles, J. Commisso (all KPMG) to discuss preliminary workplan and initial request list with a focus on trust documents and information necessary for purposes of determining project strategy and preliminary modeling. | 0.8          | \$ 744      | \$ 595.20     |
| Pete DiMatteo   | 01/03/20    | Conference call with H. Steinberg, M. Hoffenberg, T. Stone, I. Hirsch, C. Nunez, P. DiMatteo, P. Kunkel, M. Land, D. Rowles, J. Commisso (all KPMG) to discuss preliminary workplan and initial request list with a focus on trust documents and information necessary for purposes of determining project strategy and preliminary modeling. | 0.8          | \$ 650      | \$ 520.00     |
| Michael Land    | 01/03/20    | Revised initial information requests lists to incorporate Member Firm input   | 0.8          | \$ 534      | \$ 427.20     |
| Philipp Reer    | 01/03/20    | Performed Partner review of German proposed tax workplan (provided by C. Nunez) and concurrently modified as needed.  | 1.0          | \$ 765      | \$ 765.00     |
| Isaac Hirsch    | 01/03/20    | Conference with I. Hirsch and P. DiMatteo (Both KPMG) to discuss issues related to organization charts, potential deductions arising from settlement payments, and direction with respect to research to be performed regarding same  | 1.1          | \$ 819      | \$ 900.90     |
| Pete DiMatteo   | 01/03/20    | Conference with I. Hirsch and P. DiMatteo (Both KPMG) to discuss issues related to organization charts, potential deductions arising from settlement payments, and direction with respect to research to be performed regarding same  | 1.1          | \$ 650      | \$ 715.00     |
| Casey Nunez     | 01/03/20    | Performed senior manager review of updates to US tax workplan as requested by client  | 1.2          | \$ 744      | \$ 892.80     |
| Anja Poesl      | 01/03/20    | Review draft Workplan along with draft Information Request List for Germany as provided by C. Nunez (KPMG) via e-mail dated January 1, 2020.  | 1.2          | \$ 750      | \$ 900.00     |

**EXHIBIT C1**

**Purdue Pharma L.P.**

**Case No. 19-23649**

Bankruptcy Tax Consulting Services  
December 23, 2019 through January 31, 2020

| <b>Name</b>        | <b>Date</b> | <b>Description</b>  | <b>Hours</b> | <b>Rate</b> | <b>Amount</b> |
|--------------------|-------------|---|--------------|-------------|---------------|
| Dawn Krishnamurthy | 01/03/20    | 0.9 Review of court filings submitted by Purdue with regards to proposed transaction and potential tax matters to be addressed; 0.2 communication via email with C. Nunez (KPMG) discussing information request/workplan additions; 0.2 Drafted email to I. Hirsch, C. Nunez, M. Land (all KPMG) to provide details related to and copy of updated Workplan.  | 1.3          | \$ 695      | \$ 903.50     |
| Tracy Stone        | 01/03/20    | Conference call with H. Steinberg, M. Hoffenberg, T. Stone, I. Hirsch, C. Nunez, P. DiMatteo, P. Kunkel, M. Land, D. Rowles, J. Commisso (all KPMG) to discuss preliminary workplan and initial request list with a focus on trust documents and information necessary for purposes of determining project strategy and preliminary modeling; prepare list of questions related to trust classification (0.8); drafted email to I. Hirsch and C. Nunez re same (0.5).   | 1.3          | \$ 906      | \$ 1,177.80   |
| Isaac Hirsch       | 01/03/20    | (0.8) Performed International Tax Managing Director review and concurrently comment on latest version of KPMG workplan draft provided by KPMG M&A team; (0.8) communication via email with T. Stone and P. Kunkel (both KPMG) regarding preparation of list of questions to add to KPMG's information request concerning analysis of the trusts in the Purdue ownership structure   | 1.6          | \$ 819      | \$ 1,310.40   |
| Anja Poesl         | 01/03/20    | 0.9 Review of Purdue Term Sheet as provided to us by C. Nunez (KPMG) via e-mail dated January 1, 2020 to gain insight regarding planned steps; 0.9 Update Workplan and Information Request List - Germany in excel file, i.e. addition of documents required to prepare German Tax Profile and to perform Transaction Tax Analysis for Germany.   | 1.8          | \$ 750      | \$ 1,350.00   |
| Devon Rowles       | 01/03/20    | (1.6) Updates to the workplans sent from KPMG foreign member firms and concurrently revise as needed; (0.3) Discussion with J. Commisso (KPMG) regarding next steps to complete the revenue by country files - as of 1/3/2020.  | 1.9          | \$ 350      | \$ 665.00     |
| Michael Land       | 01/03/20    | Reviewed member firm initial information request lists (Israel, Italy, Germany, Netherlands, and China) in conjunction with proposed work plan  | 2.4          | \$ 534      | \$ 1,281.60   |
| Isaac Hirsch       | 01/03/20    | (1.3) Continue (from 1/2) to review Norton Rose analysis of high level tax consequences of straw man settlement and concurrently brainstormed with regards to the KPMG cash tax cost model; (0.8) review and concurrently comment on most recent draft of KPMG workplan provided by KPMG M&A team; (0.8) communication via email with T. Stone and P. Kunkel (both KPMG) regarding preparation of list of questions to add to KPMG's information request concerning analysis of the trusts in the Purdue ownership structure. | 2.9          | \$ 819      | \$ 2,375.10   |

**EXHIBIT C1**

**Purdue Pharma L.P.**

**Case No. 19-23649**

Bankruptcy Tax Consulting Services  
December 23, 2019 through January 31, 2020

| <b>Name</b>      | <b>Date</b> | <b>Description</b>  | <b>Hours</b> | <b>Rate</b> | <b>Amount</b> |
|------------------|-------------|---|--------------|-------------|---------------|
| Pete DiMatteo    | 01/03/20    | Performed analysis regarding potential deductibility of settlement payments at the individual and trust level for purposes of assessing tax cost of contemplated transactions.  | 3.4          | \$ 650      | \$ 2,210.00   |
| Jess Commisso    | 01/03/20    | Concurrently incorporating member firm workplans / information request lists into a Master file with KPMG United States' portion (3.1); creation of a supplemental tracker to track updates related to such items (0.5); Discussion with D. Rowles (KPMG) regarding next steps to complete the revenue by country files as of 1/3/2020 (0.3). | 3.9          | \$ 350      | \$ 1,365.00   |
| Jess Commisso    | 01/03/20    | Continued, from 12/31, to review assigned portion of numerous Mundipharma entities' financial statements to create a revenue breakdown pursuant to prioritizing jurisdictions for engagement of additional KPMG member firms.   | 3.9          | \$ 350      | \$ 1,365.00   |
| Sam Tyler        | 01/05/20    | Brief review of bankruptcy documentation including structure chart / information provided to-date to determine information request need for work to be performed  | 0.5          | \$ 743      | \$ 371.50     |
| Michael Land     | 01/05/20    | Preparation of updates to preliminary workplan as well as information request list to incorporate KPMG Canada input (1.1) Communication with KPMG Canada Partner (S. Tyler) via email regarding preliminary workplan / initial request list for project strategy (0.3)  | 1.4          | \$ 534      | \$ 747.60     |
| Madeleine Latham | 01/06/20    | (0.1) Meeting with A. Desai and M. Latham (both KPMG UK) to discuss additional updates to the Purdue information request list (based on results of review by G. Little); and (0.1) created initial draft of email to submit updated information request list to KPMG US.  | 0.2          | \$ 380      | \$ 76.00      |
| Arpit Desai      | 01/06/20    | (0.1) Meeting with A. Desai and M. Latham (both KPMG UK) to discuss additional updates to the Purdue information request list (based on results of review by G. Little); and (0.1) senior manager review of draft email to US to submit copy of updated information request list prior to sending to KPMG US.                                 | 0.2          | \$ 750      | \$ 150.00     |
| Isaac Hirsch     | 01/06/20    | Conference with I. Hirsch, M. Land and P. DiMatteo (all KPMG) to discuss and review information requests and workplan for purposes of identifying Canadian-specific components of the workplan and IRL.   | 0.4          | \$ 819      | \$ 327.60     |
| Michael Land     | 01/06/20    | Conference with I. Hirsch, M. Land and P. DiMatteo (all KPMG) to discuss and review information requests and workplan for purposes of identifying Canadian-specific components of the workplan and IRL.   | 0.4          | \$ 534      | \$ 213.60     |

**EXHIBIT C1**

**Purdue Pharma L.P.**

**Case No. 19-23649**

Bankruptcy Tax Consulting Services  
December 23, 2019 through January 31, 2020

| <b>Name</b>      | <b>Date</b> | <b>Description</b>  | <b>Hours</b> | <b>Rate</b> | <b>Amount</b> |
|------------------|-------------|---|--------------|-------------|---------------|
| Pete DiMatteo    | 01/06/20    | Conference with I. Hirsch, M. Land and P. DiMatteo (all KPMG) to discuss and review information requests and workplan for purposes of identifying Canadian-specific components of the workplan and IRL.   | 0.4          | \$ 650      | \$ 260.00     |
| Mark Hoffenberg  | 01/06/20    | Performed Principal Washington Nation Tax review of review of draft workplan related to Purdue Pharma bankruptcy tax consulting services.   | 0.4          | \$ 980      | \$ 392.00     |
| Pete DiMatteo    | 01/06/20    | Conference with T. Giordano and P. DiMatteo (both KPMG) to discuss the creation of a global organization chart for purposes of future planning and tax cost modeling  | 0.5          | \$ 650      | \$ 325.00     |
| Thomas Giordano  | 01/06/20    | Conference with T. Giordano and P. DiMatteo (both KPMG) to discuss the creation of a global organization chart for purposes of future planning and tax cost modeling  | 0.5          | \$ 350      | \$ 175.00     |
| Arpit Desai      | 01/06/20    | Performed senior manager review and concurrently suggest additions to the updated Purdue information request list - prepared by M. Latham (KPMG UK Associate)   | 0.5          | \$ 750      | \$ 375.00     |
| Gavin Little     | 01/06/20    | Senior manager review of updates to the Purdue Pharma information request list - prepared by A. Desai and M. Latham (both KPMG UK) and concurrently updated as needed.  | 0.5          | \$ 985      | \$ 492.50     |
| Madeleine Latham | 01/06/20    | Updated the Purdue Pharma information request list (from a UK tax perspective) based on review comments from A. Desai (KPMG UK)   | 0.5          | \$ 380      | \$ 190.00     |
| Casey Nunez      | 01/06/20    | Call with Purdue Pharma bankers and M. Hoffenberg, H. Steinberg, I. Hirsch, and C. Nunez (all KPMG) to discuss current status of deliverables, including work plan and information request list and coordination of recurring check-in calls and fee summary updates. | 0.6          | \$ 744      | \$ 446.40     |
| Howard Steinberg | 01/06/20    | Call with Purdue Pharma bankers and M. Hoffenberg, H. Steinberg, I. Hirsch, and C. Nunez (all KPMG) to discuss current status of deliverables, including work plan and information request list and coordination of recurring check-in calls and fee summary updates. | 0.6          | \$ 856      | \$ 513.60     |
| Isaac Hirsch     | 01/06/20    | Call with Purdue Pharma bankers and M. Hoffenberg, H. Steinberg, I. Hirsch, and C. Nunez (all KPMG) to discuss current status of deliverables, including work plan and information request list and coordination of recurring check-in calls and fee summary updates. | 0.6          | \$ 819      | \$ 491.40     |

**EXHIBIT C1**

**Purdue Pharma L.P.**

**Case No. 19-23649**

Bankruptcy Tax Consulting Services  
December 23, 2019 through January 31, 2020

| <b>Name</b>        | <b>Date</b> | <b>Description</b>  | <b>Hours</b> | <b>Rate</b> | <b>Amount</b> |
|--------------------|-------------|---|--------------|-------------|---------------|
| Mark Hoffenberg    | 01/06/20    | Call with Purdue Pharma bankers and M. Hoffenberg, H. Steinberg, I. Hirsch, and C. Nunez (all KPMG) to discuss current status of deliverables, including work plan and information request list and coordination of recurring check-in calls and fee summary updates. | 0.6          | \$ 980      | \$ 588.00     |
| Ashley Armfield    | 01/06/20    | Call with S. Tyler (KPMG Canada), C. Nunez, I. Hirsch, D. Krishnamurthy, M. Land, A. Armfield, D. Rowles, J. Commisso (all KPMG US) to discuss Canadian input with respect to the tax workplan and information requests for purposes of determining project strategy. | 0.6          | \$ 534      | \$ 320.40     |
| Casey Nunez        | 01/06/20    | Call with S. Tyler (KPMG Canada), C. Nunez, I. Hirsch, D. Krishnamurthy, M. Land, A. Armfield, D. Rowles, J. Commisso (all KPMG US) to discuss Canadian input with respect to the tax workplan and information requests for purposes of determining project strategy. | 0.6          | \$ 744      | \$ 446.40     |
| Dawn Krishnamurthy | 01/06/20    | Call with S. Tyler (KPMG Canada), C. Nunez, I. Hirsch, D. Krishnamurthy, M. Land, A. Armfield, D. Rowles, J. Commisso (all KPMG US) to discuss Canadian input with respect to the tax workplan and information requests for purposes of determining project strategy. | 0.6          | \$ 695      | \$ 417.00     |
| Devon Rowles       | 01/06/20    | Call with S. Tyler (KPMG Canada), C. Nunez, I. Hirsch, D. Krishnamurthy, M. Land, A. Armfield, D. Rowles, J. Commisso (all KPMG US) to discuss Canadian input with respect to the tax workplan and information requests for purposes of determining project strategy. | 0.6          | \$ 350      | \$ 210.00     |
| Isaac Hirsch       | 01/06/20    | Call with S. Tyler (KPMG Canada), C. Nunez, I. Hirsch, D. Krishnamurthy, M. Land, A. Armfield, D. Rowles, J. Commisso (all KPMG US) to discuss Canadian input with respect to the tax workplan and information requests for purposes of determining project strategy. | 0.6          | \$ 819      | \$ 491.40     |
| Jess Commisso      | 01/06/20    | Call with S. Tyler (KPMG Canada), C. Nunez, I. Hirsch, D. Krishnamurthy, M. Land, A. Armfield, D. Rowles, J. Commisso (all KPMG US) to discuss Canadian input with respect to the tax workplan and information requests for purposes of determining project strategy. | 0.6          | \$ 350      | \$ 210.00     |
| Michael Land       | 01/06/20    | Call with S. Tyler (KPMG Canada), C. Nunez, I. Hirsch, D. Krishnamurthy, M. Land, A. Armfield, D. Rowles, J. Commisso (all KPMG US) to discuss Canadian input with respect to the tax workplan and information requests for purposes of determining project strategy. | 0.6          | \$ 534      | \$ 320.40     |

**EXHIBIT C1**

**Purdue Pharma L.P.**

**Case No. 19-23649**

Bankruptcy Tax Consulting Services  
December 23, 2019 through January 31, 2020

| <b>Name</b>        | <b>Date</b> | <b>Description</b>   | <b>Hours</b> | <b>Rate</b> | <b>Amount</b> |
|--------------------|-------------|--|--------------|-------------|---------------|
| Sam Tyler          | 01/06/20    | Call with S. Tyler (KPMG Canada), C. Nunez, I. Hirsch, D. Krishnamurthy, M. Land, A. Armfield, D. Rowles, J. Commisso (all KPMG US) to discuss Canadian input with respect to the tax workplan and information requests for purposes of determining project strategy.  | 0.6          | \$ 743      | \$ 445.80     |
| Casey Nunez        | 01/06/20    | Senior manager review of workplan updated with 4 foreign jurisdictions   | 0.7          | \$ 744      | \$ 520.80     |
| Arpit Desai        | 01/06/20    | Discussion with A. Desai, G. Little and M. Latham (all KPMG UK) on the status of the project and items to include in the information request list following separate calls with the KPMG US team.  | 0.8          | \$ 750      | \$ 600.00     |
| Gavin Little       | 01/06/20    | Discussion with A. Desai, G. Little and M. Latham (all KPMG UK) on the status of the project and items to include in the information request list following separate calls with the KPMG US team.  | 0.8          | \$ 985      | \$ 788.00     |
| Madeleine Latham   | 01/06/20    | Discussion with A. Desai, G. Little and M. Latham (all KPMG UK) on the status of the project and items to include in the information request list following separate calls with the KPMG US team.  | 0.8          | \$ 380      | \$ 304.00     |
| Thomas Giordano    | 01/06/20    | Completed review of assigned portion of Purdue organizational structure materials (provided by client) and concurrently organized in excel format to facilitate use of data in the creation of an overall organization structure chart; <u>Note</u> : this was an extremely large task with review that included 3 different sources of client organizational information to compile a comprehensive listing of numerous Purdue entities, spanning 60 jurisdictions, while concurrently determining each entities relevant owner / ownership percentage - as began earlier in the day. | 0.9          | \$ 350      | \$ 315.00     |
| Madeleine Latham   | 01/06/20    | Researching Purdue companies in scope in order to prepare the information request list and communication with A Desai and G Little (both KPMG UK) regarding same (as needed).  | 0.9          | \$ 380      | \$ 342.00     |
| Isaac Hirsch       | 01/06/20    | Review Norton Rose cash tax cost calculations for purposes of implementing test run of cash tax cost model   | 0.9          | \$ 819      | \$ 737.10     |
| Devon Rowles       | 01/06/20    | Incorporation of designated portion of KPMG member firms work plan / information request list data into master file in preparation to provide to client.   | 1.3          | \$ 350      | \$ 455.00     |
| Dawn Krishnamurthy | 01/06/20    | (0.3) Manager review of KPMG Canadian member firm workplan along with suggested information request items. (1.1) Review magnitude of revenue by country for purposes of identifying key regions/jurisdictions.   | 1.4          | \$ 695      | \$ 973.00     |



**EXHIBIT C1**

**Purdue Pharma L.P.**

**Case No. 19-23649**

Bankruptcy Tax Consulting Services  
December 23, 2019 through January 31, 2020

| <b>Name</b>     | <b>Date</b> | <b>Description</b>   | <b>Hours</b> | <b>Rate</b> | <b>Amount</b> |
|-----------------|-------------|--|--------------|-------------|---------------|
| Jess Commisso   | 01/06/20    | Incorporation of assigned portion of KPMG member firms' work plans / information request lists into master file in preparation to provide to client.   | 1.8          | \$ 350      | \$ 630.00     |
| Pete DiMatteo   | 01/06/20    | Draft template for organizational entity listing for purposes of creating a global organizational chart to assist in tax cost modeling and planning  | 2.2          | \$ 650      | \$ 1,430.00   |
| Jess Commisso   | 01/06/20    | Updated KPMG shared site to include documentation provided by client as of 1/6/2020 to facilitate tax analysis.  | 2.2          | \$ 350      | \$ 770.00     |
| Michael Land    | 01/06/20    | Review and concurrently compile preliminary workplan including related information request list (IRL) based on information received from KPMG Member Firms Australia / United Kingdom.   | 2.3          | \$ 534      | \$ 1,228.20   |
| Ashley Armfield | 01/06/20    | Review of latest version of workplan in preparation to discuss with project team (same day)  | 2.7          | \$ 534      | \$ 1,441.80   |
| Jess Commisso   | 01/06/20    | Continue (from 1/3) to review assigned portion of numerous Mundipharma entities' financial statements to create a revenue breakdown pursuant to prioritizing jurisdictions for engagement of additional KPMG member firms.   | 2.8          | \$ 350      | \$ 980.00     |
| Isaac Hirsch    | 01/06/20    | Drafted details regarding logic related to the Purdue Pharma cash tax cost model.  | 2.9          | \$ 819      | \$ 2,375.10   |
| Thomas Giordano | 01/06/20    | Began review of assigned portion of Purdue organizational structure materials (provided by client) and concurrently organized in excel format to facilitate use of data in the creation of an overall organization structure chart; <u>Note</u> : this was an extremely large task with review that included 3 different sources of client organizational information to compile a comprehensive listing of numerous Purdue entities, spanning 60 jurisdictions, while concurrently determining each entities relevant owner / ownership percentage.               | 3.9          | \$ 350      | \$ 1,365.00   |
| Thomas Giordano | 01/06/20    | Continue (same day) to review assigned portion of Purdue organizational structure materials (provided by client) and concurrently organized in excel format to facilitate use of data in the creation of an overall organization structure chart; <u>Note</u> : this was an extremely large task with review that included 3 different sources of client organizational information to compile a comprehensive listing of numerous Purdue entities, spanning 60 jurisdictions, while concurrently determining each entities relevant owner / ownership percentage. | 3.9          | \$ 350      | \$ 1,365.00   |

**EXHIBIT C1**

**Purdue Pharma L.P.**

**Case No. 19-23649**

Bankruptcy Tax Consulting Services  
December 23, 2019 through January 31, 2020

| <b>Name</b>       | <b>Date</b> | <b>Description</b>   | <b>Hours</b> | <b>Rate</b> | <b>Amount</b> |
|-------------------|-------------|--|--------------|-------------|---------------|
| Carlotta Bertu    | 01/07/20    | Perform Senior Associate initial review of Purdue Pharma available documents in KPMG Central (Shared Site) with regards to request for analysis to be performed for Purdue Pharma.   | 0.5          | \$ 640      | \$ 320.00     |
| Lorenzo Bellavite | 01/07/20    | Performed initial review, from Italian tax Partner perspective, of Purdue Pharma available documents in KPMG Central (Shared Site) with regards to request for analysis to be performed for Purdue Pharma.   | 0.5          | \$ 985      | \$ 492.50     |
| Pete DiMatteo     | 01/07/20    | Conference with T. Giordano and P. DiMatteo (both KPMG) regarding entity listing for purposes of creating a global organizational chart to assist in tax cost modeling and planning  | 0.7          | \$ 650      | \$ 455.00     |
| Thomas Giordano   | 01/07/20    | Conference with T. Giordano and P. DiMatteo (both KPMG) regarding entity listing for purposes of creating a global organizational chart to assist in tax cost modeling and planning  | 0.7          | \$ 350      | \$ 245.00     |
| Thomas Giordano   | 01/07/20    | Continue, same day, to review assigned portion of Purdue organizational structure materials (provided by client) and concurrently organized in excel format to facilitate use of data in the creation of an overall organization structure chart; <u>Note</u> : this was an extremely large task with review that included 3 different sources of client organizational information to compile a comprehensive listing of numerous Purdue entities, spanning 60 jurisdictions, while concurrently determining each entities relevant owner / ownership percentage. | 0.8          | \$ 350      | \$ 280.00     |
| Michael Land      | 01/07/20    | Review of preliminary workplan along with information request list for purposes of project strategy  | 1.1          | \$ 534      | \$ 587.40     |
| Devon Rowles      | 01/07/20    | Updating current version of Purdue information request list to reflect all information necessary to complete the current drafted workplan.   | 1.2          | \$ 350      | \$ 420.00     |
| Jess Commisso     | 01/07/20    | Continue (from earlier in the day) to review assigned portion of numerous Mundipharma entities' financial statements to create a revenue breakdown pursuant to prioritizing jurisdictions for engagement of additional KPMG member firms.  | 1.4          | \$ 350      | \$ 490.00     |
| Isaac Hirsch      | 01/07/20    | Managing Director review of current draft of entity list (prepared by T. Giordano and P. DiMatteo - KPMG) compiled from virtual data room for purposes of analyzing the potential cash tax consequences of entity/asset sales  | 1.6          | \$ 819      | \$ 1,310.40   |

**EXHIBIT C1**

**Purdue Pharma L.P.**

**Case No. 19-23649**

Bankruptcy Tax Consulting Services  
December 23, 2019 through January 31, 2020

| <b>Name</b>        | <b>Date</b> | <b>Description</b>   | <b>Hours</b> | <b>Rate</b> | <b>Amount</b> |
|--------------------|-------------|--|--------------|-------------|---------------|
| Jess Commisso      | 01/07/20    | Updated Orion (KPMG share site) to include additional provided by client documentation as of 1/7/2020; (0.4) Updated working group list of broader KPMG team for newest addition of team members pursuant to providing contact information of all engagement participants to internal / external parties; (.6) Updated KPMG share site to include additional KPMG team members to facilitate review of provided by client documentation. | 1.8          | \$ 350      | \$ 630.00     |
| Casey Nunez        | 01/07/20    | Senior manager review of complete draft of workplan included first tier foreign country tax services as requested by client  | 2.1          | \$ 744      | \$ 1,562.40   |
| Isaac Hirsch       | 01/07/20    | Continue (from 1/6) to draft details regarding logic related to Purdue Pharma cash tax cost model  | 2.4          | \$ 819      | \$ 1,965.60   |
| Dawn Krishnamurthy | 01/07/20    | (1.1) Perform Manager review of updated global workplan; (1.6) Manager review of updated global information request list including member firms' requests.   | 2.7          | \$ 695      | \$ 1,876.50   |
| Dawn Krishnamurthy | 01/07/20    | Performed analysis regarding Purdue and Mundipharma structure including current status of bankruptcy, ownership, legal claims and global presence - for purposes of identifying and gaining insight regarding key areas of focus (work performed concurrently).  | 2.8          | \$ 695      | \$ 1,946.00   |
| Isaac Hirsch       | 01/07/20    | Implement test run of cash tax cost model (for purposes of analyzing the potential cash tax consequences of entity/asset sales) with respect to sale of Switzerland stock or assets  | 3.2          | \$ 819      | \$ 2,620.80   |
| Devon Rowles       | 01/07/20    | Continued (from 12/31) to track designated portion of revenue for numerous Mundipharma entities in financial statements for years 2016, 2017, 2018 pursuant to prioritizing jurisdictions for future tax analysis.   | 3.3          | \$ 350      | \$ 1,155.00   |
| Ashley Armfield    | 01/07/20    | Outlined inputs that need to be included in cash tax model based on the current version of the workplan as well as additional considerations based on the group's structure.   | 3.8          | \$ 534      | \$ 2,029.20   |
| Jess Commisso      | 01/07/20    | Continue (from 1/6) review of assigned portion of numerous Mundipharma entities' financial statements to create a revenue breakdown pursuant to prioritizing jurisdictions for engagement of additional KPMG member firms.   | 3.9          | \$ 350      | \$ 1,365.00   |

**EXHIBIT C1**

**Purdue Pharma L.P.**

**Case No. 19-23649**

Bankruptcy Tax Consulting Services  
December 23, 2019 through January 31, 2020

| <b>Name</b>        | <b>Date</b> | <b>Description</b>  | <b>Hours</b> | <b>Rate</b> | <b>Amount</b> |
|--------------------|-------------|---|--------------|-------------|---------------|
| Thomas Giordano    | 01/07/20    | Continue, from 1/6, to review assigned portion of Purdue organizational structure materials (provided by client) and concurrently organized in excel format to facilitate use of data in the creation of an overall organization structure chart; <u>Note</u> : this was an extremely large task with review that included 3 different sources of client organizational information to compile a comprehensive listing of numerous Purdue entities, spanning 60 jurisdictions, while concurrently determining each entities relevant owner / ownership percentage.                | 3.9          | \$ 350      | \$ 1,365.00   |
| Thomas Giordano    | 01/07/20    | Continue, from earlier in the day, to review assigned portion of Purdue organizational structure materials (provided by client) and concurrently organized in excel format to facilitate use of data in the creation of an overall organization structure chart; <u>Note</u> : this was an extremely large task with review that included 3 different sources of client organizational information to compile a comprehensive listing of numerous Purdue entities, spanning 60 jurisdictions, while concurrently determining each entities relevant owner / ownership percentage. | 3.9          | \$ 350      | \$ 1,365.00   |
| Andy Farinich      | 01/08/20    | Call with A. Farinich and P. DiMatteo (both KPMG) regarding the formation of / revisions to an entity listing for purposes of creating a global organizational chart to assist in tax cost modeling and planning  | 0.3          | \$ 534      | \$ 160.20     |
| Pete DiMatteo      | 01/08/20    | Call with A. Farinich and P. DiMatteo (both KPMG) regarding the formation of / revisions to an entity listing for purposes of creating a global organizational chart to assist in tax cost modeling and planning  | 0.3          | \$ 650      | \$ 195.00     |
| Aroen Rambhadjan   | 01/08/20    | Call with A. Rambhadjan, K. van Meel and L. van der Veen (all KPMG Netherlands) to discuss the Purdue Pharma companies resident in the Netherlands; K. van Meel and M. de Kleermaeker provided background on the activities of the Purdue Pharma legal entities located in the Netherlands.   | 0.5          | \$ 985      | \$ 492.50     |
| Kees van Meel      | 01/08/20    | Call with A. Rambhadjan, K. van Meel and L. van der Veen (all KPMG Netherlands) to discuss the Purdue Pharma companies resident in the Netherlands; K. van Meel and M. de Kleermaeker provided background on the activities of the Purdue Pharma legal entities located in the Netherlands.   | 0.5          | \$ 757      | \$ 378.50     |
| Lukas van der Veen | 01/08/20    | Call with A. Rambhadjan, K. van Meel and L. van der Veen (all KPMG Netherlands) to discuss the Purdue Pharma companies resident in the Netherlands; K. van Meel and M. de Kleermaeker provided background on the activities of the Purdue Pharma legal entities located in the Netherlands.   | 0.5          | \$ 730      | \$ 365.00     |

**EXHIBIT C1**

**Purdue Pharma L.P.**

**Case No. 19-23649**

Bankruptcy Tax Consulting Services  
December 23, 2019 through January 31, 2020

| <b>Name</b>        | <b>Date</b> | <b>Description</b>  | <b>Hours</b> | <b>Rate</b> | <b>Amount</b> |
|--------------------|-------------|---|--------------|-------------|---------------|
| Pete DiMatteo      | 01/08/20    | Conference with T. Giordano and P. DiMatteo (both KPMG) regarding research assignment to determine entitlement to a tax deduction upon the payment of a legal settlement.   | 0.5          | \$ 650      | \$ 325.00     |
| Thomas Giordano    | 01/08/20    | Conference with T. Giordano and P. DiMatteo (both KPMG) regarding research assignment to determine entitlement to a tax deduction upon the payment of a legal settlement.   | 0.5          | \$ 350      | \$ 175.00     |
| Anja Poesl         | 01/08/20    | Participated in initial call with C. Schmid (KPMG Germany), T. Heubach (KPMG German), A. Poesl and P. Reer (both KPMG US) to align Germany and US teams regarding next steps related to bankruptcy tax consulting project.  | 0.5          | \$ 750      | \$ 375.00     |
| Christian Schmid   | 01/08/20    | Participated in initial call with C. Schmid (KPMG Germany), T. Heubach (KPMG German), A. Poesl and P. Reer (both KPMG US) to align Germany and US teams regarding next steps related to bankruptcy tax consulting project.  | 0.5          | \$ 985      | \$ 492.50     |
| Philipp Reer       | 01/08/20    | Participated in initial call with C. Schmid (KPMG Germany), T. Heubach (KPMG German), A. Poesl and P. Reer (both KPMG US) to align Germany and US teams regarding next steps related to bankruptcy tax consulting project.  | 0.5          | \$ 765      | \$ 382.50     |
| Thomas Heubach     | 01/08/20    | Participated in initial call with C. Schmid (KPMG Germany), T. Heubach (KPMG German), A. Poesl and P. Reer (both KPMG US) to align Germany and US teams regarding next steps related to bankruptcy tax consulting project.  | 0.5          | \$ 750      | \$ 375.00     |
| Lukas van der Veen | 01/08/20    | Manager review of draft document named Preliminary Analysis Sale of the Netherlands prepared by Norton Rose Fulbright, dated November 14, 2019 with focus on legal structure  | 0.8          | \$ 730      | \$ 584.00     |
| Aroen Rambhadrjan  | 01/08/20    | Partner review of draft document "Preliminary Analysis Sale of the Netherlands" prepared by Norton Rose Fulbright, dated November 14, 2019 with focus on Purdue Pharma legal structure.   | 0.8          | \$ 985      | \$ 788.00     |
| Michael Land       | 01/08/20    | (0.3) Review of latest version of workplan and information request list to determine next steps related to bankruptcy tax consulting project; (0.6) Communication to coordinate with KPMG member firm (Netherlands) regarding administration for the anti-money laundering regime | 0.9          | \$ 534      | \$ 480.60     |
| Christian Schmid   | 01/08/20    | Participated in kick-off meeting with T. Heubach and C. Schmid (both KPMG Germany) to discuss documentation received to date, teaming with KPMG US and next steps related to Purdue Pharma tax consulting project.  | 1.0          | \$ 985      | \$ 985.00     |

**EXHIBIT C1**

**Purdue Pharma L.P.**

**Case No. 19-23649**

Bankruptcy Tax Consulting Services  
December 23, 2019 through January 31, 2020

| <b>Name</b>     | <b>Date</b> | <b>Description</b>  | <b>Hours</b> | <b>Rate</b> | <b>Amount</b> |
|-----------------|-------------|---|--------------|-------------|---------------|
| Thomas Heubach  | 01/08/20    | Participated in kick-off meeting with T. Heubach and C. Schmid (both KPMG Germany) to discuss documentation received to date, teaming with KPMG US and next steps related to Purdue Pharma tax consulting project.  | 1.0          | \$ 750      | \$ 750.00     |
| Philipp Reer    | 01/08/20    | Review of Purdue Pharma documentation (from German tax perspective) provided in the SharePoint as of 1/8/2020.  | 1.0          | \$ 765      | \$ 765.00     |
| Ashley Armfield | 01/08/20    | Revised project work plan in preparation to be circulated to the client and Purdue Pharma bankers - Per KPMG management request   | 1.1          | \$ 534      | \$ 587.40     |
| Thomas Giordano | 01/08/20    | Continue, from earlier in the day, to review assigned portion of Purdue organizational structure materials (provided by client) and concurrently organized in excel format to facilitate use of data in the creation of an overall organization structure chart; <u>Note</u> : this was an extremely large task with review that included 3 different sources of client organizational information to compile a comprehensive listing of numerous Purdue entities, spanning 60 jurisdictions, while concurrently determining each entities relevant owner / ownership percentage. | 1.3          | \$ 350      | \$ 455.00     |
| Jess Commisso   | 01/08/20    | Continued, from earlier in the day, review of assigned portion of numerous Mundipharma entities' financial statements to create a revenue breakdown pursuant to prioritizing jurisdictions for engagement of additional KPMG member firms.  | 1.3          | \$ 350      | \$ 455.00     |
| Isaac Hirsch    | 01/08/20    | (0.4) Communication via email with C. Nunez (KPMG) regarding analysis of ownership of Independent Affiliated Company for purposes of European tax analysis; (0.7) continue analysis of potential cash tax cost of settlement for purposes of preparing cash tax model; (0.3) Communication via email with P. DiMatteo (KPMG) regarding preparation of organizational charts for purposes of analyzing potential cash tax cost of settlement   | 1.4          | \$ 819      | \$ 1,146.60   |
| Devon Rowles    | 01/08/20    | Continue, from previous day, to track designated portion of revenue for numerous Mundipharma entities in financial statements for years 2016, 2017, 2018 pursuant to prioritizing jurisdictions for future tax analysis.  | 1.6          | \$ 350      | \$ 560.00     |
| Thomas Giordano | 01/08/20    | Performed research to determine entitlement to a tax deduction for settlement payments  | 1.8          | \$ 350      | \$ 630.00     |
| Devon Rowles    | 01/08/20    | Began to create a structure deck for the drafted term sheet to illustrate the sale of the Mundipharma entities  | 1.9          | \$ 350      | \$ 665.00     |
| Jess Commisso   | 01/08/20    | Began to build out cash tax model pursuant to asset versus stock sale of Mundipharma entities.  | 2.2          | \$ 350      | \$ 770.00     |

**EXHIBIT C1**

**Purdue Pharma L.P.**

**Case No. 19-23649**

Bankruptcy Tax Consulting Services  
December 23, 2019 through January 31, 2020

| <b>Name</b>        | <b>Date</b> | <b>Description</b>  | <b>Hours</b> | <b>Rate</b> | <b>Amount</b> |
|--------------------|-------------|---|--------------|-------------|---------------|
| Dawn Krishnamurthy | 01/08/20    | Review of data room documentation as of 1/8/2020 - for purposes of identifying potential Purdue Pharma tax issues   | 2.3          | \$ 695      | \$ 1,598.50   |
| Andy Farinich      | 01/08/20    | Continued (same day) to review designated portion of Purdue Pharma organizational structure documentation provided by client and concurrently organized (in excel) to facilitate creation of a comprehensive global organizational structure chart for further analysis; <u>Note</u> : this was an extremely large task with review that included 3 different sources of client organizational information to compile a comprehensive listing of numerous Purdue entities, spanning 60 jurisdictions, while concurrently determining each entities relevant owner / ownership percentage. | 2.5          | \$ 534      | \$ 1,335.00   |
| Ashley Armfield    | 01/08/20    | Meeting with A. Armfield and J. Commisso (both KPMG) for preliminary discussion related to Purdue cash tax model, focusing on set up, detail inclusion, scenario breakdown, and the end deliverable goal.   | 2.9          | \$ 534      | \$ 1,548.60   |
| Jess Commisso      | 01/08/20    | Meeting with A. Armfield and J. Commisso (both KPMG) for preliminary discussion related to Purdue cash tax model, focusing on set up, detail inclusion, scenario breakdown, and the end deliverable goal.   | 2.9          | \$ 350      | \$ 1,015.00   |
| Ashley Armfield    | 01/08/20    | Meeting with M. Land, A. Armfield, D. Krishnamurthy (all KPMG) to discuss preliminary cash tax model considerations and the various inputs necessary for purposes of project strategy   | 3.1          | \$ 534      | \$ 1,655.40   |
| Dawn Krishnamurthy | 01/08/20    | Meeting with M. Land, A. Armfield, D. Krishnamurthy (all KPMG) to discuss preliminary cash tax model considerations and the various inputs necessary for purposes of project strategy   | 3.1          | \$ 695      | \$ 2,154.50   |
| Michael Land       | 01/08/20    | Meeting with M. Land, A. Armfield, D. Krishnamurthy (all KPMG) to discuss preliminary cash tax model considerations and the various inputs necessary for purposes of project strategy   | 3.1          | \$ 534      | \$ 1,655.40   |
| Pete DiMatteo      | 01/08/20    | Perform analysis regarding entitlement to potential tax deductions (including sections 162 and 165) arising from settlement payments made by Purdue and/or its owners under alternate scenarios (e.g., payments from trusts and/or partnerships).   | 3.4          | \$ 650      | \$ 2,210.00   |

**EXHIBIT C1**

**Purdue Pharma L.P.**

**Case No. 19-23649**

Bankruptcy Tax Consulting Services  
December 23, 2019 through January 31, 2020

| <b>Name</b>     | <b>Date</b> | <b>Description</b>  | <b>Hours</b> | <b>Rate</b> | <b>Amount</b> |
|-----------------|-------------|---|--------------|-------------|---------------|
| Andy Farinich   | 01/08/20    | Began to review designated portion of Purdue Pharma organizational structure documentation provided by client and concurrently organized (in excel) to facilitate creation of a comprehensive global organizational structure chart for further analysis; <u>Note</u> : this was an extremely large task with review that included 3 different sources of client organizational information to compile a comprehensive listing of numerous Purdue entities, spanning 60 jurisdictions, while concurrently determining each entities relevant owner / ownership percentage.                    | 3.9          | \$ 534      | \$ 2,082.60   |
| Jess Commisso   | 01/08/20    | Continue (from 1/7) to review assigned portion of numerous Mundipharma entities' financial statements to create a revenue breakdown pursuant to prioritizing jurisdictions for engagement of additional KPMG member firms.  | 3.9          | \$ 350      | \$ 1,365.00   |
| Thomas Giordano | 01/08/20    | Continue, from 1/7, to review assigned portion of Purdue organizational structure materials (provided by client) and concurrently organized in excel format to facilitate use of data in the creation of an overall organization structure chart; <u>Note</u> : this was an extremely large task with review that included 3 different sources of client organizational information to compile a comprehensive listing of numerous Purdue entities, spanning 60 jurisdictions, while concurrently determining each entities relevant owner / ownership percentage.                            | 3.9          | \$ 350      | \$ 1,365.00   |
| Isaac Hirsch    | 01/09/20    | Communication via email with P. DiMatteo (KPMG) regarding preparation of organizational charts for purposes of analyzing potential cash tax cost of settlement  | 0.5          | \$ 819      | \$ 409.50     |
| Michael Land    | 01/09/20    | Meeting with D. Rowles (KPMG) to review the Purdue Pharma structure deck (for the term sheet) and concurrently discuss possible revisions   | 0.6          | \$ 534      | \$ 320.40     |
| Devon Rowles    | 01/09/20    | Meeting with M. Land (KPMG) to review the Purdue Pharma structure deck (for the term sheet) and concurrently discuss possible revisions   | 0.6          | \$ 350      | \$ 210.00     |
| Andy Farinich   | 01/09/20    | Continued (from earlier in the day) to review designated Purdue Pharma organizational structure documentation provided by client and concurrently organized (in excel) to facilitate creation of a comprehensive global organizational structure chart for further analysis; <u>Note</u> : this was an extremely large task with review that included 3 different sources of client organizational information to compile a comprehensive listing of numerous Purdue entities, spanning 60 jurisdictions, while concurrently determining each entities relevant owner / ownership percentage. | 0.7          | \$ 534      | \$ 373.80     |



**EXHIBIT C1**

**Purdue Pharma L.P.**

**Case No. 19-23649**

Bankruptcy Tax Consulting Services  
December 23, 2019 through January 31, 2020

| <b>Name</b>        | <b>Date</b> | <b>Description</b>  | <b>Hours</b> | <b>Rate</b> | <b>Amount</b> |
|--------------------|-------------|---|--------------|-------------|---------------|
| Jess Commisso      | 01/09/20    | (0.4) Updated KPMG share site to include documentation provided by client as of 1/9/2020 - to facilitate tax analysis of same; (0.4): Review of new documentation uploaded to the data room by the client to circulate to KPMG project team.  | 0.8          | \$ 350      | \$ 280.00     |
| Casey Nunez        | 01/09/20    | Review of current documentation in data room for purposes of building the cash tax model  | 0.8          | \$ 744      | \$ 595.20     |
| Anja Poesl         | 01/09/20    | Performed initial review documents provided on SharePoint for Germany related to various Purdue Pharma entities (Verwaltungsgesellschaft GmbH, Krugmann GmbH, Mundichemie GmbH, Mundipharma Biologics GmbH, Mundipharma Deutschland GmbH und Co. KG, Mundipharma GmbH, Mundipharma Medical GmbH, Mundipharma Research GmbH & Co. KG, Munidpharma Research Verwaltungs GmbH) to gain overview regarding the information available to perform analysis.   | 1.0          | \$ 750      | \$ 750.00     |
| Thomas Giordano    | 01/09/20    | Continued, from 1/8, to review assigned portion of Purdue organizational structure materials (provided by client) and concurrently organized in excel format to facilitate use of data in the creation of an overall organization structure chart; <u>Note</u> : this was an extremely large task with review that included 3 different sources of client organizational information to compile a comprehensive listing of numerous Purdue entities, spanning 60 jurisdictions, while concurrently determining each entities relevant owner / ownership percentage. | 1.5          | \$ 350      | \$ 525.00     |
| Jess Commisso      | 01/09/20    | Created assigned portion of overall jurisdiction prioritization for Mundipharma entities, based on profit & loss information provided by the client, pursuant to the engagement of additional KPMG member firms.  | 1.6          | \$ 350      | \$ 560.00     |
| Lukas van der Veen | 01/09/20    | Performed analysis related to potential non-resident taxation issue if Dutch resident Cooperative would become the Master Holding company for companies located outside the United States.  | 1.8          | \$ 730      | \$ 1,314.00   |
| Howard Steinberg   | 01/09/20    | Partner review of proposed workplan for purposes of facilitating a discussion with respect to tax scope   | 2.0          | \$ 856      | \$ 1,712.00   |
| Dawn Krishnamurthy | 01/09/20    | 0.6 Review most recent round of updates to workplan to reflect evolving understanding of tax profile of high priority jurisdictions; 1.4 Review of data room documentation as of 1/9/2020 - for purpose of identifying areas of focus for workplan.   | 2.0          | \$ 695      | \$ 1,390.00   |

**EXHIBIT C1**

**Purdue Pharma L.P.**

**Case No. 19-23649**

Bankruptcy Tax Consulting Services  
December 23, 2019 through January 31, 2020

| <b>Name</b>        | <b>Date</b> | <b>Description</b>  | <b>Hours</b> | <b>Rate</b> | <b>Amount</b> |
|--------------------|-------------|---|--------------|-------------|---------------|
| Devon Rowles       | 01/09/20    | Began to create designated portion of overall jurisdiction prioritization for Mundipharma entities - based on company personnel information provided by the client - pursuant to the engagement of additional KPMG member firms.  | 2.1          | \$ 350      | \$ 735.00     |
| Devon Rowles       | 01/09/20    | Continue (from 1/8) creating a structure deck for the drafted term sheet to illustrate the sale of the Mundipharma entities   | 2.1          | \$ 350      | \$ 735.00     |
| Thomas Giordano    | 01/09/20    | Performed research to determine entitlement to a tax deduction for settlement payments  | 2.5          | \$ 350      | \$ 875.00     |
| Thomas Giordano    | 01/09/20    | Continue, from earlier in the day, to review assigned portion of Purdue organizational structure materials (provided by client) and concurrently organized in excel format to facilitate use of data in the creation of an overall organization structure chart; <u>Note</u> : this was an extremely large task with review that included 3 different sources of client organizational information to compile a comprehensive listing of numerous Purdue entities, spanning 60 jurisdictions, while concurrently determining each entities relevant owner / ownership percentage. | 2.8          | \$ 350      | \$ 980.00     |
| Ashley Armfield    | 01/09/20    | Meeting with C. Nunez, D. Krishnamurthy, A. Armfield, M. Land (all KPMG) to discuss cash tax model, inputs, and reference tabs to develop an efficient preliminary cash tax model for purposes of project management  | 3.1          | \$ 534      | \$ 1,655.40   |
| Casey Nunez        | 01/09/20    | Meeting with C. Nunez, D. Krishnamurthy, A. Armfield, M. Land (all KPMG) to discuss cash tax model, inputs, and reference tabs to develop an efficient preliminary cash tax model for purposes of project management  | 3.1          | \$ 744      | \$ 2,306.40   |
| Dawn Krishnamurthy | 01/09/20    | Meeting with C. Nunez, D. Krishnamurthy, A. Armfield, M. Land (all KPMG) to discuss cash tax model, inputs, and reference tabs to develop an efficient preliminary cash tax model for purposes of project management  | 3.1          | \$ 695      | \$ 2,154.50   |
| Michael Land       | 01/09/20    | Meeting with C. Nunez, D. Krishnamurthy, A. Armfield, M. Land (all KPMG) to discuss cash tax model, inputs, and reference tabs to develop an efficient preliminary cash tax model for purposes of project management  | 3.1          | \$ 534      | \$ 1,655.40   |
| Pete DiMatteo      | 01/09/20    | Continue (from previous day) to perform analysis regarding entitlement to potential tax deductions (including sections 162 and 165) arising from settlement payments made by Purdue and/or its owners under alternate scenarios (e.g., payments from trusts and/or partnerships).   | 3.2          | \$ 650      | \$ 2,080.00   |

**EXHIBIT C1**

**Purdue Pharma L.P.**

**Case No. 19-23649**

Bankruptcy Tax Consulting Services  
December 23, 2019 through January 31, 2020

| <b>Name</b>     | <b>Date</b> | <b>Description</b>  | <b>Hours</b> | <b>Rate</b> | <b>Amount</b> |
|-----------------|-------------|---|--------------|-------------|---------------|
| Andy Farinich   | 01/09/20    | Continue (from 1/8) to review designated portion of Purdue Pharma organizational structure documentation provided by client and concurrently organized (in excel) to facilitate creation of a comprehensive global organizational structure chart for further analysis; <u>Note</u> : this was an extremely large task with review that included 3 different sources of client organizational information to compile a comprehensive listing of numerous Purdue entities, spanning 60 jurisdictions, while concurrently determining each entities relevant owner / ownership percentage.  | 3.9          | \$ 534      | \$ 2,082.60   |
| Andy Farinich   | 01/09/20    | Continued (same day) to review designated portion of Purdue Pharma organizational structure documentation provided by client and concurrently organized (in excel) to facilitate creation of a comprehensive global organizational structure chart for further analysis; <u>Note</u> : this was an extremely large task with review that included 3 different sources of client organizational information to compile a comprehensive listing of numerous Purdue entities, spanning 60 jurisdictions, while concurrently determining each entities relevant owner / ownership percentage. | 3.9          | \$ 534      | \$ 2,082.60   |
| Carlotta Bertu  | 01/10/20    | Reviewed KPMG Central (Shared Site) to extract new Purdue Pharma documentation available as of 1/10/2020.   | 0.1          | \$ 640      | \$ 64.00      |
| Sonia Stricker  | 01/10/20    | Communication via email with J. Commisso (KPMG US) regarding go forward procedures to analyze Purdue Pharma documentation for use in German tax analysis.   | 0.2          | \$ 380      | \$ 76.00      |
| Thomas Heubach  | 01/10/20    | Communication via email with J. Commisso (KPMG US) regarding go forward procedures to analyze Purdue Pharma documentation for use in German tax analysis.   | 0.2          | \$ 750      | \$ 150.00     |
| Jess Commisso   | 01/10/20    | Additional updates to KPMG Share site to include additional KPMG team members to allow usage of provided by client documentation for tax analysis.  | 0.4          | \$ 350      | \$ 140.00     |
| Ashley Armfield | 01/10/20    | Review of term sheet pursuant to gaining insight regarding the proposed formation of / payments to the public trust for purposes of cash tax modeling.  | 0.8          | \$ 534      | \$ 427.20     |
| Thomas Heubach  | 01/10/20    | Senior Manager review of draft list that will be used to collect information made available through the SharePoint (organizational structure and financial statements).   | 0.8          | \$ 750      | \$ 600.00     |
| Sonia Stricker  | 01/10/20    | Analyzed the corporate structure of Purdue Pharma in Germany with focus on relevant shareholder chains, number of legal entities, legal forms.  | 1.0          | \$ 380      | \$ 380.00     |

**EXHIBIT C1**

**Purdue Pharma L.P.**

**Case No. 19-23649**

Bankruptcy Tax Consulting Services  
December 23, 2019 through January 31, 2020

| <b>Name</b>        | <b>Date</b> | <b>Description</b>   | <b>Hours</b> | <b>Rate</b> | <b>Amount</b> |
|--------------------|-------------|--|--------------|-------------|---------------|
| Thomas Heubach     | 01/10/20    | Senior Manager review of analysis executed by S. Stricker (KPMG Germany) on the corporate structure of Purdue Pharma in Germany related to relevant shareholder chains, number of legal entities, legal forms.   | 1.0          | \$ 750      | \$ 750.00     |
| Thomas Giordano    | 01/10/20    | Continued, from 1/9, to review of assigned portion of Purdue organizational structure materials (provided by client) and concurrently organized in excel format to facilitate use of data in the creation of an overall organization structure chart; <u>Note</u> : this was an extremely large task with review that included 3 different sources of client organizational information to compile a comprehensive listing of numerous Purdue entities, spanning 60 jurisdictions, while concurrently determining each entities relevant owner / ownership percentage.   | 1.2          | \$ 350      | \$ 420.00     |
| Howard Steinberg   | 01/10/20    | Partner review of virtual data room information received to date for purposes of gaining insight regarding tax posture   | 1.4          | \$ 856      | \$ 1,198.40   |
| Andy Farinich      | 01/10/20    | Continued (from 1/9) to review designated portion of Purdue Pharma organizational structure documentation provided by client and concurrently organized (in excel) to facilitate creation of a comprehensive global organizational structure chart for further analysis; <u>Note</u> : this was an extremely large task with review that included 3 different sources of client organizational information to compile a comprehensive listing of numerous Purdue entities, spanning 60 jurisdictions, while concurrently determining each entities relevant owner / ownership percentage (1.2); and drafted email to P. DiMatteo (KPMG) to provide copy of same for Manager review (.2)" | 1.4          | \$ 534      | \$ 747.60     |
| Isaac Hirsch       | 01/10/20    | (0.5) Communication via email with P. DiMatteo (KPMG) regarding preparation of organizational charts for purposes of analyzing potential cash tax cost of settlement; (1.2) Perform additional review of Norton rose calculations for purposes migrating same to KPMG cash tax model   | 1.7          | \$ 819      | \$ 1,392.30   |
| Dawn Krishnamurthy | 01/10/20    | 0.4 Communication via email to coordinate with KPMG Netherlands team (A. DeHaas) regarding information request list items; 1.2 Manager review of latest round of updates to workplan along with related information request list; 0.2 communication via email with A. Armfield, C. Nunez and M. Land (all KPMG) regarding updates related to structure deck and information requests as of 1/10.   | 1.8          | \$ 695      | \$ 1,251.00   |
| Michael Land       | 01/10/20    | Review of sell side diligence report for purposes of gaining insight regarding the Purdue company's tax profile  | 1.8          | \$ 534      | \$ 961.20     |

**EXHIBIT C1**

**Purdue Pharma L.P.**

**Case No. 19-23649**

Bankruptcy Tax Consulting Services  
December 23, 2019 through January 31, 2020

| <b>Name</b>     | <b>Date</b> | <b>Description</b>   | <b>Hours</b> | <b>Rate</b> | <b>Amount</b> |
|-----------------|-------------|--|--------------|-------------|---------------|
| Pete DiMatteo   | 01/10/20    | Review of Purdue Pharma organization documentation to assist in creating global organization charts to ultimately assist in modeling / planning related to same.   | 2.1          | \$ 650      | \$ 1,365.00   |
| Pete DiMatteo   | 01/10/20    | Continued (from 1/9) to perform analysis regarding permissibility of settlement payment deductions with regards to Purdue Pharma matter.   | 2.2          | \$ 650      | \$ 1,430.00   |
| Jess Commisso   | 01/10/20    | Continue (from previous day) to create assigned portion of overall jurisdiction prioritization for Mundipharma entities, based on profit & loss information provided by the client, pursuant to the engagement of additional KPMG member firms.  | 2.3          | \$ 350      | \$ 805.00     |
| Sonia Stricker  | 01/10/20    | Preparation of a list to collect information made available through the SharePoint (organizational structure / financial statements).  | 2.3          | \$ 380      | \$ 874.00     |
| Devon Rowles    | 01/10/20    | (2.3) Continued (same day) to create designated portion of overall jurisdiction prioritization for Mundipharma entities - based on company personnel information provided by the client - pursuant to the engagement of additional KPMG member firms; (3) Update to the information request list and current workplan with regards to review comments received from D. Krishnamurthy (KPMG) as of 1/10/2020. | 2.6          | \$ 350      | \$ 910.00     |
| Andy Farinich   | 01/10/20    | Reviewed additional Purdue Pharma organizational structure documentation provided by client, as of 1/10/2020, and concurrently updated excel file to include same.   | 2.8          | \$ 534      | \$ 1,495.20   |
| Thomas Giordano | 01/10/20    | Continued (from 1/9) to perform research to determine entitlement to a tax deduction for settlement payments   | 3.0          | \$ 350      | \$ 1,050.00   |
| Ashley Armfield | 01/10/20    | Meeting with I. Hirsch, C. Nunez, M. Land, A. Armfield (all KPMG) to discuss strategy, simplifying assumptions, and expectations for member firm correspondence as it relates to cash tax modeling.  | 3.6          | \$ 534      | \$ 1,922.40   |
| Casey Nunez     | 01/10/20    | Meeting with I. Hirsch, C. Nunez, M. Land, A. Armfield (all KPMG) to discuss strategy, simplifying assumptions, and expectations for member firm correspondence as it relates to cash tax modeling.  | 3.6          | \$ 744      | \$ 2,678.40   |
| Isaac Hirsch    | 01/10/20    | Meeting with I. Hirsch, C. Nunez, M. Land, A. Armfield (all KPMG) to discuss strategy, simplifying assumptions, and expectations for member firm correspondence as it relates to cash tax modeling.  | 3.6          | \$ 819      | \$ 2,948.40   |
| Michael Land    | 01/10/20    | Meeting with I. Hirsch, C. Nunez, M. Land, A. Armfield (all KPMG) to discuss strategy, simplifying assumptions, and expectations for member firm correspondence as it relates to cash tax modeling.  | 3.6          | \$ 534      | \$ 1,922.40   |

**EXHIBIT C1**

**Purdue Pharma L.P.**

**Case No. 19-23649**

Bankruptcy Tax Consulting Services  
December 23, 2019 through January 31, 2020

| <b>Name</b>        | <b>Date</b> | <b>Description</b>   | <b>Hours</b> | <b>Rate</b> | <b>Amount</b> |
|--------------------|-------------|--|--------------|-------------|---------------|
| Jess Commisso      | 01/10/20    | Continue (same day) to create assigned portion of overall jurisdiction prioritization for Mundipharma entities, based on profit & loss information provided by the client, pursuant to the engagement of additional KPMG member firms.   | 3.9          | \$ 350      | \$ 1,365.00   |
| Devon Rowles       | 01/10/20    | Continued, from earlier in the day, to create designated portion of overall jurisdiction prioritization for Mundipharma entities - based on company personnel information provided by the client - pursuant to the engagement of additional KPMG member firms.   | 3.9          | \$ 350      | \$ 1,365.00   |
| Dawn Krishnamurthy | 01/11/20    | Review of Norton Rose data room information for purposes of gaining insight regarding structure and tax profile of Mundipharma entities.   | 2.1          | \$ 695      | \$ 1,459.50   |
| Dawn Krishnamurthy | 01/11/20    | 1.1 Review of tax profile of Purdue and Mundipharma entities for the purpose of gaining insight regarding the structure and identifying open items/questions; 2.3 Continue review (same day) of Purdue and Mundipharma structure charts and information provided in the data room for purposes of identifying issues and preliminary questions | 3.4          | \$ 695      | \$ 2,363.00   |
| Dawn Krishnamurthy | 01/12/20    | 1.3 Review of Norton Rose Independent Affiliated Company (IAC) Tax Meeting Combined file with focus on calculations/trust structure; 1.0 Review of rules with respect to taxation of distributions between trusts.   | 2.3          | \$ 695      | \$ 1,598.50   |
| Andy Farinich      | 01/13/20    | Conference with P. DiMatteo and A. Farinich (both KPMG) to discuss creating a visual depiction of the Norton Rose Calculations on the organizational charts provided by client   | 0.3          | \$ 534      | \$ 160.20     |
| Pete DiMatteo      | 01/13/20    | Conference with P. DiMatteo and A. Farinich (both KPMG) to discuss creating a visual depiction of the Norton Rose Calculations on the organizational charts provided by client   | 0.3          | \$ 650      | \$ 195.00     |
| Oron Zeevi         | 01/13/20    | Discussion with A. Eytan (KPMG) regarding the Purdue Pharma structure in Israel with regards to tax analysis to be performed   | 0.3          | \$ 450      | \$ 135.00     |
| Arik Eytan         | 01/13/20    | Discussion with O. Zeevi (KPMG) regarding the Purdue Pharma structure in Israel with regards to tax analysis to be performed   | 0.3          | \$ 555      | \$ 166.50     |

**EXHIBIT C1**

**Purdue Pharma L.P.**

**Case No. 19-23649**

Bankruptcy Tax Consulting Services  
December 23, 2019 through January 31, 2020

| <b>Name</b>     | <b>Date</b> | <b>Description</b>   | <b>Hours</b> | <b>Rate</b> | <b>Amount</b> |
|-----------------|-------------|--|--------------|-------------|---------------|
| Thomas Giordano | 01/13/20    | Continued, from 1/10, to review assigned portion of Purdue organizational structure materials (provided by client) and concurrently organized in excel format to facilitate use of data in the creation of an overall organization structure chart; <u>Note</u> : this was an extremely large task with review that included 3 different sources of client organizational information to compile a comprehensive listing of numerous Purdue entities, spanning 60 jurisdictions, while concurrently determining each entities relevant owner / ownership percentage. | 0.4          | \$ 350      | \$ 140.00     |
| Isaac Hirsch    | 01/13/20    | Managing Director review of updated IRL along with current version of the Purdue cash tax model - with regards to comments received from M&A team  | 0.5          | \$ 819      | \$ 409.50     |
| Jess Commisso   | 01/13/20    | Continue (same day) to update the cash tax model to include assumptions / sale analysis data provided by the client to develop disposition strategies of Mundipharma entities.   | 0.6          | \$ 350      | \$ 210.00     |
| Casey Nunez     | 01/13/20    | Senior Manager Review of latest round of updates to Purdue information request list as of 1/13/2020.   | 0.7          | \$ 744      | \$ 520.80     |
| Thomas Giordano | 01/13/20    | 0.3 Reviewed client provided computations associated with various distributions between entities in global organization structure; 0.5 depicted various distributions between entities in global organization structure based on client provided computations / organization structures.   | 0.8          | \$ 350      | \$ 280.00     |
| Oron Zeevi      | 01/13/20    | Performed initial review of Purdue Pharma's structure along with related financial statements  | 0.8          | \$ 450      | \$ 360.00     |
| Pete DiMatteo   | 01/13/20    | Review Norton Rose computations to determine plan to map cash flows on Norton Rose org charts for ease of review.  | 0.8          | \$ 650      | \$ 520.00     |
| Ashley Armfield | 01/13/20    | Revised draft of email to KPMG UK team relating to structuring of the disposition of Mundipharma assets and distribution of proceeds at the trust/beneficiary level pursuant to identifying applicable taxes for structuring per manager review comments received from D. Krishnamurthy (KPMG)   | 0.8          | \$ 534      | \$ 427.20     |
| Devon Rowles    | 01/13/20    | Meeting with M. Land (KPMG) and D. Rowles (KPMG) to discuss research into deductibility of settlement payment  | 1.1          | \$ 350      | \$ 385.00     |
| Michael Land    | 01/13/20    | Meeting with M. Land (KPMG) and D. Rowles (KPMG) to discuss research into deductibility of settlement payment  | 1.1          | \$ 534      | \$ 587.40     |

**EXHIBIT C1**

**Purdue Pharma L.P.**

**Case No. 19-23649**

Bankruptcy Tax Consulting Services  
December 23, 2019 through January 31, 2020

| <b>Name</b>      | <b>Date</b> | <b>Description</b>   | <b>Hours</b> | <b>Rate</b> | <b>Amount</b> |
|------------------|-------------|--|--------------|-------------|---------------|
| Andy Farinich    | 01/13/20    | Continue, from earlier in the day, to create a visual representation of the Norton Rose Calculations and concurrently incorporated cash-flows on the organizational charts provided by client; <u>Note</u> : this is a very large task because cash-flow depictions were made on PDF organizational charts (approximately 20 provided by client) to depict the flow of cash as a result of the scenario described in the Norton Rose Calculation and some scenarios depicted up to 25 steps, each of which was to be depicted on the corresponding organizational chart. The 20 scenarios compared and contrasted, from a dollar perspective, the differences between an asset sale versus stock sale of certain entities and the associated tax implications under each scenario and included where cash was moving - as a result of the particular scenario. | 1.2          | \$ 534      | \$ 640.80     |
| Andy Farinich    | 01/13/20    | Continued (from 1/10) to review organizational structure materials provided by client in order to finalize the excel workbook created (.7); drafted email to send to P. DiMatteo (KPMG) to review same with regards to the use of this data in the creation of an overall organizational structure chart (0.3); Drafted additional email to P. DiMatteo (KPMG) explaining the updates that were made to the excel file (with organization structure data) (0.2).   | 1.2          | \$ 534      | \$ 640.80     |
| Ashley Armfield  | 01/13/20    | Continued (same day) Meeting with J. Commisso and A. Armfield (both KPMG) to develop cash tax methodology based on prior discussions from management team, and next steps related to inputs and disposition scenario for Switzerland Mundipharma MEA GmbH.   | 1.4          | \$ 534      | \$ 747.60     |
| Jess Commisso    | 01/13/20    | Continued (same day) Meeting with J. Commisso and A. Armfield (both KPMG) to develop cash tax methodology based on prior discussions from management team, and next steps related to inputs and disposition scenario for Switzerland Mundipharma MEA GmbH.   | 1.4          | \$ 350      | \$ 490.00     |
| Thomas Heubach   | 01/13/20    | Performed analysis over 9 entities (screened on same day) with focus on determining how the entities are treated for tax purposes, i.e. taxed as a corporation or flow-through partnership based on the financial statements provided.   | 1.5          | \$ 750      | \$ 1,125.00   |
| Christian Schmid | 01/13/20    | Initial Partner review of Purdue Pharma documentation provided to date with regards to German tax analysis.  | 1.6          | \$ 985      | \$ 1,576.00   |
| Howard Steinberg | 01/13/20    | Performed Partner review of proposed information request list with regards to high priority jurisdictions  | 2.0          | \$ 856      | \$ 1,712.00   |



**EXHIBIT C1**

**Purdue Pharma L.P.**

**Case No. 19-23649**

Bankruptcy Tax Consulting Services  
December 23, 2019 through January 31, 2020

| <b>Name</b>        | <b>Date</b> | <b>Description</b>  | <b>Hours</b> | <b>Rate</b> | <b>Amount</b> |
|--------------------|-------------|---|--------------|-------------|---------------|
| Devon Rowles       | 01/13/20    | Begin review of documentation (case law, treasury regulations, etc.) to find pro/con support regarding the deductibility of restitution payments - pursuant to drafting a memo regarding deductibility of retribute payments for the debtors  | 2.1          | \$ 350      | \$ 735.00     |
| Ashley Armfield    | 01/13/20    | Developing US cash tax calculation for Switzerland Mundipharma MEA GmbH pursuant to preparing a draft cash tax model related to the disposition of certain entities.  | 2.5          | \$ 534      | \$ 1,335.00   |
| Devon Rowles       | 01/13/20    | (2.7) Update jurisdiction prioritization file to include a master summary pursuant to engaging additional KPMG member firms.  | 2.7          | \$ 350      | \$ 945.00     |
| Thomas Heubach     | 01/13/20    | Screening of the individual / consolidated audited financial statements (FS) under local GAAP for the financial years 2016, 2017 and 2018 for the following legal entities unless stated otherwise:<br>1. Germany Verwaltungsgesellschaft GmbH (0.4)<br>2. Krugmann GmbH (0.4)<br>3. Mundichemie GmbH (0.4)<br>4. Mundipharma Deutschland GmbH & Co. KG (0.4)<br>5. Mundipharma GmbH (0.4)<br>6. Mundipharma Medical GmbH (0.4)<br>7. Mundipharma Research GmbH & Co. KG (0.4)<br>8. Mundipharma Research Verwaltungsgesellschaft - (only FS 2016 provided) (0.2) | 3.0          | \$ 750      | \$ 2,250.00   |
| Dawn Krishnamurthy | 01/13/20    | 0.4 Manager review of updates to information request list (IRL) as of 1/13/2020 that incorporates KPMG member firm input. 0.6 Manager review of email to the UK member firm regarding tax consequences of distribution from UK entity to US entity; 2.1 review of Project Malta reports for tax relevant information.   | 3.1          | \$ 695      | \$ 2,154.50   |
| Ashley Armfield    | 01/13/20    | 1.4 Researching the deductibility of restitution payments pursuant to writing a KPMG opinion; 0.4 drafting email to D. Rowles (KPMG) relating to drafting memo of deductibility of restitution payment (including sources); 1.4 Drafting email to KPMG UK team relating to structuring of the disposition of Mundipharma assets and distribution of proceeds at the trust/beneficiary level pursuant to identifying applicable taxes for structuring.   | 3.2          | \$ 534      | \$ 1,708.80   |

**EXHIBIT C1**

**Purdue Pharma L.P.**

**Case No. 19-23649**

Bankruptcy Tax Consulting Services  
December 23, 2019 through January 31, 2020

| <b>Name</b>        | <b>Date</b> | <b>Description</b>  | <b>Hours</b> | <b>Rate</b> | <b>Amount</b> |
|--------------------|-------------|---|--------------|-------------|---------------|
| Devon Rowles       | 01/13/20    | (2.1) Reviewed documentation on the Prime Clerk docket for tax relevant information related to financial position, restitution payments, etc. (1.3) updating the term sheet structure deck to reflect additional comments received from M. Land (KPMG) in preparation to circulate to the entire KPMG project team  | 3.4          | \$ 350      | \$ 1,190.00   |
| Dawn Krishnamurthy | 01/13/20    | 1.2 Review of financial statements for high priority jurisdictions for tax exposure information; 0.8 Manager review of PowerPoint deck depiction of proposed settlement prepared by D. Rowles (KPMG). 1.4 Review of Project Malta reports with focus on tax exposures   | 3.4          | \$ 695      | \$ 2,363.00   |
| Michael Land       | 01/13/20    | Review of sell side diligence report for purposes of gaining insight regarding the Mundipharma entities.  | 3.4          | \$ 534      | \$ 1,815.60   |
| Sonia Stricker     | 01/13/20    | Compiled initial data related to Purdue Key Financials (sales, profit, balance sheet total and employees) for entities 6 - 8 for years 2016-2018 and for entry 9 for year 2016  | 3.6          | \$ 380      | \$ 1,368.00   |
| Pete DiMatteo      | 01/13/20    | Began to review entity-specific organization charts to compile a global list (in excel) of numerous Purdue Pharma entities for purposes of creating a global organization chart.  | 3.8          | \$ 650      | \$ 2,470.00   |
| Andy Farinich      | 01/13/20    | Began creating a visual representation of the Norton Rose Calculations and incorporated cash-flows on the org. charts provided by client; <u>Note</u> : this is a very large task because cash-flow depictions were made on PDF organizational charts (approximately 20 provided by client) to depict the flow of cash as a result of the scenario described in the Norton Rose Calculation and some scenarios depicted up to 25 steps, each of which was to be depicted on the corresponding organizational chart. The 20 scenarios compared and contrasted, from a dollar perspective, the differences between an asset sale versus stock sale of certain entities and the associated tax implications under each scenario and included where cash was moving - as a result of the particular scenario. | 3.9          | \$ 534      | \$ 2,082.60   |
| Thomas Giordano    | 01/13/20    | Continue, from earlier in the day, to review of assigned portion of Purdue organizational structure materials (provided by client) and concurrently organized in excel format to facilitate use of data in the creation of an overall organization structure chart; <u>Note</u> : this was an extremely large task with review that included 3 different sources of client organizational information to compile a comprehensive listing of numerous Purdue entities, spanning 60 jurisdictions, while concurrently determining each entities relevant owner / ownership percentage.  | 3.9          | \$ 350      | \$ 1,365.00   |

**EXHIBIT C1**

**Purdue Pharma L.P.**

**Case No. 19-23649**

Bankruptcy Tax Consulting Services  
December 23, 2019 through January 31, 2020

| <b>Name</b>     | <b>Date</b> | <b>Description</b>  | <b>Hours</b> | <b>Rate</b> | <b>Amount</b> |
|-----------------|-------------|---|--------------|-------------|---------------|
| Thomas Giordano | 01/13/20    | Continued, from same day, to review of assigned portion of Purdue organizational structure materials (provided by client) and concurrently organized in excel format to facilitate use of data in the creation of an overall organization structure chart; <u>Note</u> : this was an extremely large task with review that included 3 different sources of client organizational information to compile a comprehensive listing of numerous Purdue entities, spanning 60 jurisdictions, while concurrently determining each entities relevant owner / ownership percentage.   | 3.9          | \$ 350      | \$ 1,365.00   |
| Sonia Stricker  | 01/13/20    | Extract and concurrently compile initial data related to Purdue Key Financials (sales, profit, balance sheet total and employees) for entities 1 - 5 for years 2016-2018.   | 3.9          | \$ 380      | \$ 1,482.00   |
| Ashley Armfield | 01/13/20    | Meeting with J. Commisso and A. Armfield (both KPMG) to develop cash tax methodology based on prior discussions from management team, with specific regards to inputs / disposition scenarios for Switzerland Mundipharma MEA GmbH  | 3.9          | \$ 534      | \$ 2,082.60   |
| Jess Commisso   | 01/13/20    | Meeting with J. Commisso and A. Armfield (both KPMG) to develop cash tax methodology based on prior discussions from management team, with specific regards to inputs / disposition scenarios for Switzerland Mundipharma MEA GmbH  | 3.9          | \$ 350      | \$ 1,365.00   |
| Jess Commisso   | 01/13/20    | Updated the cash tax model to include assumptions / sale analysis data provided by the client, as of 1/13/20, to develop disposition strategies of Mundipharma entities.  | 3.9          | \$ 350      | \$ 1,365.00   |
| Andy Farinich   | 01/14/20    | Continued (same day) to create a visual representation of the Norton Rose Calculations and incorporated cash-flows on the org. charts provided by client; <u>Note</u> : this is a very large task because cash-flow depictions were made on PDF organizational charts (approximately 20 provided by client) to depict the flow of cash as a result of the scenario described in the Norton Rose Calculation and some scenarios depicted up to 25 steps, each of which was to be depicted on the corresponding organizational chart. The 20 scenarios compared and contrasted, from a dollar perspective, the differences between an asset sale versus stock sale of certain entities and the associated tax implications under each scenario and included where cash was moving - as a result of the particular scenario. | 0.3          | \$ 534      | \$ 160.20     |
| Oron Zeevi      | 01/14/20    | Draft email to J. Commisso (KPMG) with respect to the Purdue Pharma structure and shareholders tax status   | 0.4          | \$ 450      | \$ 180.00     |

**EXHIBIT C1**

**Purdue Pharma L.P.**

**Case No. 19-23649**

Bankruptcy Tax Consulting Services  
December 23, 2019 through January 31, 2020

| <b>Name</b>        | <b>Date</b> | <b>Description</b>  | <b>Hours</b> | <b>Rate</b> | <b>Amount</b> |
|--------------------|-------------|---|--------------|-------------|---------------|
| Dawn Krishnamurthy | 01/14/20    | Conference with I. Hirsch, D. Krishnamurthy, P. DiMatteo and M. Land (all KPMG) to discuss latest version of model and required updates.  | 0.9          | \$ 695      | \$ 625.50     |
| Isaac Hirsch       | 01/14/20    | Conference with I. Hirsch, D. Krishnamurthy, P. DiMatteo and M. Land (all KPMG) to discuss latest version of model and required updates.  | 0.9          | \$ 819      | \$ 737.10     |
| Michael Land       | 01/14/20    | Conference with I. Hirsch, D. Krishnamurthy, P. DiMatteo and M. Land (all KPMG) to discuss latest version of model and required updates.  | 0.9          | \$ 534      | \$ 480.60     |
| Pete DiMatteo      | 01/14/20    | Conference with I. Hirsch, D. Krishnamurthy, P. DiMatteo and M. Land (all KPMG) to discuss latest version of model and required updates.  | 0.9          | \$ 650      | \$ 585.00     |
| Ashley Armfield    | 01/14/20    | Perform Senior associate review of research results prepared by D. Rowles (KPMG) on restitution deduction pursuant to drafting a restitution memo   | 0.9          | \$ 534      | \$ 480.60     |
| Devon Rowles       | 01/14/20    | Continued, from earlier in the day, to perform tax research in Westlaw, BNA, etc. pursuant to writing a draft memo regarding the deductibility of restitution payments  | 1.1          | \$ 350      | \$ 385.00     |
| Ashley Armfield    | 01/14/20    | Meeting with M. Land and A. Armfield (both KPMG) to discuss preparation of cash tax model for purposes of project strategy and cashflow for Canada  | 1.1          | \$ 534      | \$ 587.40     |
| Michael Land       | 01/14/20    | Meeting with M. Land and A. Armfield (both KPMG) to discuss preparation of cash tax model for purposes of project strategy and cashflow for Canada  | 1.1          | \$ 534      | \$ 587.40     |
| Pete DiMatteo      | 01/14/20    | Review Norton Rose computational organization charts annotated by KPMG to depict cash flows from proposed asset and/or stock sales.   | 1.1          | \$ 650      | \$ 715.00     |
| Michael Land       | 01/14/20    | Review of Project Malta (sell side diligence report) volume 2 for purposes of gaining insight regarding the foreign company structure and activities  | 1.1          | \$ 534      | \$ 587.40     |
| Pete DiMatteo      | 01/14/20    | Continue (from 1/13) to review entity-specific organization charts to create an excel based global organization chart for purposes of generating global organization charts consisting of numerous Purdue Pharma entities | 1.5          | \$ 650      | \$ 975.00     |
| Jess Commisso      | 01/14/20    | Performed research on restitution deduction pursuant to the drafting a restitution memo.  | 1.8          | \$ 350      | \$ 630.00     |
| Ashley Armfield    | 01/14/20    | Meeting with M. Land, A. Armfield and J. Commisso (all KPMG) to discuss latest version of Purdue cash tax model and next steps related to possible updates.   | 1.9          | \$ 534      | \$ 1,014.60   |

**EXHIBIT C1**

**Purdue Pharma L.P.**

**Case No. 19-23649**

Bankruptcy Tax Consulting Services  
December 23, 2019 through January 31, 2020

| <b>Name</b>        | <b>Date</b> | <b>Description</b>  | <b>Hours</b> | <b>Rate</b> | <b>Amount</b> |
|--------------------|-------------|---|--------------|-------------|---------------|
| Jess Commisso      | 01/14/20    | Meeting with M. Land, A. Armfield and J. Commisso (all KPMG) to discuss latest version of Purdue cash tax model and next steps related to possible updates.   | 1.9          | \$ 350      | \$ 665.00     |
| Michael Land       | 01/14/20    | Meeting with M. Land, A. Armfield and J. Commisso (all KPMG) to discuss latest version of Purdue cash tax model and next steps related to possible updates.   | 1.9          | \$ 534      | \$ 1,014.60   |
| Thomas Heubach     | 01/14/20    | Performed analysis of Purdue structure for tax purposes, with specific regards to tracking down stand-alone taxed entities / tax grouping arrangements in place for income tax and VAT purposes, based on the financial statements provided.  | 2.0          | \$ 750      | \$ 1,500.00   |
| Dawn Krishnamurthy | 01/14/20    | 1.8 Drafted Manager review comments related to term sheet summary in PowerPoint (prepared for purposes of gaining insight regarding tax consequences of initial proposed transaction); 0.4 Review of similar bankruptcy case with regards to the deductibility of payments to claimants with regards to Purdue Pharma case - to gain insight regarding treatment under facts for a similarly situated taxpayer.       | 2.2          | \$ 695      | \$ 1,529.00   |
| Ashley Armfield    | 01/14/20    | Perform updates to model structure based on manager review comments (pursuant to cash tax model) with specific regards to inputs tab, sale analysis layout and coding.  | 2.3          | \$ 534      | \$ 1,228.20   |
| Devon Rowles       | 01/14/20    | Continue (same day) to review case law, treasury regulations, etc. to find pro/con support regarding the deductibility of restitution payments - pursuant to drafting a memo  | 2.4          | \$ 350      | \$ 840.00     |
| Sonia Stricker     | 01/14/20    | Compiled initial data on high-level facts / particularities / extraordinary transactions and arrangements (e.g. reorganizations, disposals, acquisitions, silent partnerships) out of the financial statements for entities 6 - 8 for years 2016 - 2018 and for entry 9 for year 2016.  | 2.5          | \$ 380      | \$ 950.00     |
| Thomas Heubach     | 01/14/20    | Analyzed the size, business purpose and financial situation (profitability, materiality) of each Purdue legal entity (2016-2018) with focus on each entities' business model, risk profile and maintained functions (e.g. holding, operating or special purpose entity; financing, procurement or distribution functions, etc.; low-risk, medium-risk or high-risk, main entrepreneur, customer-contract risks, etc.) | 2.8          | \$ 750      | \$ 2,100.00   |
| Sonia Stricker     | 01/14/20    | Compiled initial data on high-level facts / particularities / extraordinary transactions and arrangements (e.g. reorganizations, disposals, acquisitions, silent partnerships) out of the financial statements for Purdue entities 1 - 5 for years 2016-2018.   | 3.0          | \$ 380      | \$ 1,140.00   |

**EXHIBIT C1**

**Purdue Pharma L.P.**

**Case No. 19-23649**

Bankruptcy Tax Consulting Services  
December 23, 2019 through January 31, 2020

| <b>Name</b>        | <b>Date</b> | <b>Description</b>  | <b>Hours</b> | <b>Rate</b> | <b>Amount</b> |
|--------------------|-------------|---|--------------|-------------|---------------|
| Dawn Krishnamurthy | 01/14/20    | Review of "Malta" report (a sell side diligence report) for purpose of identifying potential tax issues   | 3.3          | \$ 695      | \$ 2,293.50   |
| Dawn Krishnamurthy | 01/14/20    | 2.2 Manager review of project team comments to information request list while concurrently cross checking against Norton Rose structure decks for purpose of finalizing information requests; 1.3 Performed Manager review of restitution payment research for purpose of gaining insight regarding tax treatment   | 3.5          | \$ 695      | \$ 2,432.50   |
| Jess Commisso      | 01/14/20    | Additional updates to the Purdue cash tax model to include assumptions / sale analysis data provided by the client to develop disposition strategies of Mundipharma entities  | 3.9          | \$ 350      | \$ 1,365.00   |
| Andy Farinich      | 01/14/20    | Continue (from earlier in the day) to create a visual representation of the Norton Rose Calculations and incorporated cash-flows on the org. charts provided by client; <u>Note</u> : this is a very large task because cash-flow depictions were made on PDF organizational charts (approximately 20 provided by client) to depict the flow of cash as a result of the scenario described in the Norton Rose Calculation and some scenarios depicted up to 25 steps, each of which was to be depicted on the corresponding organizational chart. The 20 scenarios compared and contrasted, from a dollar perspective, the differences between an asset sale versus stock sale of certain entities and the associated tax implications under each scenario and included where cash was moving - as a result of the particular scenario. | 3.9          | \$ 534      | \$ 2,082.60   |
| Thomas Giordano    | 01/14/20    | Continue, from 1/13, to review of assigned portion of Purdue organizational structure materials (provided by client) and concurrently organized in excel format to facilitate use of data in the creation of an overall organization structure chart; <u>Note</u> : this was an extremely large task with review that included 3 different sources of client organizational information to compile a comprehensive listing of numerous Purdue entities, spanning 60 jurisdictions, while concurrently determining each entities relevant owner / ownership percentage.  | 3.9          | \$ 350      | \$ 1,365.00   |
| Devon Rowles       | 01/14/20    | Continue, from previous day, to review case law, treasury regulations, etc. to find pro/con support regarding the deductibility of restitution payments - pursuant to drafting a memo   | 3.9          | \$ 350      | \$ 1,365.00   |

**EXHIBIT C1**

**Purdue Pharma L.P.**

**Case No. 19-23649**

Bankruptcy Tax Consulting Services  
December 23, 2019 through January 31, 2020

| <b>Name</b>     | <b>Date</b> | <b>Description</b>  | <b>Hours</b> | <b>Rate</b> | <b>Amount</b> |
|-----------------|-------------|---|--------------|-------------|---------------|
| Andy Farinich   | 01/14/20    | Continued (from 1/13) creating a visual representation of the Norton Rose Calculations and incorporated cash-flows on the org. charts provided by client; <u>Note</u> : this is a very large task because cash-flow depictions were made on PDF organizational charts (approximately 20 provided by client) to depict the flow of cash as a result of the scenario described in the Norton Rose Calculation and some scenarios depicted up to 25 steps, each of which was to be depicted on the corresponding organizational chart. The 20 scenarios compared and contrasted, from a dollar perspective, the differences between an asset sale versus stock sale of certain entities and the associated tax implications under each scenario and included where cash was moving - as a result of the particular scenario. | 3.9          | \$ 534      | \$ 2,082.60   |
| Jess Commisso   | 01/14/20    | Mapping out sale calculations of Mundipharma MEA and Mundipharma DC BV with focus on where values are derived from / where clarification from client is necessary.  | 3.9          | \$ 350      | \$ 1,365.00   |
| Ashley Armfield | 01/14/20    | Meeting with M. Land and A. Armfield (both KPMG) to continue (from same day) discussions regarding preparation of cash tax model for purposes of project strategy and cash flow for Switzerland   | 3.9          | \$ 534      | \$ 2,082.60   |
| Michael Land    | 01/14/20    | Meeting with M. Land and A. Armfield (both KPMG) to continue (from same day) discussions regarding preparation of cash tax model for purposes of project strategy and cash flow for Switzerland   | 3.9          | \$ 534      | \$ 2,082.60   |
| Ashley Armfield | 01/14/20    | Meeting with M. Land and A. Armfield (both KPMG) to discuss preparation of cash tax model for purposes of project strategy and cashflow on general inputs tabs  | 3.9          | \$ 534      | \$ 2,082.60   |
| Michael Land    | 01/14/20    | Meeting with M. Land and A. Armfield (both KPMG) to discuss preparation of cash tax model for purposes of project strategy and cashflow on general inputs tabs  | 3.9          | \$ 534      | \$ 2,082.60   |
| Devon Rowles    | 01/14/20    | Performed tax research in Westlaw, BNA, etc. pursuant to writing a draft memo regarding the deductibility of restitution payments   | 3.9          | \$ 350      | \$ 1,365.00   |

**EXHIBIT C1**

**Purdue Pharma L.P.**

**Case No. 19-23649**

Bankruptcy Tax Consulting Services  
December 23, 2019 through January 31, 2020

| <b>Name</b>     | <b>Date</b> | <b>Description</b>  | <b>Hours</b> | <b>Rate</b> | <b>Amount</b> |
|-----------------|-------------|---|--------------|-------------|---------------|
| Thomas Giordano | 01/14/20    | Continue, from earlier in the day, to review assigned portion of Purdue organizational structure materials (provided by client) and concurrently organized in excel format to facilitate use of data in the creation of an overall organization structure chart; <u>Note</u> : this was an extremely large task with review that included 3 different sources of client organizational information to compile a comprehensive listing of numerous Purdue entities, spanning 60 jurisdictions, while concurrently determining each entities relevant owner / ownership percentage. | 4.1          | \$ 350      | \$ 1,435.00   |
| Karen Erickson  | 01/15/20    | Conference call with P. DiMatteo, T. Giordano and K. Erickson (all KPMG) to discuss the excel formatted global organization structure to facilitate creation of a global organization structure chart.  | 0.4          | \$ 690      | \$ 276.00     |
| Pete DiMatteo   | 01/15/20    | Conference call with P. DiMatteo, T. Giordano and K. Erickson (all KPMG) to discuss the excel formatted global organization structure to facilitate creation of a global organization structure chart.  | 0.4          | \$ 650      | \$ 260.00     |
| Thomas Giordano | 01/15/20    | Conference call with P. DiMatteo, T. Giordano and K. Erickson (all KPMG) to discuss the excel formatted global organization structure to facilitate creation of a global organization structure chart.  | 0.4          | \$ 350      | \$ 140.00     |
| Devon Rowles    | 01/15/20    | Continue - on same day - to analyze provided by client documentation involving an asset versus stock sale calculation of various Mundipharma entities to provide clarification on cash flow - as began on same day.   | 0.6          | \$ 350      | \$ 210.00     |
| Devon Rowles    | 01/15/20    | Continued, from earlier in the day, to perform tax research in Westlaw, BNA, etc. pursuant to writing a draft memo regarding the deductibility of restitution payments.   | 0.6          | \$ 350      | \$ 210.00     |
| Pete DiMatteo   | 01/15/20    | Continued (from 1/14) to review of entity-specific organization charts to create an excel based global organization chart for purposes of generating global organization charts consisting of numerous Purdue Pharma entities   | 1.1          | \$ 650      | \$ 715.00     |
| Ashley Armfield | 01/15/20    | Creating US Tax calculation tab in the cash tax model to calculate individual shareholder taxation for US federal income and state tax purposes (flowing from Foreign tax credits tab).   | 1.9          | \$ 534      | \$ 1,014.60   |



**EXHIBIT C1**

**Purdue Pharma L.P.**

**Case No. 19-23649**

Bankruptcy Tax Consulting Services  
December 23, 2019 through January 31, 2020

| <b>Name</b>        | <b>Date</b> | <b>Description</b>  | <b>Hours</b> | <b>Rate</b> | <b>Amount</b> |
|--------------------|-------------|---|--------------|-------------|---------------|
| Sonia Stricker     | 01/15/20    | Compiled information on tax profile, tax compliance status (years for which tax returns have been filed and assessed, open tax years, tax payments), tax audit status (tax years covered by the audit, open tax years) for entities 6 - 8 for years 2016 - 2018 and for entry 9 for year 2016 based on the financial statements provided. | 2.0          | \$ 380      | \$ 760.00     |
| Dawn Krishnamurthy | 01/15/20    | 2.2 Review of PLCONV_LEG_LR 10.12.19.xlsx, tax litigation file, Project Malta Reports, EY flowchart, Term Sheet, etc. (performed concurrently to cross-check information) in preparation for Norton Rose meeting.   | 2.2          | \$ 695      | \$ 1,529.00   |
| Jess Commisso      | 01/15/20    | Continued (same day) to analyze assigned portion of PBC documentation involving an asset versus stock sale calculation of various Mundipharma entities to provide clarification on cash flow; this task required a detailed analysis of cash flow calculations related to the sales of a total of 8 Mundipharma entities.                 | 2.4          | \$ 350      | \$ 840.00     |
| Sonia Stricker     | 01/15/20    | Compiled information on tax profile, tax compliance status (years for which tax returns have been filed and assessed, open tax years, tax payments), tax audit status (tax years covered by the audit, open tax years) for entities 1 - 5 for years 2016 - 2018 based on the financial statements provided.                               | 2.5          | \$ 380      | \$ 950.00     |
| Dawn Krishnamurthy | 01/15/20    | 1.2 Manager review of draft Organization Listing compiled - with focus on Mundipharma structure; 1.4 Manager review of material jurisdiction calculations (including supporting information); 0.2 Manager review of draft email regarding deductibility of restitution payments   | 2.8          | \$ 695      | \$ 1,946.00   |
| Ashley Armfield    | 01/15/20    | 1.9 Updating cash tax model to include Mundipharma Singapore Holding Pte. Limited disposition scenario; 0.9 Updated cash tax model in preparation for manager review / external presentation.   | 2.8          | \$ 534      | \$ 1,495.20   |
| Casey Nunez        | 01/15/20    | Finalized updates to initial information request list based on virtual data room review   | 2.8          | \$ 744      | \$ 2,083.20   |
| Dawn Krishnamurthy | 01/15/20    | Performed Manager review of Independent Affiliated Company (IAC) combined structure file  | 2.8          | \$ 695      | \$ 1,946.00   |
| Ashley Armfield    | 01/15/20    | Updating foreign tax credits calculation tab in the cash tax model to serve as a baseline for future calculations pursuant to forecasting expected cash taxes.  | 2.8          | \$ 534      | \$ 1,495.20   |
| Ashley Armfield    | 01/15/20    | 1.7 Updating cash tax model to include Napp Pharmaceutical Holdings Limited disposition scenario; 1.2 Updating cash tax model to include Mundipharma Deutschland GmbH & Co. KG disposition scenario.  | 2.9          | \$ 534      | \$ 1,548.60   |

**EXHIBIT C1**

**Purdue Pharma L.P.**

**Case No. 19-23649**

Bankruptcy Tax Consulting Services  
December 23, 2019 through January 31, 2020

| <b>Name</b>   | <b>Date</b> | <b>Description</b>   | <b>Hours</b> | <b>Rate</b> | <b>Amount</b> |
|---------------|-------------|--|--------------|-------------|---------------|
| Jess Commisso | 01/15/20    | Revised the cash tax model by including assumptions / updated Mundipharma entity data to develop disposition strategies of Mundipharma entities.   | 2.9          | \$ 350      | \$ 1,015.00   |
| Michael Land  | 01/15/20    | 2.4 Senior associate review of summary of deduction analysis under Code section 162 for purposes of gaining insight regarding the deductibility of settlement payments; 0.6 review of information request list / virtual data room documentation to determine if additional information was provided as of 1/15/2020; 0.2 Performed Senior Associate review of most recent round of assumptions for Purdue cash tax model as of 1/15/2020. | 3.2          | \$ 534      | \$ 1,708.80   |
| Renay Gosen   | 01/15/20    | Research section 170 charitable contribution deduction in relation to writing memo showing whether settlement payments to the public could be categorized as a "charitable contribution."  | 3.2          | \$ 350      | \$ 1,120.00   |
| Devon Rowles  | 01/15/20    | Analyzed designated portion of provided by client documentation involving an asset versus stock sale calculation of various Mundipharma entities to provide clarification on cash flow.  | 3.9          | \$ 350      | \$ 1,365.00   |
| Jess Commisso | 01/15/20    | Began to analyze assigned portion of provided by client (PBC) documentation involving an asset versus stock sale calculation of various Mundipharma entities to provide clarification on cash flow; this task required a detailed analysis of cash flow calculations related to the sales of a total of 8 Mundipharma entities.  | 3.9          | \$ 350      | \$ 1,365.00   |
| Devon Rowles  | 01/15/20    | Continue (from previous day) to perform tax research in Westlaw, BNA, etc. pursuant to writing a draft memo regarding the deductibility of restitution payments  | 3.9          | \$ 350      | \$ 1,365.00   |
| Jess Commisso | 01/15/20    | Continue, on same day, to analyze assigned portion of PBC documentation involving an asset versus stock sale calculation of various Mundipharma entities to provide clarification on cash flow; this task required a detailed analysis of cash flow calculations related to the sales of a total of 8 Mundipharma entities.  | 3.9          | \$ 350      | \$ 1,365.00   |
| Jess Commisso | 01/15/20    | Continued (from earlier in the day) to analyze assigned portion of PBC documentation involving an asset versus stock sale calculation of various Mundipharma entities to provide clarification on cash flow; this task required a detailed analysis of cash flow calculations related to the sales of a total of 8 Mundipharma entities.   | 3.9          | \$ 350      | \$ 1,365.00   |
| Devon Rowles  | 01/15/20    | Draft memo regarding the deductibility of restitution payments for a more-likely-than-not tax position.  | 3.9          | \$ 350      | \$ 1,365.00   |

**EXHIBIT C1**

**Purdue Pharma L.P.**

**Case No. 19-23649**

Bankruptcy Tax Consulting Services  
December 23, 2019 through January 31, 2020

| <b>Name</b>        | <b>Date</b> | <b>Description</b>   | <b>Hours</b> | <b>Rate</b> | <b>Amount</b> |
|--------------------|-------------|--|--------------|-------------|---------------|
| Michael Land       | 01/15/20    | Meeting with M. Land and A. Armfield (KPMG) to discuss various cash tax inputs in relation to impact on overall cash tax model   | 3.9          | \$ 534      | \$ 2,082.60   |
| Ashley Armfield    | 01/15/20    | Meeting with M. Land and A. Armfield (KPMG) to discuss various cash tax inputs in relation to impact on overall cash tax model   | 3.9          | \$ 534      | \$ 2,082.60   |
| Ashley Armfield    | 01/15/20    | Meeting between M. Land and A. Armfield (both KPMG) to discuss foreign tax credits inputs to cash tax model  | 3.9          | \$ 534      | \$ 2,082.60   |
| Michael Land       | 01/15/20    | Meeting between M. Land and A. Armfield (both KPMG) to discuss foreign tax credits inputs to cash tax model  | 3.9          | \$ 534      | \$ 2,082.60   |
| Casey Nunez        | 01/15/20    | Meeting with H. Steinberg and C. Nunez (both KPMG) for purpose of clarifying and reducing information requests; this was a meeting reviewing, in detail, our workplan as well as the related information request list before they were to be sent to attorneys regarding numerous Purdue Pharma entities with focus on nine jurisdictions including: 1. Australia, 2. Canada, 3. China, 4. Germany, 5. Israel, 6. Italy, 7. Netherlands, 8. South Korea and 9. UK. | 3.9          | \$ 744      | \$ 2,901.60   |
| Howard Steinberg   | 01/15/20    | Meeting with H. Steinberg and C. Nunez (both KPMG) for purpose of clarifying and reducing information requests; this was a meeting reviewing, in detail, our workplan as well as the related information request list before they were to be sent to attorneys regarding numerous Purdue Pharma entities with focus on nine jurisdictions including: 1. Australia, 2. Canada, 3. China, 4. Germany, 5. Israel, 6. Italy, 7. Netherlands, 8. South Korea and 9. UK. | 3.9          | \$ 856      | \$ 3,338.40   |
| Dawn Krishnamurthy | 01/15/20    | Meeting with H. Steinberg and C. Nunez (both KPMG) for purpose of clarifying and reducing information requests; this was a meeting reviewing, in detail, our workplan as well as the related information request list before they were to be sent to attorneys regarding numerous Purdue Pharma entities with focus on nine jurisdictions including: 1. Australia, 2. Canada, 3. China, 4. Germany, 5. Israel, 6. Italy, 7. Netherlands, 8. South Korea and 9. UK. | 3.9          | \$ 695      | \$ 2,710.50   |
| Michael Land       | 01/15/20    | Performed research regarding deduction of settlement payment for purposes of cash tax model.   | 3.9          | \$ 534      | \$ 2,082.60   |
| Devon Rowles       | 01/15/20    | Review of additional documentation (case law, treasury regulations, etc.) to find pro/con support regarding the deductibility of restitution payments - pursuant to drafting a memo  | 3.9          | \$ 350      | \$ 1,365.00   |
| Dawn Krishnamurthy | 01/16/20    | Communication with I. Hirsch KPMG) regarding objectives related to Norton Rose meeting (on same day).  | 0.2          | \$ 695      | \$ 139.00     |

**EXHIBIT C1**

**Purdue Pharma L.P.**

**Case No. 19-23649**

Bankruptcy Tax Consulting Services  
December 23, 2019 through January 31, 2020

| <b>Name</b>        | <b>Date</b> | <b>Description</b>   | <b>Hours</b> | <b>Rate</b> | <b>Amount</b> |
|--------------------|-------------|--|--------------|-------------|---------------|
| Dawn Krishnamurthy | 01/16/20    | Participated in post-Norton Rose debrief meeting with H. Steinberg, M. Hoffenberg, I. Hirsch and D. Krishnamurthy (all KPMG) for the purpose of addressing issues raised by Debevoise and Norton Rose, including scope of analysis and availability of tax information | 0.3          | \$ 695      | \$ 208.50     |
| Howard Steinberg   | 01/16/20    | Participated in post-Norton Rose debrief meeting with H. Steinberg, M. Hoffenberg, I. Hirsch and D. Krishnamurthy (all KPMG) for the purpose of addressing issues raised by Debevoise and Norton Rose, including scope of analysis and availability of tax information | 0.3          | \$ 856      | \$ 256.80     |
| Isaac Hirsch       | 01/16/20    | Participated in post-Norton Rose debrief meeting with H. Steinberg, M. Hoffenberg, I. Hirsch and D. Krishnamurthy (all KPMG) for the purpose of addressing issues raised by Debevoise and Norton Rose, including scope of analysis and availability of tax information | 0.3          | \$ 819      | \$ 245.70     |
| Mark Hoffenberg    | 01/16/20    | Participated in post-Norton Rose debrief meeting with H. Steinberg, M. Hoffenberg, I. Hirsch and D. Krishnamurthy (all KPMG) for the purpose of addressing issues raised by Debevoise and Norton Rose, including scope of analysis and availability of tax information | 0.3          | \$ 980      | \$ 294.00     |
| Sonia Stricker     | 01/16/20    | Meeting with S. Stricker and T. Heubach (both KPMG) to update information request list based on data received to date and add additional required documents.   | 1.0          | \$ 380      | \$ 380.00     |
| Thomas Heubach     | 01/16/20    | Meeting with S. Stricker and T. Heubach (both KPMG) to update information request list based on data received to date and add additional required documents.   | 1.0          | \$ 750      | \$ 750.00     |
| Michael Land       | 01/16/20    | 0.3 Updates to Purdue cash tax model with regards to German foreign branch tax; 0.8 review of updated information request list received.   | 1.1          | \$ 534      | \$ 587.40     |
| Thomas Giordano    | 01/16/20    | Continue (same day) to conduct research to determine entitlement to a tax deduction for settlement payments including review and analysis of statutory and common law.   | 1.1          | \$ 350      | \$ 385.00     |
| Dawn Krishnamurthy | 01/16/20    | 1.0 Review of data room documentation for purpose of gaining an understanding regarding tax exam/audit profile of Canada, China, Germany, Israel, Italy, Netherlands, South Korea, Switzerland, UK; 0.4 Review of Project Malta reports.                               | 1.4          | \$ 695      | \$ 973.00     |
| Christian Schmid   | 01/16/20    | Partner review of interim collection of data prepared by T. Heubach and S. Stricker (both KPMG Germany).   | 1.4          | \$ 985      | \$ 1,379.00   |

**EXHIBIT C1**

**Purdue Pharma L.P.**

**Case No. 19-23649**

Bankruptcy Tax Consulting Services  
December 23, 2019 through January 31, 2020

| <b>Name</b>        | <b>Date</b> | <b>Description</b>  | <b>Hours</b> | <b>Rate</b> | <b>Amount</b> |
|--------------------|-------------|---|--------------|-------------|---------------|
| Dawn Krishnamurthy | 01/16/20    | Meeting with J. Rosen (Debevoise), J. Robins, L. Kelly and L. Schreyer (all Norton Rose), H. Steinberg, M. Hoffenberg, I. Hirsch and D. Krishnamurthy (all KPMG) at Norton Rose to discuss priority jurisdictions, initial tax request list items and modeling considerations, including assumptions used in Norton Rose's model. | 2.0          | \$ 695      | \$ 1,390.00   |
| Howard Steinberg   | 01/16/20    | Meeting with J. Rosen (Debevoise), J. Robins, L. Kelly and L. Schreyer (all Norton Rose), H. Steinberg, M. Hoffenberg, I. Hirsch and D. Krishnamurthy (all KPMG) at Norton Rose to discuss priority jurisdictions, initial tax request list items and modeling considerations, including assumptions used in Norton Rose's model. | 2.0          | \$ 856      | \$ 1,712.00   |
| Isaac Hirsch       | 01/16/20    | Meeting with J. Rosen (Debevoise), J. Robins, L. Kelly and L. Schreyer (all Norton Rose), H. Steinberg, M. Hoffenberg, I. Hirsch and D. Krishnamurthy (all KPMG) at Norton Rose to discuss priority jurisdictions, initial tax request list items and modeling considerations, including assumptions used in Norton Rose's model. | 2.0          | \$ 819      | \$ 1,638.00   |
| Mark Hoffenberg    | 01/16/20    | Meeting with J. Rosen (Debevoise), J. Robins, L. Kelly and L. Schreyer (all Norton Rose), H. Steinberg, M. Hoffenberg, I. Hirsch and D. Krishnamurthy (all KPMG) at Norton Rose to discuss priority jurisdictions, initial tax request list items and modeling considerations, including assumptions used in Norton Rose's model. | 2.0          | \$ 980      | \$ 1,960.00   |
| Isaac Hirsch       | 01/16/20    | Preparation for meeting with Norton Rose (on same day), including review of Norton Rose calculation (1.5), KPMG in-process cash tax model (0.7), and Purdue organizational charts (0.4).  | 2.6          | \$ 819      | \$ 2,129.40   |
| Thomas Heubach     | 01/16/20    | Review of interim collection of data prepared by S. Stricker (KPMG Germany) and reconcile concurrently with financial statements.   | 3.2          | \$ 750      | \$ 2,400.00   |
| Dawn Krishnamurthy | 01/16/20    | Performed analysis to compare calculations of asset versus stock scenarios in Norton Rose calculations in comparison to KPMG draft model.   | 3.3          | \$ 695      | \$ 2,293.50   |
| Devon Rowles       | 01/16/20    | (2.2) Continued to analyze designated portion of provided by client (PBC) documentation involving an asset versus stock sale calculation of various Mundipharma entities to provide clarification on cash flow; (1.2) update the information request list to account for all provided by client information as of 1/16/2020.      | 3.4          | \$ 350      | \$ 1,190.00   |

**EXHIBIT C1**

**Purdue Pharma L.P.**

**Case No. 19-23649**

Bankruptcy Tax Consulting Services  
December 23, 2019 through January 31, 2020

| <b>Name</b>        | <b>Date</b> | <b>Description</b>   | <b>Hours</b> | <b>Rate</b> | <b>Amount</b> |
|--------------------|-------------|--|--------------|-------------|---------------|
| Ashley Armfield    | 01/16/20    | 1.4 Senior associate review of priority jurisdiction file pursuant to providing information to team for client/banker meeting; 2.1 Senior associate review of KPMG review of Norton Rose calculation and concurrently noted outstanding items.   | 3.5          | \$ 534      | \$ 1,869.00   |
| Jess Commisso      | 01/16/20    | Continue (from 1/15) to analyze assigned portion of PBC documentation involving an asset versus stock sale calculation of various Mundipharma entities to provide clarification on cash flow; this task required a detailed analysis of cash flow calculations related to the sales of a total of 8 Mundipharma entities.  | 3.6          | \$ 350      | \$ 1,260.00   |
| Dawn Krishnamurthy | 01/16/20    | 2.7 Continued review of tax profile by jurisdiction for purposes of identifying material jurisdictions; 1.2 Updates to information requests based on Norton Rose Meeting Notes   | 3.9          | \$ 695      | \$ 2,710.50   |
| Thomas Giordano    | 01/16/20    | Began to conduct research to determine entitlement to a tax deduction for settlement payments including review and analysis of statutory and common law.   | 3.9          | \$ 350      | \$ 1,365.00   |
| Thomas Giordano    | 01/17/20    | Continued to perform research to determine rules surrounding foreign tax payments and potential tax benefits to be obtained from such payments - (as began on same day).   | 0.9          | \$ 350      | \$ 315.00     |
| Isaac Hirsch       | 01/17/20    | Performed Managing Director review of review of IRM updates by D. Krishnamurthy (KPMG) and concurrently draft review comments  | 1.1          | \$ 819      | \$ 900.90     |
| Thomas Giordano    | 01/17/20    | 0.8 Continued, from previous day, to conduct research to determine entitlement to a tax deduction for settlement payments including review and analysis of statutory and common law; 0.5 drafted outline of initial findings based on research performed to determine entitlement to a tax deduction for settlement payments including review and analysis of statutory and common law | 1.3          | \$ 350      | \$ 455.00     |
| Michael Land       | 01/17/20    | Review of cash tax model with regards to partnership waterfall allocations in the United Kingdom   | 1.3          | \$ 534      | \$ 694.20     |
| Pete DiMatteo      | 01/17/20    | Performed analysis regarding mechanics of foreign tax credits for trusts/individuals for purposes of refining overall tax cost model   | 1.6          | \$ 650      | \$ 1,040.00   |
| Howard Steinberg   | 01/17/20    | Performed Partner review of information request list updates related to high priority jurisdictions  | 1.7          | \$ 856      | \$ 1,455.20   |
| Dawn Krishnamurthy | 01/17/20    | 1.1 Continued (from 1/16) review of data room documents for purpose of identifying most relevant jurisdictions from a tax perspective; 0.7 Updates to information request list based on information provided by Norton Rose with respect to Switzerland.   | 1.8          | \$ 695      | \$ 1,251.00   |

**EXHIBIT C1**

**Purdue Pharma L.P.**

**Case No. 19-23649**

Bankruptcy Tax Consulting Services  
December 23, 2019 through January 31, 2020

| <b>Name</b>        | <b>Date</b> | <b>Description</b>   | <b>Hours</b> | <b>Rate</b> | <b>Amount</b> |
|--------------------|-------------|--|--------------|-------------|---------------|
| Jess Commisso      | 01/17/20    | Review of documentation in virtual data room as of 1/17/2020 to determine if we need to request the client provided structure charts, trust documentation or partnership agreements pursuant to further diligence of Mundipharma entities.   | 2.8          | \$ 350      | \$ 980.00     |
| Casey Nunez        | 01/17/20    | 0.8 Senior manager review of updated information request list based on feedback from January 16th meeting with Norton Rose and Debevoise; 1.9 review of new Purdue Pharma documentation available in data room as of 1/17; 0.6 review of sell side diligence report for Project Malta. | 3.3          | \$ 744      | \$ 2,455.20   |
| Dawn Krishnamurthy | 01/17/20    | Review of structure charts / financial statements to gain insight regarding tax impacts of potential sale scenarios in high priority jurisdictions.  | 3.3          | \$ 695      | \$ 2,293.50   |
| Thomas Giordano    | 01/17/20    | Performed research to determine rules surrounding foreign tax payments and potential tax benefits to be obtained from such payments.   | 3.9          | \$ 350      | \$ 1,365.00   |
| Howard Steinberg   | 01/18/20    | Partner review of virtual data room information received as of 1/18/20 for purposes of determining relevant tax information available.   | 1.0          | \$ 856      | \$ 856.00     |
| Dawn Krishnamurthy | 01/18/20    | Continue, from earlier in the day, to review documentation in the Norton Rose data room for purpose of determining most significant jurisdictions/identifying areas of focus.  | 1.4          | \$ 695      | \$ 973.00     |
| Dawn Krishnamurthy | 01/18/20    | Review of information provided in the Norton Rose data room as of 1/18/20, including Project Malta reports, financial statements and litigation summaries with regards to updating the information request list.   | 2.8          | \$ 695      | \$ 1,946.00   |
| Dawn Krishnamurthy | 01/18/20    | Continued (same day) to review documents provided in data room as of 1/18/20 for purposes of updating / tailoring the information request list.  | 3.1          | \$ 695      | \$ 2,154.50   |
| Howard Steinberg   | 01/19/20    | Perform Partner review of financial statement summary for purposes of gaining insight regarding tax posture  | 1.5          | \$ 856      | \$ 1,284.00   |
| Dawn Krishnamurthy | 01/19/20    | Review of financial statements provided in Norton Rose data room for purposes of updating information request list.  | 3.4          | \$ 695      | \$ 2,363.00   |
| Pete DiMatteo      | 01/20/20    | Conference call with P. DiMatteo and T. Giordano (both KPMG) discussing the rules surrounding foreign tax payments and potential tax benefits to be obtained from such payments.   | 0.4          | \$ 650      | \$ 260.00     |
| Thomas Giordano    | 01/20/20    | Conference call with P. DiMatteo and T. Giordano (both KPMG) discussing the rules surrounding foreign tax payments and potential tax benefits to be obtained from such payments.   | 0.4          | \$ 350      | \$ 140.00     |

**EXHIBIT C1**

**Purdue Pharma L.P.**

**Case No. 19-23649**

Bankruptcy Tax Consulting Services  
December 23, 2019 through January 31, 2020

| <b>Name</b>        | <b>Date</b> | <b>Description</b>  | <b>Hours</b> | <b>Rate</b> | <b>Amount</b> |
|--------------------|-------------|---|--------------|-------------|---------------|
| Dawn Krishnamurthy | 01/20/20    | Discussion with M. Land and D. Krishnamurthy (KPMG) to discuss status of ongoing tax reserves and audits as related to project Malta (sell side diligence report).  | 0.4          | \$ 695      | \$ 278.00     |
| Michael Land       | 01/20/20    | Discussion with M. Land and D. Krishnamurthy (KPMG) to discuss status of ongoing tax reserves and audits as related to project Malta (sell side diligence report).  | 0.4          | \$ 534      | \$ 213.60     |
| Thomas Heubach     | 01/20/20    | Communication via email with D. Krishnamurthy (KPMG US) and P. Reer (KPMG Partner German Int'l Tax) regarding various items related to Purdue Pharma including process to update information request and best approach/next steps related to tax consulting services to be provided.  | 0.5          | \$ 750      | \$ 375.00     |
| Howard Steinberg   | 01/20/20    | Call with H. Steinberg (KPMG), M. Hoffenberg (KPMG) and counsel at Akin regarding Norton Rose due diligence process   | 0.8          | \$ 856      | \$ 684.80     |
| Mark Hoffenberg    | 01/20/20    | Call with H. Steinberg (KPMG), M. Hoffenberg (KPMG) and counsel at Akin regarding Norton Rose due diligence process   | 0.8          | \$ 980      | \$ 784.00     |
| Thomas Heubach     | 01/20/20    | Review and concurrently compare received Purdue information with IRL (0.5); follow up via email on missing information with D. Krishnamurthy (KPMG US) and P. Reer (KPMG Partner German Intl Tax) (0.3).  | 0.8          | \$ 750      | \$ 600.00     |
| Christian Schmid   | 01/20/20    | Partner review of Purdue Pharma information compiled to date from T. Heubach and S. Stricker (both KPMG Germany)  | 1.0          | \$ 985      | \$ 985.00     |
| Karen Erickson     | 01/20/20    | Prepared entity schedule (provided by P. DiMatteo and T. Giordano - both KPMG), addressing discrepancies, for import into Legal Entity Manager in support of charting (0.8) and exchange emails with P. DiMatteo and T. Giordano (both KPMG) re specific items in schedule, such as preferred equity and country confirmation as well as chart presentation preferences (0.4) | 1.2          | \$ 690      | \$ 828.00     |
| Isaac Hirsch       | 01/20/20    | Perform Managing Director review of updates to bankruptcy tax consulting workplan (0.8) and Purdue Pharma organizational charts as of 1/20/2020 (0.7)   | 1.5          | \$ 819      | \$ 1,228.50   |
| Ashley Armfield    | 01/20/20    | Senior Associate review of latest information request list to be sent to the client as of 1/20/2020.  | 1.5          | \$ 534      | \$ 801.00     |
| Dawn Krishnamurthy | 01/20/20    | 1.9 Review of Purdue organizational charts for high priority jurisdictions for purpose of finalizing initial requests. 0.2 Preparing email listing litigation and audits (by jurisdiction) for purposes of gaining insight regarding tax exposures.   | 2.1          | \$ 695      | \$ 1,459.50   |
| Pete DiMatteo      | 01/20/20    | Performed analysis regarding the application of the foreign tax credit rules to trusts and individuals to aid in planning and tax cost modeling   | 2.1          | \$ 650      | \$ 1,365.00   |



**EXHIBIT C1**

**Purdue Pharma L.P.**

**Case No. 19-23649**

Bankruptcy Tax Consulting Services  
December 23, 2019 through January 31, 2020

| <b>Name</b>        | <b>Date</b> | <b>Description</b>  | <b>Hours</b> | <b>Rate</b> | <b>Amount</b> |
|--------------------|-------------|---|--------------|-------------|---------------|
| Casey Nunez        | 01/20/20    | Performed Senior manager review of data room findings for purposes of updating Purdue Pharma information request list.  | 2.1          | \$ 744      | \$ 1,562.40   |
| Dawn Krishnamurthy | 01/20/20    | Performed review of data room documentation as of 1/20 with focus on global structure.  | 2.3          | \$ 695      | \$ 1,598.50   |
| Jess Commisso      | 01/20/20    | Performed analysis to determine whether assigned portion of Purdue financial statements are audited versus unaudited for member firm Mundipharma entities - pursuant to correspondence with member firms to request their review of such documentation.   | 2.6          | \$ 350      | \$ 910.00     |
| Michael Land       | 01/20/20    | 0.7 Review of correspondence with KPMG Germany regarding tax reserve / audits to gain insight regarding German tax profile; 0.7 review of correspondence with KPMG Korea regarding tax reserve / audits to gain insight regarding Korean tax profile; 0.7 review of correspondence with KPMG UK regarding tax reserve / audits to gain insight regarding UK tax profile; 0.6 review of correspondence with KPMG China re tax reserve / audits to gain insight regarding Chinese tax profile | 2.7          | \$ 534      | \$ 1,441.80   |
| Dawn Krishnamurthy | 01/20/20    | 0.7 Review of tax exam history described in meeting notes, E&Y Flowchart, Litigation Summaries and Project Malta due diligence report for purpose of identifying material tax exams (performed concurrently); 1.3 Manager review of financial statements provided in data room with focus on materiality; 0.8 Manager review of information request list as well as information received to date with respect to Swiss / South Korean updates.  | 2.8          | \$ 695      | \$ 1,946.00   |
| Maggie Scully      | 01/20/20    | Comparing the information request list to the virtual data room to ensure KPMG US team has accurately accounted for all provided by client information received to date.  | 3.1          | \$ 350      | \$ 1,085.00   |
| Devon Rowles       | 01/20/20    | Analysis to determine whether designated portion of Purdue financial statements are audited versus unaudited for my designated portion of member firm Mundipharma entities - pursuant to correspondence with member firms to request their review of such documentation.  | 3.4          | \$ 350      | \$ 1,190.00   |
| Thomas Giordano    | 01/20/20    | Continued (same day) to perform research to determine rules surrounding foreign tax payments and potential tax benefits to be obtained from such payments   | 3.6          | \$ 350      | \$ 1,260.00   |
| Jess Commisso      | 01/20/20    | Compiling the organizational charts of all Mundipharma entities provided by the client into a single file pursuant to mapping out relationships between jurisdictions and the global organizational chart.  | 3.9          | \$ 350      | \$ 1,365.00   |

**EXHIBIT C1**

**Purdue Pharma L.P.**

**Case No. 19-23649**

Bankruptcy Tax Consulting Services  
December 23, 2019 through January 31, 2020

| <b>Name</b>        | <b>Date</b> | <b>Description</b>  | <b>Hours</b> | <b>Rate</b> | <b>Amount</b> |
|--------------------|-------------|---|--------------|-------------|---------------|
| Thomas Giordano    | 01/20/20    | Continued (from 1/17/2020) to perform research to determine rules surrounding foreign tax payments and potential tax benefits to be obtained from such payments   | 3.9          | \$ 350      | \$ 1,365.00   |
| Aroen Rambhadjan   | 01/21/20    | Partner review of draft e-mail prepared by L. van der Veen (KPMG Netherlands) commenting on tax attributes available at the level of Dutch Purdue companies and recommendation related to a review of the (potential) impact of Dutch anti-hybrid rules on Dutch Purdue companies - prior to sending to D. Rowles (KPMG US) | 0.5          | \$ 985      | \$ 492.50     |
| Dong-Ju Shin       | 01/21/20    | Reviewed the Korean accounting standards for recognizing tax reserve and disclosing tax audits - with respect to request from D. Rowles (KPMG US) to review tax reserve, tax loss carryforwards, and tax audits in the audit reports of Mundipharma Korea Ltd.  | 0.5          | \$ 750      | \$ 375.00     |
| Ashley Armfield    | 01/21/20    | Call with I. Hirsch (KPMG) and A. Armfield (KPMG) to discuss next round of updates that need to be made to cash tax model as of 1/21/2020.  | 0.9          | \$ 534      | \$ 480.60     |
| Isaac Hirsch       | 01/21/20    | Call with I. Hirsch (KPMG) and A. Armfield (KPMG) to discuss next round of updates that need to be made to cash tax model as of 1/21/2020.  | 0.9          | \$ 819      | \$ 737.10     |
| Lukas van der Veen | 01/21/20    | Draft e-mail sent to D. Rowles (KPMG US) detailing comments related to tax attributes available at the level of Dutch Purdue companies including recommending a review of the (potential) impact of Dutch anti-hybrid rules on Dutch Purdue companies.  | 0.9          | \$ 730      | \$ 657.00     |
| Anja Poesl         | 01/21/20    | Reviewed collection of tax information available for German entities (tax reserves, open tax audits or controversies and tax attribute carryforwards) with regards to German tax analysis to be performed.  | 0.9          | \$ 750      | \$ 675.00     |
| Kyung-Min Kim      | 01/21/20    | (0.8) Per request from D. Rowles (KPMG US), reviewed 2016-2018 audit reports for Mundipharma Korea Ltd with focus on the existence of tax reserve, tax loss carryforwards, and tax audits; (0.2) responded to KPMG US email regarding same.   | 1.0          | \$ 750      | \$ 750.00     |
| Dawn Krishnamurthy | 01/21/20    | Call with D. Holland, I. Hirsch, P. DiMatteo and D. Krishnamurthy (all KPMG) to discuss Norton Rose calculations, Mundipharma structure, and trust issues for purposes of identifying key focus areas.  | 1.1          | \$ 695      | \$ 764.50     |
| Douglas Holland    | 01/21/20    | Call with D. Holland, I. Hirsch, P. DiMatteo and D. Krishnamurthy (all KPMG) to discuss Norton Rose calculations, Mundipharma structure, and trust issues for purposes of identifying key focus areas.  | 1.1          | \$ 985      | \$ 1,083.50   |

**EXHIBIT C1**

**Purdue Pharma L.P.**

**Case No. 19-23649**

Bankruptcy Tax Consulting Services  
December 23, 2019 through January 31, 2020

| <b>Name</b>        | <b>Date</b> | <b>Description</b>   | <b>Hours</b> | <b>Rate</b> | <b>Amount</b> |
|--------------------|-------------|--|--------------|-------------|---------------|
| Isaac Hirsch       | 01/21/20    | Call with D. Holland, I. Hirsch, P. DiMatteo and D. Krishnamurthy (all KPMG) to discuss Norton Rose calculations, Mundipharma structure, and trust issues for purposes of identifying key focus areas.   | 1.1          | \$ 819      | \$ 900.90     |
| Pete DiMatteo      | 01/21/20    | Call with D. Holland, I. Hirsch, P. DiMatteo and D. Krishnamurthy (all KPMG) to discuss Norton Rose calculations, Mundipharma structure, and trust issues for purposes of identifying key focus areas.   | 1.1          | \$ 650      | \$ 715.00     |
| Jess Commisso      | 01/21/20    | Continued (from same day) to research types of trusts, taxation of trusts, and details on Jersey trusts concurrently noting outcome of research to provide to team members, pursuant to trust analysis.  | 1.2          | \$ 350      | \$ 420.00     |
| Ashley Armfield    | 01/21/20    | Reviewing comments provided by I. Hirsch (KPMG) to be discussed during upcoming call (same day) pursuant to cash tax modeling.   | 1.4          | \$ 534      | \$ 747.60     |
| Howard Steinberg   | 01/21/20    | Performed Partner level review of high priority tax issue summary for purposes of gaining insight on tax posture   | 1.5          | \$ 856      | \$ 1,284.00   |
| Thomas Giordano    | 01/21/20    | 0.6 Drafted an outline deductibility research findings to circulate to team; 0.2 drafted email to outline on deductibility research to P. DiMatteo (KPMG); 0.7 Reviewed excel formatted organization structure to verify accurate country codes to be used in overall global organization structure.                                       | 1.5          | \$ 350      | \$ 525.00     |
| Philipp Reer       | 01/21/20    | German Tax Partner review of summary of tax positions in financial statements prepared by T. Heubach (KPMG).   | 1.6          | \$ 765      | \$ 1,224.00   |
| Karen Erickson     | 01/21/20    | For purposes of having a dynamic presentation of the legal entity structure: Set up project in Legal Entity Manager (LEM) (0.1) and create relevant entity attributes (0.4). Transfer entity information presentation to necessary import templates (1.0) and follow up with P. DiMatteo and T. Giordano (both KPMG) on information (0.3). | 1.8          | \$ 690      | \$ 1,242.00   |
| Dawn Krishnamurthy | 01/21/20    | 1.8 Performed analysis regarding Pharmaceutical Research Associates Taiwan, Inc. for purpose of gaining insight regarding ownership; 0.2 Manager review of summary of high priority tax issues for purposes of gain insight regarding rationale for information requests.  | 2.0          | \$ 695      | \$ 1,390.00   |
| Pete DiMatteo      | 01/21/20    | Additional analysis regarding deductibility of settlement payments, including cases where restitution deductions were deemed permissible.  | 2.1          | \$ 650      | \$ 1,365.00   |

**EXHIBIT C1**

**Purdue Pharma L.P.**

**Case No. 19-23649**

Bankruptcy Tax Consulting Services  
December 23, 2019 through January 31, 2020

| <b>Name</b>        | <b>Date</b> | <b>Description</b>   | <b>Hours</b> | <b>Rate</b> | <b>Amount</b> |
|--------------------|-------------|--|--------------|-------------|---------------|
| Jess Commisso      | 01/21/20    | Continued (from 1/20) to compile the organizational charts of all Mundipharma entities provided by the client into a single file pursuant to mapping out relationships between jurisdictions and the global organizational chart   | 2.2          | \$ 350      | \$ 770.00     |
| Isaac Hirsch       | 01/21/20    | Performed analysis of Purdue cash tax model to build out for foreign tax credit categories.  | 2.9          | \$ 819      | \$ 2,375.10   |
| Thomas Giordano    | 01/21/20    | Continue, from 1/20/2020, to perform research to determine rules surrounding foreign tax payments and potential tax benefits to be obtained from such payments.  | 3.0          | \$ 350      | \$ 1,050.00   |
| Pete DiMatteo      | 01/21/20    | Perform analysis on the permissibility of deductions for settlement payments, including whether an individual is deemed to operate a business under section 162  | 3.2          | \$ 650      | \$ 2,080.00   |
| Lukas van der Veen | 01/21/20    | Upon request of D. Rowles (KPMG US), review information included in share file on Dutch Purdue companies for 2016 - 2018 including financial statements / local Dutch transfer pricing documentation in order to identify tax attributes available at the level of the Dutch Purdue companies. | 3.2          | \$ 730      | \$ 2,336.00   |
| Thomas Heubach     | 01/21/20    | Senior Manager review and concurrently reconcile information prepared by S. Stricker (KPMG Germany) as requested by D. Rowles (KPMG US) regarding tax reserves, open tax audits and tax attributes carryforwards for all Purdue entities (total of 9).   | 3.5          | \$ 750      | \$ 2,625.00   |
| Devon Rowles       | 01/21/20    | (2.3) Creating an excel tracker to keep inventory of all the information received from KPMG member firms to date (1.3) Review of virtual data room for additional documents uploaded as of 1/21/20.  | 3.6          | \$ 350      | \$ 1,260.00   |
| Ashley Armfield    | 01/21/20    | Updated the Purdue cash tax model relating to the disposition scenarios i.e., stock versus asset functionality.  | 3.6          | \$ 534      | \$ 1,922.40   |
| Sonia Stricker     | 01/21/20    | Compiled and concurrently reviewed information requested by D. Rowles (KPMG US) regarding tax reserves, open tax audits and tax attributes carryforwards for all Purdue entities (total of 9).   | 3.8          | \$ 380      | \$ 1,444.00   |
| Jess Commisso      | 01/21/20    | Researched types of trusts, taxation of trusts, as well as details on Jersey trusts, while simultaneously noting outcome of research to provide to rest of the team, pursuant to trust analysis.   | 3.9          | \$ 350      | \$ 1,365.00   |
| Sam Tyler          | 01/21/20    | Call with G. Bell and J. Lau (both KPMG Canada) to discuss overview of Purdue Canadian structure to understand potential tax implications of a disposition   | 0.5          | \$ 743      | \$ 371.50     |
| Jonas Lau          | 01/21/20    | Call with G. Bell and J. Lau (both KPMG Canada) to discuss overview of Purdue Canadian structure to understand potential tax implications of a disposition   | 0.5          | \$ 614      | \$ 307.00     |

**EXHIBIT C1**

**Purdue Pharma L.P.**

**Case No. 19-23649**

Bankruptcy Tax Consulting Services  
December 23, 2019 through January 31, 2020

| <b>Name</b>   | <b>Date</b> | <b>Description</b>   | <b>Hours</b> | <b>Rate</b> | <b>Amount</b> |
|---------------|-------------|--|--------------|-------------|---------------|
| Gregory Bell  | 01/21/20    | Call with G. Bell and J. Lau (both KPMG Canada) to discuss overview of Purdue Canadian structure to understand potential tax implications of a disposition   | 0.5          | \$ 743      | \$ 371.50     |
| Jonas Lau     | 01/21/20    | Began to perform initial Senior Manager review of Purdue Canadian organizational charts/entities in conjunction with available financial statements to gain insight regarding client structure.  | 0.5          | \$ 614      | \$ 307.00     |
| Jonas Lau     | 01/22/20    | Continued, from 1/21, to perform a Senior Manager level review of Purdue Canadian organizational charts/entities in conjunction with available financial statements to gain insight regarding client structure.                                    | 2.0          | \$ 614      | \$ 1,228.00   |
| Gregory Bell  | 01/21/20    | Performed initial Partner review provided by client documentation in the data room from a Canadian tax perspective.  | 0.5          | \$ 743      | \$ 371.50     |
| Oron Zeevi    | 01/22/20    | Discussion with A. Eytan (KPMG) regarding the Purdue Pharma Israeli entity financial statements, current data available related to tax reserves and other tax attributes, as well as what additional information should be requested from KPMG US. | 0.5          | \$ 450      | \$ 225.00     |
| Arik Eytan    | 01/22/20    | Discussion with A. Eytan (KPMG) regarding the Purdue Pharma Israeli entity financial statements, current data available related to tax reserves and other tax attributes, as well as what additional information should be requested from KPMG US. | 0.5          | \$ 555      | \$ 277.50     |
| Gavin Little  | 01/22/20    | Performed Senior manager review of the analysis prepared by A. Desai and M. Latham (both KPMG UK) of the Purdue UK companies prior to submission to the KPMG US team.  | 0.5          | \$ 985      | \$ 492.50     |
| Gavin Little  | 01/22/20    | Review of the term sheet provided by KPMG US while concurrently drafting comments regarding UK tax analysis along with the review comments provided by A. Desai (KPMG UK Senior Manager) related to same.  | 0.5          | \$ 985      | \$ 492.50     |
| Arpit Desai   | 01/22/20    | Reviewed term sheet provided by KPMG US and concurrently draft comments regarding UK tax analysis to provide to G. Little (KPMG UK Director).  | 0.5          | \$ 750      | \$ 375.00     |
| Isaac Hirsch  | 01/22/20    | Conference with I. Hirsch and P. DiMatteo (both KPMG) to discuss / refine research regarding deductions arising from settlement payments to aid in tax planning and modeling   | 0.8          | \$ 819      | \$ 655.20     |
| Pete DiMatteo | 01/22/20    | Conference with I. Hirsch and P. DiMatteo (both KPMG) to discuss / refine research regarding deductions arising from settlement payments to aid in tax planning and modeling   | 0.8          | \$ 650      | \$ 520.00     |

**EXHIBIT C1**

**Purdue Pharma L.P.**

**Case No. 19-23649**

Bankruptcy Tax Consulting Services  
December 23, 2019 through January 31, 2020

| <b>Name</b>        | <b>Date</b> | <b>Description</b>  | <b>Hours</b> | <b>Rate</b> | <b>Amount</b> |
|--------------------|-------------|---|--------------|-------------|---------------|
| Karen Erickson     | 01/22/20    | Provide import templates as well as sample organizational charts for consideration to P. DiMatteo and T. Giordano (0.2); Initiated alternate sorting of entities to mitigate separation of parent and sub in chart where possible (0.6)   | 0.8          | \$ 690      | \$ 552.00     |
| Dawn Krishnamurthy | 01/22/20    | 0.8 Review of most recent data uploaded to Norton Rose data room as of 1/22/2020 to identify tax relevant items; 0.2 Performed Manager review of draft email prepared by A. Armfield (KPMG) to be sent to KPMG Swiss member firm for purpose of engaging Swiss team to perform services for Purdue.   | 1.0          | \$ 695      | \$ 695.00     |
| Oron Zeevi         | 01/22/20    | Drafted email to J. Commisso (KPMG US) detailing initial findings following the review of the financial statements with respect to tax reserves, tax attributes, etc.   | 1.0          | \$ 450      | \$ 450.00     |
| Arik Eytan         | 01/22/20    | Partner level review of the 2016 - 2018 financial statements of the Purdue Pharma Israeli entity in order to assess available tax reserves, tax attributes, operations and financial results.   | 1.0          | \$ 555      | \$ 555.00     |
| Pete DiMatteo      | 01/22/20    | Continue (same day) to perform analysis related to the deductibility of settlement payments - relating to contemplated payments made by trusts/individual beneficiaries to the settlement vehicle under section 162.  | 1.5          | \$ 650      | \$ 975.00     |
| Thomas Heubach     | 01/22/20    | Review of audited financial statements (including related findings) of S. Stricker (KPMG Germany) related to quantified tax audit adjustments requested by D. Krishnamurthy (KPMG US) for Purdue entities Mundipharma Deutschland GmbH & Co. KG and Mundipharma GmbH  | 1.7          | \$ 750      | \$ 1,275.00   |
| Pete DiMatteo      | 01/22/20    | Review of legal entity manager output for purposes of creating a global organization chart  | 1.8          | \$ 650      | \$ 1,170.00   |
| Madeleine Latham   | 01/22/20    | Meeting with A. Desai (KPMG UK) to analyze and concurrently discuss the accounts for the Purdue UK companies in scope in order to identify tax reserves, open tax audits or controversies, and tax attributes, as requested by KPMG US in an email dated 01/21/20. Note: two individuals performed this task given the volume of material to analyze (for 15 companies across three financial years) and the deadline set by KPMG US. | 2.0          | \$ 380      | \$ 760.00     |

**EXHIBIT C1**

**Purdue Pharma L.P.**

**Case No. 19-23649**

Bankruptcy Tax Consulting Services  
December 23, 2019 through January 31, 2020

| <b>Name</b>     | <b>Date</b> | <b>Description</b>   | <b>Hours</b> | <b>Rate</b> | <b>Amount</b> |
|-----------------|-------------|--|--------------|-------------|---------------|
| Arpit Desai     | 01/22/20    | Meeting with M. Latham (KPMG UK) to analyze and concurrently discuss the accounts for the Purdue UK companies in scope in order to identify tax reserves, open tax audits or controversies, and tax attributes, as requested by KPMG US in an email dated 01/21/20. Note: two individuals performed this task given the volume of material to analyze (for 15 companies across three financial years) and the deadline set by KPMG US. | 2.0          | \$ 750      | \$ 1,500.00   |
| Ashley Armfield | 01/22/20    | 0.8 Performed Senior Associate review of preliminary structuring deck for Mundipharma MEA GmbH tax consequences pursuant to preparing a structure deck of tax consequences. 1.4 Created cash tax model inputs summary tab to allow functionality between scenario inputs.  | 2.2          | \$ 534      | \$ 1,174.80   |
| Ashley Armfield | 01/22/20    | Perform updates to cash tax model to include functionality of different foreign tax credit baskets (i.e., GILTI, passive), income classification baskets (i.e., GILTI, US-Source), and character (i.e., ordinary versus capital) - this was all one task as all items are related.   | 2.2          | \$ 534      | \$ 1,174.80   |
| Sonia Stricker  | 01/22/20    | Analyze / investigate audited financial statements for quantified tax audit adjustments requested by D. Krishnamurthy (KPMG US) for Purdue entities Mundipharma Deutschland GmbH & Co. KG and Mundipharma GmbH   | 2.5          | \$ 380      | \$ 950.00     |
| Oron Zeevi      | 01/22/20    | Senior Manager level review of the 2016 - 2018 financial statements of the Purdue Pharma Israeli entity in order to assess available tax reserves, tax attributes, operations and financial results.   | 2.5          | \$ 450      | \$ 1,125.00   |
| Thomas Giordano | 01/22/20    | Continued, from earlier in the day, to cross-check LEM created global organization structure chart (of approximately 325 entities) with excel formatted organization structure to determine accuracy of overall global organization structure.   | 2.6          | \$ 350      | \$ 910.00     |
| Jess Commisso   | 01/22/20    | Continue (same day) to create assigned portion of illustrative structure deck based on Norton Rose sale computations of Mundipharma entities pursuant to sharing with our member firms for sale and tax analysis purposes.   | 2.7          | \$ 350      | \$ 945.00     |
| Ashley Armfield | 01/22/20    | Updates to cash tax model based on managing director comments to combine US tax and foreign tax credit calculations into one tab.  | 2.9          | \$ 534      | \$ 1,548.60   |
| Devon Rowles    | 01/22/20    | Began to create an outline to cover tax research around the deductibility of restitution payments.   | 3.2          | \$ 350      | \$ 1,120.00   |

**EXHIBIT C1**

**Purdue Pharma L.P.**

**Case No. 19-23649**

Bankruptcy Tax Consulting Services  
December 23, 2019 through January 31, 2020

| <b>Name</b>        | <b>Date</b> | <b>Description</b>   | <b>Hours</b> | <b>Rate</b> | <b>Amount</b> |
|--------------------|-------------|--|--------------|-------------|---------------|
| Dawn Krishnamurthy | 01/22/20    | 1.1 Review of Norton Rose data room financial statements in conjunction with Advance Pricing Agreement (APA) agreements for purpose of updating information request list; 1.6 Manager review of trust research performed by J. Commisso (KPMG); 0.8 Manager review of German audit exposure issue for purpose of drafting follow-up email to German team.  | 3.5          | \$ 695      | \$ 2,432.50   |
| Dawn Krishnamurthy | 01/22/20    | 2.9 Perform analysis related to trust / disregarded entity tax treatment for purposes of understanding treatment of potential distribution of Mundipharma sales proceeds; 0.4 Performed analysis related to Section 481 adjustments with regards to Purdue Pharma tax matter; 0.4 performed additional analysis regarding ownership of Pharmaceutical Research Associates Taiwan Inc. for risk management purposes.  | 3.7          | \$ 695      | \$ 2,571.50   |
| Jess Commisso      | 01/22/20    | Began to create assigned portion of illustrative structure deck based on Norton Rose sale computations of Mundipharma entities pursuant to sharing with our member firms for sale and tax analysis purposes. <u>Note</u> : this is an exceptionally large task that will be ongoing including continuous updates to the deck (based on additional data received) and will be performed by several KPMG professionals assigned to different facets of structure deck. | 3.9          | \$ 350      | \$ 1,365.00   |
| Thomas Giordano    | 01/22/20    | Began to cross-check LEM created global organization structure chart (related to numerous Purdue Pharma entities) with excel formatted organization structure to determine accuracy of overall global organization structure.  | 3.9          | \$ 350      | \$ 1,365.00   |
| Thomas Giordano    | 01/22/20    | Continue, same day, to cross-check LEM created global organization structure chart (related to numerous Purdue Pharma entities) with excel formatted organization structure to determine accuracy of overall global organization structure.  | 3.9          | \$ 350      | \$ 1,365.00   |
| Pete DiMatteo      | 01/22/20    | Performed analysis related to the deductibility of settlement payments - relating to contemplated payments made by trusts/individual beneficiaries to the settlement vehicle under section 162.  | 3.9          | \$ 650      | \$ 2,535.00   |
| Jonas Lau          | 01/22/20    | Meeting with G. Bell and S. Tyler (both KPMG Canada) to discuss results of reviews related to Purdue Canadian entities, Canadian organizational charts and available financial statements.   | 0.5          | \$ 614      | \$ 307.00     |
| Sam Tyler          | 01/22/20    | Meeting with G. Bell and S. Tyler (both KPMG Canada) to discuss results of reviews related to Purdue Canadian entities, Canadian organizational charts and available financial statements.   | 0.5          | \$ 743      | \$ 371.50     |



**EXHIBIT C1**

**Purdue Pharma L.P.**

**Case No. 19-23649**

Bankruptcy Tax Consulting Services  
December 23, 2019 through January 31, 2020

| <b>Name</b>     | <b>Date</b> | <b>Description</b>  | <b>Hours</b> | <b>Rate</b> | <b>Amount</b> |
|-----------------|-------------|---|--------------|-------------|---------------|
| Gregory Bell    | 01/22/20    | Meeting with G. Bell and S. Tyler (both KPMG Canada) to discuss results of reviews related to Purdue Canadian entities, Canadian organizational charts and available financial statements.                            | 0.5          | \$ 743      | \$ 371.50     |
| Sam Tyler       | 01/22/20    | Partner review of all available documentation in data room to consider Canadian tax issues (0.4) and drafted respond to request from KPMG US (0.4)  | 0.8          | \$ 743      | \$ 594.40     |
| Christin Witt   | 01/23/20    | Call with T. Heubach, P. Reer and C. Witt (KPMG German team) to discuss status of German tax analysis and next steps as of 1/23/2020.   | 0.4          | \$ 650      | \$ 260.00     |
| Philipp Reer    | 01/23/20    | Call with T. Heubach, P. Reer and C. Witt (KPMG German team) to discuss status of German tax analysis and next steps as of 1/23/2020.   | 0.4          | \$ 765      | \$ 306.00     |
| Anja Poesl      | 01/23/20    | Call with T. Heubach, P. Reer and C. Witt (KPMG German team) to discuss status of German tax analysis and next steps as of 1/23/2020.   | 0.4          | \$ 750      | \$ 300.00     |
| Thomas Giordano | 01/23/20    | Continue, on same day, to create assigned portion of global organization structure related to numerous Purdue Pharma entities in Visio leveraging LEM created global organization structure                           | 0.5          | \$ 350      | \$ 175.00     |
| Jess Commisso   | 01/23/20    | Continued (from 1/21) to research types of trusts, taxation of trusts, as well as details on Jersey trusts, while simultaneously creating notes for distribution to the rest of the team, pursuant to trust analysis. | 0.8          | \$ 350      | \$ 280.00     |
| Isaac Hirsch    | 01/23/20    | Participate in call with I. Hirsch, P. DiMatteo K. Erickson, and T. Giordano (all KPMG) regarding questions as well as recommendations for data presentation in LEM for efficient charting alternatives.              | 0.9          | \$ 819      | \$ 737.10     |
| Karen Erickson  | 01/23/20    | Participate in call with I. Hirsch, P. DiMatteo K. Erickson, and T. Giordano (all KPMG) regarding questions as well as recommendations for data presentation in LEM for efficient charting alternatives.              | 0.9          | \$ 690      | \$ 621.00     |
| Pete DiMatteo   | 01/23/20    | Participate in call with I. Hirsch, P. DiMatteo K. Erickson, and T. Giordano (all KPMG) regarding questions as well as recommendations for data presentation in LEM for efficient charting alternatives.              | 0.9          | \$ 650      | \$ 585.00     |
| Thomas Giordano | 01/23/20    | Participate in call with I. Hirsch, P. DiMatteo K. Erickson, and T. Giordano (all KPMG) regarding questions as well as recommendations for data presentation in LEM for efficient charting alternatives.              | 0.9          | \$ 350      | \$ 315.00     |

**EXHIBIT C1**

**Purdue Pharma L.P.**

**Case No. 19-23649**

Bankruptcy Tax Consulting Services  
December 23, 2019 through January 31, 2020

| <b>Name</b>        | <b>Date</b> | <b>Description</b>   | <b>Hours</b> | <b>Rate</b> | <b>Amount</b> |
|--------------------|-------------|--|--------------|-------------|---------------|
| Dawn Krishnamurthy | 01/23/20    | Performed analysis regarding ownership structure of Mundipharma entities with focus on tax issues related to distribution of sales proceeds.   | 1.2          | \$ 695      | \$ 834.00     |
| Ashley Armfield    | 01/23/20    | Discussion with C. Nunez, I. Hirsch, D. Krishnamurthy, A. Armfield, J. Commisso (all KPMG) regarding cash tax model set up and structure deck illustration pursuant to Mundipharma MEA GmbH (Switzerland) entity analysis  | 1.3          | \$ 534      | \$ 694.20     |
| Casey Nunez        | 01/23/20    | Discussion with C. Nunez, I. Hirsch, D. Krishnamurthy, A. Armfield, J. Commisso (all KPMG) regarding cash tax model set up and structure deck illustration pursuant to Mundipharma MEA GmbH (Switzerland) entity analysis  | 1.3          | \$ 744      | \$ 967.20     |
| Dawn Krishnamurthy | 01/23/20    | Discussion with C. Nunez, I. Hirsch, D. Krishnamurthy, A. Armfield, J. Commisso (all KPMG) regarding cash tax model set up and structure deck illustration pursuant to Mundipharma MEA GmbH (Switzerland) entity analysis  | 1.3          | \$ 695      | \$ 903.50     |
| Isaac Hirsch       | 01/23/20    | Discussion with C. Nunez, I. Hirsch, D. Krishnamurthy, A. Armfield, J. Commisso (all KPMG) regarding cash tax model set up and structure deck illustration pursuant to Mundipharma MEA GmbH (Switzerland) entity analysis  | 1.3          | \$ 819      | \$ 1,064.70   |
| Jess Commisso      | 01/23/20    | Discussion with C. Nunez, I. Hirsch, D. Krishnamurthy, A. Armfield, J. Commisso (all KPMG) regarding cash tax model set up and structure deck illustration pursuant to Mundipharma MEA GmbH (Switzerland) entity analysis  | 1.3          | \$ 350      | \$ 455.00     |
| Jess Commisso      | 01/23/20    | Incorporated UK financial statement analysis of tax attributes, reserves and audits into a combined file of all member firm entities pursuant to Mundipharma entity analysis.  | 1.3          | \$ 350      | \$ 455.00     |
| Isaac Hirsch       | 01/23/20    | Managing Director review of latest set of updates to organizational charts sent by P. DiMatteo (KPMG)  | 1.5          | \$ 819      | \$ 1,228.50   |
| Ashley Armfield    | 01/23/20    | Updated cash tax model structure / data (about the Mundipharma entities as provided in the Norton Rose calculations) for Mundipharma Deutschland GmbH & Co KG to conform with all prior updates.   | 2.1          | \$ 534      | \$ 1,121.40   |
| Ashley Armfield    | 01/23/20    | Discussion with J. Commisso, D. Rowles and A. Armfield (all KPMG) regarding cash flow steps involved with the sale of Mundipharma entities, including intercompany rationalization and redemption of preferred shares, to determine tax treatment of associated contributions and distributions pursuant to providing a structure chart in PowerPoint. | 2.2          | \$ 534      | \$ 1,174.80   |

**EXHIBIT C1**

**Purdue Pharma L.P.**

**Case No. 19-23649**

Bankruptcy Tax Consulting Services  
December 23, 2019 through January 31, 2020

| <b>Name</b>     | <b>Date</b> | <b>Description</b>   | <b>Hours</b> | <b>Rate</b> | <b>Amount</b> |
|-----------------|-------------|--|--------------|-------------|---------------|
| Devon Rowles    | 01/23/20    | Discussion with J. Commisso, D. Rowles and A. Armfield (all KPMG) regarding cash flow steps involved with the sale of Mundipharma entities, including intercompany rationalization and redemption of preferred shares, to determine tax treatment of associated contributions and distributions pursuant to providing a structure chart in PowerPoint. | 2.2          | \$ 350      | \$ 770.00     |
| Jess Commisso   | 01/23/20    | Discussion with J. Commisso, D. Rowles and A. Armfield (all KPMG) regarding cash flow steps involved with the sale of Mundipharma entities, including intercompany rationalization and redemption of preferred shares, to determine tax treatment of associated contributions and distributions pursuant to providing a structure chart in PowerPoint. | 2.2          | \$ 350      | \$ 770.00     |
| Jess Commisso   | 01/23/20    | Continue (from 1/22) to create assigned portion of illustrative structure deck based on Norton Rose sale computations of Mundipharma entities pursuant to sharing with our member firms for sale and tax analysis purposes.  | 2.4          | \$ 350      | \$ 840.00     |
| Isaac Hirsch    | 01/23/20    | Review modifications to cash tax model incorporating latest round of comments from the project team sent by A. Armfield (KPMG)   | 3.1          | \$ 819      | \$ 2,538.90   |
| Devon Rowles    | 01/23/20    | 1.1 Created a summary / index of all of the VDR documents received to date in preparation to provide to KPMG US and member firm project teams; 2.1 Continue (from 1/22) to create an outline to cover tax research around the deductibility of restitution payments  | 3.2          | \$ 350      | \$ 1,120.00   |
| Pete DiMatteo   | 01/23/20    | Continue (same day) drafting organizational structures necessary to create PowerPoint slides depicting potential transactions related to the contemplated Mundipharma sales (16 potential sale scenarios).   | 3.2          | \$ 650      | \$ 2,080.00   |
| Pete DiMatteo   | 01/23/20    | Draft organizational structures necessary to create PowerPoint slides depicting potential transactions related to the contemplated Mundipharma sales (16 potential sale scenarios).  | 3.4          | \$ 650      | \$ 2,210.00   |
| Ashley Armfield | 01/23/20    | Updating cash tax model to add interim step and concurrently compile all data (i.e., cash flows to local country authorities, different types of taxable income) from entity level tabs into one main tab.   | 3.5          | \$ 534      | \$ 1,869.00   |
| Thomas Giordano | 01/23/20    | Continue (from 1/22) to cross-check LEM created global organization structure chart related to numerous Purdue Pharma entities with excel formatted organization structure to determine accuracy of overall global organization structure  | 3.6          | \$ 350      | \$ 1,260.00   |

**EXHIBIT C1**

**Purdue Pharma L.P.**

**Case No. 19-23649**

Bankruptcy Tax Consulting Services  
December 23, 2019 through January 31, 2020

| <b>Name</b>         | <b>Date</b> | <b>Description</b>  | <b>Hours</b> | <b>Rate</b> | <b>Amount</b> |
|---------------------|-------------|---|--------------|-------------|---------------|
| Thomas Giordano     | 01/23/20    | Began to create assigned portion of global organization structure related to numerous Purdue Pharma entities in Visio leveraging LEM created global organization structure  | 3.9          | \$ 350      | \$ 1,365.00   |
| Dawn Krishnamurthy  | 01/23/20    | 0.2 Drafting email to C. Nunez (KPMG) regarding ownership of Pharmaceutical Research Associates Taiwan, Inc.; 2.3 Comparison of Norton Rose Calculations to KPMG draft model; 0.6 Manager review of Swiss PowerPoint asset/stock sale analysis structure - prepared by J. Commisso (KPMG); 0.9 Review of Purdue court filings to identify entity ownership information. | 4.0          | \$ 695      | \$ 2,780.00   |
| Andy Farinich       | 01/23/20    | Created 5 slides depicting various distribution scenarios which showed the potential tax consequences if payments were to be made from the beneficiary level, or from the trust level, into the settlement vehicle.   | 1.5          | \$ 534      | \$ 801.00     |
| Andy Farinich       | 01/23/20    | Began to create a Visio file depicting designated portion of the global organizational structure, of numerous Purdue Pharma entities, leveraging the LEM global organization file (task not completed)  | 3.5          | \$ 534      | \$ 1,869.00   |
| Sam Tyler           | 01/23/20    | Review draft email from J. Lau (KPMG Canada) summarizing Canadian tax review of available document and concurrently draft review comments   | 0.3          | \$ 743      | \$ 222.90     |
| Danielle Moloughney | 01/23/20    | Performed Associate level review of Purdue Canadian financial statements and other available documentation for purposes of understanding Purdue Canada's financial position   | 1.6          | \$ 172      | \$ 275.20     |
| Jonas Lau           | 01/23/20    | Continued to review organizational charts along with other available financial statements concurrently to identify potential tax exposures (1.5), email correspondence with KPMG US to describe findings related to same (0.5)  | 2.0          | \$ 614      | \$ 1,228.00   |
| Karen Erickson      | 01/24/20    | Complete revisions of structure of entities for better positioning of owner and subsidiaries in the Purdue Pharma organizational chart (0.4). Import schedules to LEM - based on data and notes updates as of 1/24/2020 (0.1).  | 0.5          | \$ 690      | \$ 345.00     |
| Casey Nunez         | 01/24/20    | Performed a senior manager review of data room updates as of 1/24 to identify new Purdue Pharma documents.  | 1.2          | \$ 744      | \$ 892.80     |
| Howard Steinberg    | 01/24/20    | Partner review of data room updates as of 1/24/2020 to identify new tax relevant documents  | 1.3          | \$ 856      | \$ 1,112.80   |
| Ashley Armfield     | 01/24/20    | Discussion with J. Commisso, D. Rowles, and A. Armfield (all KPMG) regarding the cash flow steps involved with the sale of Mundipharma MEA GmbH pursuant to providing a structure chart in PowerPoint.  | 1.6          | \$ 534      | \$ 854.40     |

**EXHIBIT C1**

**Purdue Pharma L.P.**

**Case No. 19-23649**

Bankruptcy Tax Consulting Services  
December 23, 2019 through January 31, 2020

| <b>Name</b>        | <b>Date</b> | <b>Description</b>  | <b>Hours</b> | <b>Rate</b> | <b>Amount</b> |
|--------------------|-------------|---|--------------|-------------|---------------|
| Devon Rowles       | 01/24/20    | Discussion with J. Commisso, D. Rowles, and A. Armfield (all KPMG) regarding the cash flow steps involved with the sale of Mundipharma MEA GmbH pursuant to providing a structure chart in PowerPoint.  | 1.6          | \$ 350      | \$ 560.00     |
| Jess Commisso      | 01/24/20    | Discussion with J. Commisso, D. Rowles, and A. Armfield (all KPMG) regarding the cash flow steps involved with the sale of Mundipharma MEA GmbH pursuant to providing a structure chart in PowerPoint.  | 1.6          | \$ 350      | \$ 560.00     |
| Ashley Armfield    | 01/24/20    | Drafting template and corresponding email discussing structure deck outline for potential dispositions to be send to KPMG project team (i.e., P. DiMatteo, I. Hirsch, C. Nunez).  | 1.6          | \$ 534      | \$ 854.40     |
| Devon Rowles       | 01/24/20    | Finalized outline to cover tax research around the deductibility of restitution payments - continued from 1/23.   | 1.8          | \$ 350      | \$ 630.00     |
| Ashley Armfield    | 01/24/20    | Discussion with D. Rowles and A. Armfield (both KPMG) regarding the cash flow steps involved with the sale of Purdue Pharma (Canada) pursuant to providing a structure chart in PowerPoint.   | 2.1          | \$ 534      | \$ 1,121.40   |
| Devon Rowles       | 01/24/20    | Discussion with D. Rowles and A. Armfield (both KPMG) regarding the cash flow steps involved with the sale of Purdue Pharma (Canada) pursuant to providing a structure chart in PowerPoint.   | 2.1          | \$ 350      | \$ 735.00     |
| Jess Commisso      | 01/24/20    | Continued, from previous day, to create assigned portion of illustrative structure deck based on Norton Rose sale computations of Mundipharma entities pursuant to sharing with our member firms for sale and tax analysis purposes   | 2.5          | \$ 350      | \$ 875.00     |
| Thomas Giordano    | 01/24/20    | Continued (from 1/23) to create assigned portion of global organization structure related to numerous Purdue Pharma entities in Visio leveraging LEM created global organization structure.   | 2.7          | \$ 350      | \$ 945.00     |
| Dawn Krishnamurthy | 01/24/20    | 1.3 Review of Project Malta financial due diligence reports with focus on vendor due diligence findings; 0.1 Review new document "FW IAC Follow Up Requests.msg" in Norton Rose Data Room; 1.1 Review of terms of Purdue transfer of assets to Newco in term sheet; 0.3 Manager review of schedule of assets and liabilities of Purdue Pharma LP for tax liens/liabilities. | 2.8          | \$ 695      | \$ 1,946.00   |
| Dawn Krishnamurthy | 01/24/20    | 2.6 Drafted summary of tax relevant information contained in Project Malta Report Volume 1 (report was over 400 pages); 0.2 Manager review of Project Malta summary prepared by M. Land (KPMG).   | 2.8          | \$ 695      | \$ 1,946.00   |

**EXHIBIT C1**

**Purdue Pharma L.P.**

**Case No. 19-23649**

Bankruptcy Tax Consulting Services  
December 23, 2019 through January 31, 2020

| <b>Name</b>        | <b>Date</b> | <b>Description</b>   | <b>Hours</b> | <b>Rate</b> | <b>Amount</b> |
|--------------------|-------------|--|--------------|-------------|---------------|
| Dawn Krishnamurthy | 01/24/20    | 1.2 Review of Debtors Informational Brief filed by Purdue with focus on whether the organizational structure had been disclosed as well as what payments were going to be required (and from which entities) in order to gain insight regarding where the cash needs to move within the structure to identify potential tax issues); 2.0 Perform research regarding proposed settlement as described in bankruptcy court filings | 3.2          | \$ 695      | \$ 2,224.00   |
| Isaac Hirsch       | 01/24/20    | (1.4) Continued (from 1/23) Managing Director review of updates to organizational charts sent by P. DiMatteo (KPMG) (2.3) Drafted comments related to cash tax model to account for rate disparity rules   | 3.7          | \$ 819      | \$ 3,030.30   |
| Pete DiMatteo      | 01/24/20    | Continued (from 1/23) to draft and concurrently analyze organizational structures necessary to create PowerPoint slides depicting potential transactions related to the contemplated Mundipharma sales (16 potential sale scenarios).  | 3.8          | \$ 650      | \$ 2,470.00   |
| Jess Commisso      | 01/24/20    | Continue (same day) to create assigned portion of illustrative structure deck based on Norton Rose sale computations of Mundipharma entities pursuant to sharing with our member firms for sale and tax analysis purposes - as began earlier in the day.   | 3.9          | \$ 350      | \$ 1,365.00   |
| Thomas Giordano    | 01/24/20    | Continued (from earlier in the day) to create assigned portion of global organizational structure related to numerous Purdue Pharma entities in Visio leveraging LEM created global organization structure.  | 3.9          | \$ 350      | \$ 1,365.00   |
| Thomas Giordano    | 01/24/20    | Continued (from same day) to create global organizational structure related to numerous Purdue Pharma entities in Visio leveraging LEM created global organization structure.  | 3.9          | \$ 350      | \$ 1,365.00   |
| Andy Farinich      | 01/24/20    | Continued, from earlier in the day, to create a Visio file depicting designated portion of the global organizational structure, of numerous Purdue Pharma entities, leveraging the LEM global organization file (task not completed)   | 1.5          | \$ 534      | \$ 801.00     |
| Andy Farinich      | 01/24/20    | Continue, from previous day, to create a Visio file depicting designated portion of the global organizational structure, of numerous Purdue Pharma entities, leveraging the LEM global organization file (task not completed)  | 3.9          | \$ 534      | \$ 2,082.60   |
| Andy Farinich      | 01/24/20    | Continued, same day, to create a Visio file depicting designated portion of the global organizational structure, of numerous Purdue Pharma entities, leveraging the LEM global organization file (task not completed)  | 3.9          | \$ 534      | \$ 2,082.60   |
| Dawn Krishnamurthy | 01/26/20    | Review of Project Malta report Volume 1 for purpose of identifying potential tax exposures.  | 0.8          | \$ 695      | \$ 556.00     |

**EXHIBIT C1**

**Purdue Pharma L.P.**

**Case No. 19-23649**

Bankruptcy Tax Consulting Services  
December 23, 2019 through January 31, 2020

| <b>Name</b>        | <b>Date</b> | <b>Description</b>   | <b>Hours</b> | <b>Rate</b> | <b>Amount</b> |
|--------------------|-------------|--|--------------|-------------|---------------|
| Pete DiMatteo      | 01/26/20    | Perform Manager review and concurrently revise Visio organization structures to confirm ownership for purposes of draft a slide deck depicting relevant contemplated transactions. | 3.1          | \$ 650      | \$ 2,015.00   |
| Pete DiMatteo      | 01/27/20    | Call with A. Farinich and P. DiMatteo (KPMG) to discuss next steps related to the drafting of slides depicting alternative transactions for 3 UK entities and German entities.     | 0.5          | \$ 650      | \$ 325.00     |
| Andy Farinich      | 01/27/20    | Call with A. Farinich and P. DiMatteo (KPMG) to discuss next steps related to the drafting of slides depicting alternative transactions for 3 UK entities and German entities.     | 0.5          | \$ 534      | \$ 267.00     |
| Ashley Armfield    | 01/27/20    | Meeting with I. Hirsch, M. Land, A. Armfield, D. Rowles (all KPMG) to discuss structuring scenarios related to individual country dispositions                                     | 1.2          | \$ 534      | \$ 640.80     |
| Devon Rowles       | 01/27/20    | Meeting with I. Hirsch, M. Land, A. Armfield, D. Rowles (all KPMG) to discuss structuring scenarios related to individual country dispositions                                     | 1.2          | \$ 350      | \$ 420.00     |
| Isaac Hirsch       | 01/27/20    | Meeting with I. Hirsch, M. Land, A. Armfield, D. Rowles (all KPMG) to discuss structuring scenarios related to individual country dispositions                                     | 1.2          | \$ 819      | \$ 982.80     |
| Michael Land       | 01/27/20    | Meeting with I. Hirsch, M. Land, A. Armfield, D. Rowles (all KPMG) to discuss structuring scenarios related to individual country dispositions                                     | 1.2          | \$ 534      | \$ 640.80     |
| Michael Land       | 01/27/20    | Meeting with M. Land and A. Armfield (all KPMG) to discuss structuring alternatives re Switzerland disposition   | 1.3          | \$ 534      | \$ 694.20     |
| Ashley Armfield    | 01/27/20    | Meeting with M. Land and A. Armfield (all KPMG) to discuss structuring alternatives regarding Switzerland disposition  | 1.3          | \$ 534      | \$ 694.20     |
| Ashley Armfield    | 01/27/20    | Meeting with A. Armfield and M. Land (all KPMG) discuss structuring alternatives re Canada disposition   | 1.4          | \$ 534      | \$ 747.60     |
| Michael Land       | 01/27/20    | Meeting with A. Armfield and M. Land (all KPMG) discuss structuring alternatives re Canada disposition   | 1.4          | \$ 534      | \$ 747.60     |
| Devon Rowles       | 01/27/20    | Creating a structure deck for Purdue Pharma (Canada) related to individual country dispositions and foreign tax consequences   | 1.9          | \$ 350      | \$ 665.00     |
| Ashley Armfield    | 01/27/20    | Meeting with I. Hirsch, K. Krishnamurthy, M. Land, A. Armfield, D. Rowles (all KPMG) to discuss updates to the Purdue cash tax model with regards to foreign tax consequences      | 1.9          | \$ 534      | \$ 1,014.60   |
| Dawn Krishnamurthy | 01/27/20    | Meeting with I. Hirsch, K. Krishnamurthy, M. Land, A. Armfield, D. Rowles (all KPMG) to discuss updates to the Purdue cash tax model with regards to foreign tax consequences      | 1.9          | \$ 695      | \$ 1,320.50   |

**EXHIBIT C1**

**Purdue Pharma L.P.**

**Case No. 19-23649**

Bankruptcy Tax Consulting Services  
December 23, 2019 through January 31, 2020

| <b>Name</b>        | <b>Date</b> | <b>Description</b>   | <b>Hours</b> | <b>Rate</b> | <b>Amount</b> |
|--------------------|-------------|--|--------------|-------------|---------------|
| Devon Rowles       | 01/27/20    | Meeting with I. Hirsch, K. Krishnamurthy, M. Land, A. Armfield, D. Rowles (all KPMG) to discuss updates to the Purdue cash tax model with regards to foreign tax consequences  | 1.9          | \$ 350      | \$ 665.00     |
| Isaac Hirsch       | 01/27/20    | Meeting with I. Hirsch, K. Krishnamurthy, M. Land, A. Armfield, D. Rowles (all KPMG) to discuss updates to the Purdue cash tax model with regards to foreign tax consequences  | 1.9          | \$ 819      | \$ 1,556.10   |
| Michael Land       | 01/27/20    | Meeting with I. Hirsch, K. Krishnamurthy, M. Land, A. Armfield, D. Rowles (all KPMG) to discuss updates to the Purdue cash tax model with regards to foreign tax consequences  | 1.9          | \$ 534      | \$ 1,014.60   |
| Isaac Hirsch       | 01/27/20    | (1.4) Update comments to cash tax model to incorporate foreign tax credit baskets in preparation for meeting with team regarding same; (0.8) review of Purdue updated organizational charts for purposes of preparing cash tax cost analysis   | 2.2          | \$ 819      | \$ 1,801.80   |
| Jess Commisso      | 01/27/20    | 0.4 Correspondence with KPMG Canada regarding information requests pursuant to tax analysis; 1.9 Incorporated Canada financial statement analysis of tax attributes, reserves and audits into a combined file of all Member Firm (MF) entities pursuant to Mundipharma entity analysis | 2.3          | \$ 350      | \$ 805.00     |
| Pete DiMatteo      | 01/27/20    | Perform detailed manager review of 8 organizational structures to be used in a PowerPoint presentation depicting contemplated transactions for purposes of assisting in tax cost modeling.   | 3.2          | \$ 650      | \$ 2,080.00   |
| Dawn Krishnamurthy | 01/27/20    | Performed Manager review of latest version of Purdue draft cash tax model as of 1/27.  | 3.3          | \$ 695      | \$ 2,293.50   |
| Ashley Armfield    | 01/27/20    | Creating Mundipharma MEA GmbH structure and initial steps in PowerPoint pursuant to preparing structuring deck to share with member firms.   | 3.5          | \$ 534      | \$ 1,869.00   |
| Andy Farinich      | 01/27/20    | Began creating designated portion of slides for structure deck disposition scenarios related to three United Kingdom entities and one German entity, including depictions, assumptions, and transaction steps.   | 3.9          | \$ 534      | \$ 2,082.60   |
| Andy Farinich      | 01/27/20    | Continued (in same day) creating designated portion of slides for structure deck disposition scenarios related to three United Kingdom entities and one German entity, including depictions, assumptions, and transaction steps.   | 3.9          | \$ 534      | \$ 2,082.60   |



EXHIBIT C1

Purdue Pharma L.P.

Case No. 19-23649

Bankruptcy Tax Consulting Services  
December 23, 2019 through January 31, 2020

| Name               | Date     | Description   | Hours | Rate   | Amount      |
|--------------------|----------|---|-------|--------|-------------|
| Thomas Giordano    | 01/27/20 | Began to manually create assigned portion of slides for structure deck disposition scenarios related to three United Kingdom entities and one German entity, including depictions, assumptions, and transaction steps; <u>Note</u> : These were very complicated organizational structures because of numerous instances of cross ownership. Thus, depictions were very difficult to create / consolidate. Further, the transactions steps depended on PBC data which was sometimes partially unreadable.                               | 4.0   | \$ 350 | \$ 1,400.00 |
| Thomas Giordano    | 01/27/20 | Continued (from earlier in the day) to manually create assigned portion of slides for structure deck disposition scenarios related to three United Kingdom entities and one German entity, including depictions, assumptions, and transaction steps; <u>Note</u> : These were very complicated organizational structures because of numerous instances of cross ownership. Thus, depictions were very difficult to create / consolidate. Further, the transactions steps depended on PBC data which was sometimes partially unreadable. | 4.0   | \$ 350 | \$ 1,400.00 |
| Dawn Krishnamurthy | 01/28/20 | 0.9 Continued, same day, to review Project Malta Reports with focus on tax profile of Mundipharma entities.   | 0.9   | \$ 695 | \$ 625.50   |
| Andy Farinich      | 01/28/20 | Meeting with M. Land, A. Armfield, A. Farinich, T. Giordano (all KPMG) to discuss structure deck disposition scenarios related to Switzerland Mundipharma.  | 0.9   | \$ 534 | \$ 480.60   |
| Ashley Armfield    | 01/28/20 | Meeting with M. Land, A. Armfield, A. Farinich, T. Giordano (all KPMG) to discuss structure deck disposition scenarios related to Switzerland Mundipharma.  | 0.9   | \$ 534 | \$ 480.60   |
| Michael Land       | 01/28/20 | Meeting with M. Land, A. Armfield, A. Farinich, T. Giordano (all KPMG) to discuss structure deck disposition scenarios related to Switzerland Mundipharma.  | 0.9   | \$ 534 | \$ 480.60   |
| Thomas Giordano    | 01/28/20 | Meeting with M. Land, A. Armfield, A. Farinich, T. Giordano (all KPMG) to discuss structure deck disposition scenarios related to Switzerland Mundipharma.  | 0.9   | \$ 350 | \$ 315.00   |
| Jess Commisso      | 01/28/20 | 0.6 Correspondence with UK Member Firm to discuss tax implications of deemed distributions of trusts and what is needed from the client in regards to trust information. 0.8 Researched types of trusts, taxation of trusts as well as details on Jersey trusts while simultaneously preparing notes to disseminate to project team, pursuant to trust analysis.  | 1.4   | \$ 350 | \$ 490.00   |
| Ashley Armfield    | 01/28/20 | Updating assumptions for structure deck based on review comments received from I. Hirsch (KPMG) as of 1/28/2020.  | 1.6   | \$ 534 | \$ 854.40   |
| Ashley Armfield    | 01/28/20 | Created structure deck support file in excel to outline calculations used for the Purdue Pharma structure deck.   | 1.9   | \$ 534 | \$ 1,014.60 |

**EXHIBIT C1**

**Purdue Pharma L.P.**

**Case No. 19-23649**

Bankruptcy Tax Consulting Services  
December 23, 2019 through January 31, 2020

| <b>Name</b>        | <b>Date</b> | <b>Description</b>  | <b>Hours</b> | <b>Rate</b> | <b>Amount</b> |
|--------------------|-------------|---|--------------|-------------|---------------|
| Jess Commisso      | 01/28/20    | Continued (from same day), to create assigned portion of illustrative structure deck based on Norton Rose sale computations of Mundipharma entities pursuant to sharing with our member firms for sale and tax analysis purposes  | 2.7          | \$ 350      | \$ 945.00     |
| Michael Land       | 01/28/20    | Continued, from earlier in the day, to prepare initial draft of Mundipharma DC B.V.'s asset disposition scenario  | 2.7          | \$ 534      | \$ 1,441.80   |
| Michael Land       | 01/28/20    | Review of Mundipharma DC B.V. structure in conjunction with the Purdue cash flow model for purposes of structuring  | 2.9          | \$ 534      | \$ 1,548.60   |
| Devon Rowles       | 01/28/20    | Continue, from earlier in the day, to create a structure deck for Purdue Pharma (Canada) related to individual country dispositions and foreign tax consequences.   | 3.1          | \$ 350      | \$ 1,085.00   |
| Dawn Krishnamurthy | 01/28/20    | Manager review of notes prepared by M. Land (KPMG) from Project Malta reports Volumes 1- 2 for the purpose of gaining insight regarding tax profile of the Mundipharma entities.  | 3.4          | \$ 695      | \$ 2,363.00   |
| Dawn Krishnamurthy | 01/28/20    | 0.8 Review of financial statements of Purdue Indian entities to identify relevant tax information; 2.7 Review of Project Malta report Volume I with focus on tax profile of Mundipharma entities.   | 3.5          | \$ 695      | \$ 2,432.50   |
| Thomas Giordano    | 01/28/20    | Continued, from earlier in the day, to manually create assigned portion of slides for structure deck disposition scenarios related to three United Kingdom entities and one German entity, including depictions, assumptions, and transaction steps; Note: These were very complicated organizational structures because of numerous instances of cross ownership. Thus, depictions were very difficult to create / consolidate. Further, the transactions steps depended on PBC data which was Sometimes partially unreadable. | 3.6          | \$ 350      | \$ 1,260.00   |
| Ashley Armfield    | 01/28/20    | Senior associate review of structure deck for CH13 - Mundipharma MEA GmbH asset sale scenario.  | 3.6          | \$ 534      | \$ 1,922.40   |
| Frank Caratzola    | 01/28/20    | 2.7 Performed research related to the applicability of Section 162 deduction for ordinary and necessary expenses paid or incurred in carrying on a "trade or business" to client facts; 1.0 Performed research related to the applicability of Section 165 and Section 212 deductions to client facts   | 3.7          | \$ 534      | \$ 1,975.80   |
| Devon Rowles       | 01/28/20    | Creating a simplified excel model for Purdue Pharma (Canada) to correlate with Purdue Pharma (Canada) structure deck with regards to individual country dispositions and tax consequences.  | 3.7          | \$ 350      | \$ 1,295.00   |
| Michael Land       | 01/28/20    | Begin to prepare initial draft of Mundipharma DC B.V.'s asset disposition scenario  | 3.9          | \$ 534      | \$ 2,082.60   |

**EXHIBIT C1**

**Purdue Pharma L.P.**

**Case No. 19-23649**

Bankruptcy Tax Consulting Services  
December 23, 2019 through January 31, 2020

| <b>Name</b>      | <b>Date</b> | <b>Description</b>  | <b>Hours</b> | <b>Rate</b> | <b>Amount</b> |
|------------------|-------------|---|--------------|-------------|---------------|
| Andy Farinich    | 01/28/20    | Continue (from previous day) creating designated portion of slides for structure deck disposition scenarios related to three United Kingdom entities and one German entity, including depictions, assumptions, and transaction steps.   | 3.9          | \$ 534      | \$ 2,082.60   |
| Andy Farinich    | 01/28/20    | Continue (same day) creating designated portion of slides for structure deck disposition scenarios related to three United Kingdom entities and one German entity, including depictions, assumptions, and transaction steps.  | 3.9          | \$ 534      | \$ 2,082.60   |
| Jess Commisso    | 01/28/20    | Continued (from 1/24), to create assigned portion of illustrative structure deck based on Norton Rose sale computations of Mundipharma entities pursuant to sharing with our member firms for sale and tax analysis purposes. Note: this is an exceptionally large task that will be ongoing including continuous updates to the deck (based on additional data received) and will be performed by several KPMG professionals assigned to different facets of structure deck.                                     | 3.9          | \$ 350      | \$ 1,365.00   |
| Thomas Giordano  | 01/28/20    | Continued (from 1/27) to manually create assigned portion of slides for structure deck disposition scenarios related to three United Kingdom entities and one German entity, including depictions, assumptions, and transaction steps; Note: These were very complicated organizational structures because of numerous instances of cross ownership. Thus, depictions were very difficult to create / consolidate. Further, the transactions steps depended on PBC data which was Sometimes partially unreadable. | 3.9          | \$ 350      | \$ 1,365.00   |
| Howard Steinberg | 01/28/20    | Partner review of updated workplan for purposes of determining project strategy   | 1.7          | \$ 856      | \$ 1,455.20   |
| Ashley Armfield  | 01/29/20    | Meeting with A. Armfield, J. Commisso, and D. Rowles (all KPMG) to discuss updates that need to be made to the proposed disposition structure deck (asset versus stock analysis) of entities - as provided by Norton Rose.  | 0.4          | \$ 534      | \$ 213.60     |
| Devon Rowles     | 01/29/20    | Meeting with A. Armfield, J. Commisso, and D. Rowles (all KPMG) to discuss updates that need to be made to the proposed disposition structure deck (asset versus stock analysis) of entities - as provided by Norton Rose.  | 0.4          | \$ 350      | \$ 140.00     |
| Jess Commisso    | 01/29/20    | Meeting with A. Armfield, J. Commisso, and D. Rowles (all KPMG) to discuss updates that need to be made to the proposed disposition structure deck (asset versus stock analysis) of entities - as provided by Norton Rose.  | 0.4          | \$ 350      | \$ 140.00     |

**EXHIBIT C1**

**Purdue Pharma L.P.**

**Case No. 19-23649**

Bankruptcy Tax Consulting Services  
December 23, 2019 through January 31, 2020

| <b>Name</b>        | <b>Date</b> | <b>Description</b>   | <b>Hours</b> | <b>Rate</b> | <b>Amount</b> |
|--------------------|-------------|--|--------------|-------------|---------------|
| Thomas Giordano    | 01/29/20    | Continue (on same day) additional development structure deck disposition scenarios for Napp Pharmaceutical Holdings Limited.   | 1.1          | \$ 350      | \$ 385.00     |
| Thomas Giordano    | 01/29/20    | Continued (same day) additional development of structure deck disposition scenarios regarding Mundipharma Medical Company Limited  | 1.1          | \$ 350      | \$ 385.00     |
| Ashley Armfield    | 01/29/20    | Meeting with A. Armfield and M. Land (all KPMG) to discuss structuring alternative scenarios with regards to overall strategy  | 1.1          | \$ 534      | \$ 587.40     |
| Michael Land       | 01/29/20    | Meeting with A. Armfield and M. Land (all KPMG) to discuss structuring alternative scenarios with regards to overall strategy  | 1.1          | \$ 534      | \$ 587.40     |
| Ashley Armfield    | 01/29/20    | Meeting with A. Armfield and M. Land (all KPMG) to discuss structuring alternatives related to Mundipharma MEA GmbH.   | 1.2          | \$ 534      | \$ 640.80     |
| Michael Land       | 01/29/20    | Meeting with A. Armfield and M. Land (all KPMG) to discuss structuring alternatives related to Mundipharma MEA GmbH.   | 1.2          | \$ 534      | \$ 640.80     |
| Isaac Hirsch       | 01/29/20    | Communication via email with P. DiMatteo (KPMG) regarding research related to the deductibility of settlement payments   | 1.3          | \$ 819      | \$ 1,064.70   |
| Dawn Krishnamurthy | 01/29/20    | Review of Purdue Pharma transfer pricing documentation for purpose of identifying potential tax exposures.   | 1.5          | \$ 695      | \$ 1,042.50   |
| Pete DiMatteo      | 01/29/20    | Update outline detailing section 162 research for purposes of determining whether a deduction is permissible for settlement payments   | 1.6          | \$ 650      | \$ 1,040.00   |
| Ashley Armfield    | 01/29/20    | Meeting with A. Armfield and M. Land (all KPMG) to discuss structuring alternatives related to Mundipharma DC B.V.   | 2.3          | \$ 534      | \$ 1,228.20   |
| Michael Land       | 01/29/20    | Meeting with A. Armfield and M. Land (all KPMG) to discuss structuring alternatives related to Mundipharma DC B.V.   | 2.3          | \$ 534      | \$ 1,228.20   |
| Devon Rowles       | 01/29/20    | Update the Switzerland structure deck (per direction from A. Armfield and M. Land - both of KPMG) with specific regards to individual country dispositions / tax consequences  | 2.4          | \$ 350      | \$ 840.00     |
| Frank Caratzola    | 01/29/20    | 0.3 Compiled a listing of the trusts in Client's entity structure and concurrently identified the beneficiaries of each in an excel workbook; 2.3 Performed research regarding foreign tax credit ("FTC") rules under sections 901/904 as they related to the specific entity structures in Client's facts | 2.6          | \$ 534      | \$ 1,388.40   |
| Isaac Hirsch       | 01/29/20    | Performed Managing Director review and concurrently analyze research prepared by P. DiMatteo (KPMG) related to deductibility of settlement payments  | 2.8          | \$ 819      | \$ 2,293.20   |

**EXHIBIT C1**

**Purdue Pharma L.P.**

**Case No. 19-23649**

Bankruptcy Tax Consulting Services  
December 23, 2019 through January 31, 2020

| <b>Name</b>        | <b>Date</b> | <b>Description</b>  | <b>Hours</b> | <b>Rate</b> | <b>Amount</b> |
|--------------------|-------------|---|--------------|-------------|---------------|
| Ashley Armfield    | 01/29/20    | Preparing Mundipharma MEA GmbH tax steps associated with a stock disposition pursuant to preparing structuring deck to be sent to KPMG member firms to facilitate tax analyses.   | 2.9          | \$ 534      | \$ 1,548.60   |
| Dawn Krishnamurthy | 01/29/20    | 0.3 Review of information request list for purpose of identifying most critical items; 2.7 Manager review of data room information related to entities located in high priority jurisdictions for purposes of disposition scenario structure deck.  | 3.0          | \$ 695      | \$ 2,085.00   |
| Pete DiMatteo      | 01/29/20    | Continue (same day) to draft a PowerPoint presentation with focus on depicting contemplated transactions  | 3.2          | \$ 650      | \$ 2,080.00   |
| Devon Rowles       | 01/29/20    | Updated the Netherlands structure deck (per direction from A. Armfield and M. Land - both of KPMG) with specific regards to individual country dispositions / tax consequences  | 3.3          | \$ 350      | \$ 1,155.00   |
| Pete DiMatteo      | 01/29/20    | Drafted a PowerPoint presentation depicting contemplated asset/stock sales and subsequent distributions.  | 3.6          | \$ 650      | \$ 2,340.00   |
| Frank Caratzola    | 01/29/20    | 2.3 Continued (from 1/28/2020) to perform research related to the applicability of Section 162 deduction for ordinary and necessary expenses paid or incurred in carrying on a "trade or business" to Client facts; 1.4 Continued (from 1/28/2020) to perform research related to the applicability of Section 165 and Section 212 deductions to the Client facts   | 3.7          | \$ 534      | \$ 1,975.80   |
| Thomas Giordano    | 01/29/20    | Additional development/updates to the structure deck disposition scenarios for Mundipharma Medical Company Limited with regard to clarification received, based on discussion with the project team, regarding best approach to interpret previously received PBC data that was partially unreadable (with respect to transaction steps).   | 3.9          | \$ 350      | \$ 1,365.00   |
| Thomas Giordano    | 01/29/20    | Additional development/updates to the structure deck disposition scenarios for Napp Pharmaceutical Holdings Limited with regard to clarification received, based on discussion with the project team, regarding best approach to interpret previously received PBC data that was partially unreadable (with respect to transaction steps).  | 3.9          | \$ 350      | \$ 1,365.00   |
| Jess Commisso      | 01/29/20    | Continue, from earlier in the day, to create assigned portion of illustrative structure deck based on Norton Rose sale computations of Mundipharma entities pursuant to sharing with our member firms for sale and tax analysis purposes. Note: this is an exceptionally large task that will be ongoing including continuous updates to the deck (based on additional data received) and will be performed by several KPMG professionals assigned to different facets of structure deck. | 3.9          | \$ 350      | \$ 1,365.00   |

**EXHIBIT C1**

**Purdue Pharma L.P.**

**Case No. 19-23649**

Bankruptcy Tax Consulting Services  
December 23, 2019 through January 31, 2020

| <b>Name</b>        | <b>Date</b> | <b>Description</b>   | <b>Hours</b> | <b>Rate</b> | <b>Amount</b> |
|--------------------|-------------|--|--------------|-------------|---------------|
| Jess Commisso      | 01/29/20    | Continued (from 1/24) to create illustrative structure deck based on Norton Rose sale computations of Mundipharma entities pursuant to sharing with our member firms for sale and tax analysis purposes.   | 3.9          | \$ 350      | \$ 1,365.00   |
| Howard Steinberg   | 01/29/20    | Perform Partner review of data room information for purposes of determining tax posture  | 1.0          | \$ 856      | \$ 856.00     |
| Thomas Giordano    | 01/30/20    | Continued (same day) to draft detailed email to project team explaining an identified ownership depiction issue regarding four entities in the Mundipharma MEA GmbH organization structure that had effects across multiple entities' organization structures  | 0.3          | \$ 350      | \$ 105.00     |
| Thomas Giordano    | 01/30/20    | Continued (same day) to further refine the structure deck disposition scenarios for Mundipharma Medical Company Limited as of 1/30/2020 with respect to new information received as well as updates to layout/format of the deck (which evolves and will continue to evolve) - the layout and presentation of the slide deck is a work in process, therefore, the refinement and revisions will continue to occur for the foreseeable future with respect to these same decks all of which will need to be consistent. | 0.5          | \$ 350      | \$ 175.00     |
| Thomas Giordano    | 01/30/20    | Continue (on same day) to further refine the structure deck disposition scenarios for Mundibiopharma Limited as of 1/30/2020 with respect to new information received as well as updates to layout/format of the deck (which evolves and will continue to evolve - the layout and presentation of the slide deck is a work in process, therefore, the refinement and revisions will continue to occur for the foreseeable future with respect to these same decks all of which will need to consistent).               | 0.6          | \$ 350      | \$ 210.00     |
| Thomas Giordano    | 01/30/20    | Began to draft detailed email to project team regarding the identified ownership depiction issue related to four entities in the MundipharmaMEA GmbH organization structure that had effects across multiple entities' organization structures   | 0.7          | \$ 350      | \$ 245.00     |
| Michael Land       | 01/30/20    | Review of United Kingdom disposition scenarios for purposes of assessing the optimal structure to maximize distributable proceeds  | 1.1          | \$ 534      | \$ 587.40     |
| Dawn Krishnamurthy | 01/30/20    | Review structure decks for purpose of gaining insight regarding materiality and potential tax issues involved in disposition: Argentina - Bermuda  | 1.2          | \$ 695      | \$ 834.00     |
| Michael Land       | 01/30/20    | Review of Singapore cash flow calculation with regards to asset versus stock sale  | 1.3          | \$ 534      | \$ 694.20     |

**EXHIBIT C1**

**Purdue Pharma L.P.**

**Case No. 19-23649**

Bankruptcy Tax Consulting Services  
December 23, 2019 through January 31, 2020

| <b>Name</b>        | <b>Date</b> | <b>Description</b>  | <b>Hours</b> | <b>Rate</b> | <b>Amount</b> |
|--------------------|-------------|---|--------------|-------------|---------------|
| Jess Commisso      | 01/30/20    | Continue (from earlier in the day) to create assigned portion of illustrative structure deck based on Norton Rose sale computations of Mundipharma entities pursuant to sharing with our member firms for sale and tax analysis purposes.   | 1.4          | \$ 350      | \$ 490.00     |
| Isaac Hirsch       | 01/30/20    | Continued (from previous day) to perform Managing Director review and concurrently analyze research prepared by P. DiMatteo (KPMG) related to deductibility of settlement payments  | 1.4          | \$ 819      | \$ 1,146.60   |
| Ashley Armfield    | 01/30/20    | Meeting with A. Armfield and M. Land (KPMG) to discuss updates required to be performed to the cash tax model, including but not limited to the payment of intercompany obligations and preferred equity in connection with the proposed disposition of the Mundipharma entities.   | 1.4          | \$ 534      | \$ 747.60     |
| Michael Land       | 01/30/20    | Meeting with A. Armfield and M. Land (KPMG) to discuss updates required to be performed to the cash tax model, including but not limited to the payment of intercompany obligations and preferred equity in connection with the proposed disposition of the Mundipharma entities.   | 1.4          | \$ 534      | \$ 747.60     |
| Frank Caratzola    | 01/30/20    | 1.0 Performed research regarding branch ordering rules with regard to how FTCs would be treated in the client structure 1.0 Performed research regarding Section 731 distributions with regard to how FTCs would be treated in the client structure   | 2.0          | \$ 534      | \$ 1,068.00   |
| Devon Rowles       | 01/30/20    | Continue (same day) to revise structure deck for Purdue Pharma (Canada) (per A. Armfield and M. Land – both of KPMG) with specific regards to individual country dispositions and foreign tax consequences  | 2.4          | \$ 350      | \$ 840.00     |
| Dawn Krishnamurthy | 01/30/20    | Review structure decks for purpose of gaining insight regarding materiality and potential tax issues involved in disposition: Brazil- Finland   | 2.4          | \$ 695      | \$ 1,668.00   |
| Ashley Armfield    | 01/30/20    | 0.8 Performed research related to Internal Revenue Code Section 904(b) relating to foreign tax credit limitation calculation pursuant to cash tax model; 0.8 Performed research related to Internal Revenue Code Section 901 relating to foreign tax credits pursuant to cash tax model. 0.9 Performed research related to Internal Revenue Code Sections 861-865 relating to income sourcing pursuant to cash tax model. | 2.5          | \$ 534      | \$ 1,335.00   |
| Michael Land       | 01/30/20    | 1.1 Review of Germany disposition scenarios with regards to asset versus stock sale 1.4 Review of Singapore disposition scenarios with regards to asset versus stock sale   | 2.5          | \$ 534      | \$ 1,335.00   |

**EXHIBIT C1**

**Purdue Pharma L.P.**

**Case No. 19-23649**

Bankruptcy Tax Consulting Services  
December 23, 2019 through January 31, 2020

| <b>Name</b>        | <b>Date</b> | <b>Description</b>  | <b>Hours</b> | <b>Rate</b> | <b>Amount</b> |
|--------------------|-------------|---|--------------|-------------|---------------|
| Ashley Armfield    | 01/30/20    | Performed structural updates to the cash tax model (based on comments received from I. Hirsch and discussions with M. Land - both KPMG) including the calculation of foreign tax credits and income classification.   | 2.8          | \$ 534      | \$ 1,495.20   |
| Michael Land       | 01/30/20    | 1.4 Review of Canada disposition scenarios with regards to asset versus stock sale<br>1.6 Review of Canada cash flow calculation regarding asset versus stock sale  | 3.0          | \$ 534      | \$ 1,602.00   |
| Dawn Krishnamurthy | 01/30/20    | 2.1 Review of structure decks for purpose of gaining insight regarding materiality and potential tax issues involved in disposition: France - Japan; 0.9 Review of structure decks for purpose of gaining insight regarding materiality and potential tax issues involved in disposition: Luxembourg - UK.  | 3.0          | \$ 695      | \$ 2,085.00   |
| Thomas Giordano    | 01/30/20    | Further refined the structure deck disposition scenarios for Mundibiopharma Limited as of 1/30/2020 with respect to new information received as well as updates to layout/format of the deck (which evolves and will continue to evolve - the layout and presentation of the slide deck is a work in process, therefore, the refinement and revisions will continue to occur for the foreseeable future with respect to these same decks all of which will need to consistent).                   | 3.4          | \$ 350      | \$ 1,190.00   |
| Pete DiMatteo      | 01/30/20    | Continue, from previous day, to draft PowerPoint presentation depicting contemplated transactions   | 3.5          | \$ 650      | \$ 2,275.00   |
| Thomas Giordano    | 01/30/20    | Further refined the structure deck disposition scenarios for Mundipharma Medical Company Limited, as of 1/30/2020, with respect to new information received as well as updates to layout/format of the deck (which evolves and will continue to evolve - the layout and presentation of the slide deck is a work in process, therefore, the refinement and revisions will continue to occur for the foreseeable future with respect to these same decks all of which will need to be consistent). | 3.5          | \$ 350      | \$ 1,225.00   |
| Pete DiMatteo      | 01/30/20    | Continue (from 1/29) to update outline detailing section 162 research to include results of additional research for purposes of determining whether a deduction is permissible for settlement payments.   | 3.7          | \$ 650      | \$ 2,405.00   |
| Frank Caratzola    | 01/30/20    | Continued (from 1/29/2020) to perform research regarding foreign tax credit ("FTC") rules under sections 901/904 as they related to the specific entity structures in client's facts  | 3.7          | \$ 534      | \$ 1,975.80   |
| Jess Commisso      | 01/30/20    | Continue (same day) to create assigned portion of illustrative structure deck based on Norton Rose sale computations of Mundipharma entities pursuant to sharing with our member firms for sale and tax analysis purposes.  | 3.9          | \$ 350      | \$ 1,365.00   |



**EXHIBIT C1**

**Purdue Pharma L.P.**

**Case No. 19-23649**

Bankruptcy Tax Consulting Services  
December 23, 2019 through January 31, 2020

| <b>Name</b>     | <b>Date</b> | <b>Description</b>   | <b>Hours</b> | <b>Rate</b> | <b>Amount</b> |
|-----------------|-------------|--|--------------|-------------|---------------|
| Devon Rowles    | 01/30/20    | Continued (from 1/28) to revise the structure deck for Purdue Pharma (Canada) (per A. Armfield and M. Land – both of KPMG) with specific regards to individual country dispositions and foreign tax consequences.            | 3.9          | \$ 350      | \$ 1,365.00   |
| Jess Commisso   | 01/30/20    | Continued (from 1/29) to create assigned portion of illustrative structure deck based on Norton Rose sale computations of Mundipharma entities pursuant to sharing with our member firms for sale and tax analysis purposes. | 3.9          | \$ 350      | \$ 1,365.00   |
| Nick Morgan     | 01/30/20    | Review of Purdue Term Sheet (0.5) and Purdue Term Sheet Summary client deliverable (0.5) with specific regards to facts of the case in order to render future advice per client deliverables.                                | 1.0          | \$ 350      | \$ 350.00     |
| Nick Morgan     | 01/30/20    | Review of client deliverable structure deck provided by KPMG International tax (P. DiMatteo and T. Giordano) with specific regards to deal transaction scope of work From KPMG International service line.                   | 1.3          | \$ 350      | \$ 455.00     |
| Nick Morgan     | 01/30/20    | Review of documentation (provided by client documents as well as documents included in VDR) with focus on deal transaction / scope of work.  | 2.7          | \$ 350      | \$ 945.00     |
| Ashley Armfield | 01/31/20    | Meeting with A. Armfield and M. Land (all KPMG) to discuss updates to cash tax model related to preferred equity distributions   | 0.4          | \$ 534      | \$ 213.60     |
| Michael Land    | 01/31/20    | Meeting with A. Armfield and M. Land (all KPMG) to discuss updates to cash tax model related to preferred equity distributions   | 0.4          | \$ 534      | \$ 213.60     |
| Ashley Armfield | 01/31/20    | Meeting with A. Armfield, K. Krishnamurthy, D. Rowles and N. Morgan (all KPMG) to discuss structure decks related to Purdue Pharma Inc. (Canada) asset/stock dispositions and related tax consequences                       | 0.7          | \$ 534      | \$ 373.80     |
| Nick Morgan     | 01/31/20    | Meeting with A. Armfield, K. Krishnamurthy, D. Rowles and N. Morgan (all KPMG) to discuss structure decks related to Purdue Pharma Inc. (Canada) asset/stock dispositions and related tax consequences                       | 0.7          | \$ 350      | \$ 245.00     |
| Devon Rowles    | 01/31/20    | Meeting with A. Armfield, K. Krishnamurthy, D. Rowles and N. Morgan (all KPMG) to discuss structure decks related to Purdue Pharma Inc. (Canada) asset/stock dispositions and related tax consequences                       | 0.7          | \$ 350      | \$ 245.00     |
| Michael Land    | 01/31/20    | Meeting with A. Armfield, K. Krishnamurthy, D. Rowles and N. Morgan (all KPMG) to discuss structure decks related to Purdue Pharma Inc. (Canada) asset/stock dispositions and related tax consequences                       | 0.7          | \$ 534      | \$ 373.80     |

**EXHIBIT C1**

**Purdue Pharma L.P.**

**Case No. 19-23649**

Bankruptcy Tax Consulting Services  
December 23, 2019 through January 31, 2020

| <b>Name</b>     | <b>Date</b> | <b>Description</b>   | <b>Hours</b> | <b>Rate</b> | <b>Amount</b> |
|-----------------|-------------|--|--------------|-------------|---------------|
| Ashley Armfield | 01/31/20    | Meeting with K. Krishnamurthy, A. Armfield, D. Rowles and N. Morgan (all KPMG) to discuss structure decks related to Mundipharma DC BV (Netherlands) asset/stock dispositions and related tax consequences               | 0.7          | \$ 534      | \$ 373.80     |
| Nick Morgan     | 01/31/20    | Meeting with K. Krishnamurthy, A. Armfield, D. Rowles and N. Morgan (all KPMG) to discuss structure decks related to Mundipharma DC BV (Netherlands) asset/stock dispositions and related tax consequences               | 0.7          | \$ 350      | \$ 245.00     |
| Devon Rowles    | 01/31/20    | Meeting with K. Krishnamurthy, A. Armfield, D. Rowles and N. Morgan (all KPMG) to discuss structure decks related to Mundipharma DC BV (Netherlands) asset/stock dispositions and related tax consequences               | 0.7          | \$ 350      | \$ 245.00     |
| Michael Land    | 01/31/20    | Meeting with K. Krishnamurthy, A. Armfield, D. Rowles and N. Morgan (all KPMG) to discuss structure decks related to Mundipharma DC BV (Netherlands) asset/stock dispositions and related tax consequences               | 0.7          | \$ 534      | \$ 373.80     |
| Jess Commisso   | 01/31/20    | Meeting with P. DiMatteo, M. Land, J. Commisso, T. Giordano (all KPMG) to discuss structure decks related to Mundipharma Singapore Holdings Pte. Limited asset/stock dispositions and related tax consequences.          | 0.7          | \$ 350      | \$ 245.00     |
| Michael Land    | 01/31/20    | Meeting with P. DiMatteo, M. Land, J. Commisso, T. Giordano (all KPMG) to discuss structure decks related to Mundipharma Singapore Holdings Pte. Limited asset/stock dispositions and related tax consequences.          | 0.7          | \$ 534      | \$ 373.80     |
| Pete DiMatteo   | 01/31/20    | Meeting with P. DiMatteo, M. Land, J. Commisso, T. Giordano (all KPMG) to discuss structure decks related to Mundipharma Singapore Holdings Pte. Limited asset/stock dispositions and related tax consequences.          | 0.7          | \$ 650      | \$ 455.00     |
| Thomas Giordano | 01/31/20    | Meeting with P. DiMatteo, M. Land, J. Commisso, T. Giordano (all KPMG) to discuss structure decks related to Mundipharma Singapore Holdings Pte. Limited asset/stock dispositions and related tax consequences.          | 0.7          | \$ 350      | \$ 245.00     |
| Jess Commisso   | 01/31/20    | Meeting with P. DiMatteo, M. Land, J. Commisso, T. Giordano (all KPMG) to discuss structure decks related to the Mundipharma Medical Company Ltd. (United Kingdom) asset/stock dispositions and related tax consequences | 0.7          | \$ 350      | \$ 245.00     |
| Michael Land    | 01/31/20    | Meeting with P. DiMatteo, M. Land, J. Commisso, T. Giordano (all KPMG) to discuss structure decks related to the Mundipharma Medical Company Ltd. (United Kingdom) asset/stock dispositions and related tax consequences | 0.7          | \$ 534      | \$ 373.80     |

**EXHIBIT C1**

**Purdue Pharma L.P.**

**Case No. 19-23649**

Bankruptcy Tax Consulting Services  
December 23, 2019 through January 31, 2020

| <b>Name</b>     | <b>Date</b> | <b>Description</b>  | <b>Hours</b> | <b>Rate</b> | <b>Amount</b> |
|-----------------|-------------|---|--------------|-------------|---------------|
| Pete DiMatteo   | 01/31/20    | Meeting with P. DiMatteo, M. Land, J. Commisso, T. Giordano (all KPMG) to discuss structure decks related to the Mundipharma Medical Company Ltd. (United Kingdom) asset/stock dispositions and related tax consequences  | 0.7          | \$ 650      | \$ 455.00     |
| Thomas Giordano | 01/31/20    | Meeting with P. DiMatteo, M. Land, J. Commisso, T. Giordano (all KPMG) to discuss structure decks related to the Mundipharma Medical Company Ltd. (United Kingdom) asset/stock dispositions and related tax consequences  | 0.7          | \$ 350      | \$ 245.00     |
| Michael Land    | 01/31/20    | Performed research related to foreign tax credit calculations with regards to the Purdue Pharma cash tax model  | 1.1          | \$ 534      | \$ 587.40     |
| Isaac Hirsch    | 01/31/20    | Managing Director review and concurrently analyze research prepared by P. DiMatteo (KPMG) related to deductibility of settlement payments.  | 1.2          | \$ 819      | \$ 982.80     |
| Ashley Armfield | 01/31/20    | Meeting with A. Armfield and M. Land (all KPMG) to discuss updates to the Purdue cash tax model with regards to foreign tax credits   | 1.2          | \$ 534      | \$ 640.80     |
| Michael Land    | 01/31/20    | Meeting with A. Armfield and M. Land (all KPMG) to discuss updates to the Purdue cash tax model with regards to foreign tax credits   | 1.2          | \$ 534      | \$ 640.80     |
| Jess Commisso   | 01/31/20    | Extract and concurrently compile newly uploaded United Kingdom tax documentation from the virtual data room to share with the global team pursuant to their tax analysis.   | 1.3          | \$ 350      | \$ 455.00     |
| Jess Commisso   | 01/31/20    | Continue, from earlier in the day, to create assigned portion of illustrative structure deck based on Norton Rose sale computations of Mundipharma entities pursuant to sharing with our member firms for sale and tax analysis purposes.   | 1.4          | \$ 350      | \$ 490.00     |
| Michael Land    | 01/31/20    | 0.8 Reviewed Ernst & Young question & answer documentation uploaded to the virtual data room with focus on the independent associated companies tax profile; 0.8 review of Ernst & Young updated financial information on jurisdiction-by-jurisdiction basis uploaded to the virtual data room to determine potential high priority jurisdictions | 1.6          | \$ 534      | \$ 854.40     |
| Frank Caratzola | 01/31/20    | Analyzed entity list created by EY in comparison with KPMG entity list as requested by P. DiMatteo (KPMG) to determine the accuracy of KPMG entity list / identify any potential discrepancies.   | 1.6          | \$ 534      | \$ 854.40     |
| Pete DiMatteo   | 01/31/20    | Continued, from previous day) to perform analysis regarding section 162 deductions in the context of trust/partnership trade or business attribution as part of overall analysis regarding allowability of deductions.  | 2.2          | \$ 650      | \$ 1,430.00   |

**EXHIBIT C1**

**Purdue Pharma L.P.**

**Case No. 19-23649**

Bankruptcy Tax Consulting Services  
December 23, 2019 through January 31, 2020

| <b>Name</b>        | <b>Date</b> | <b>Description</b>  | <b>Hours</b> | <b>Rate</b> | <b>Amount</b> |
|--------------------|-------------|---|--------------|-------------|---------------|
| Devon Rowles       | 01/31/20    | Extract and concurrently compiled Singapore tax documentation from the virtual data room as of 1/31/2020 to share with Singapore pursuant to their tax analysis.  | 2.3          | \$ 350      | \$ 805.00     |
| Dawn Krishnamurthy | 01/31/20    | 2.4 Manager review of Mundipharma ownership structures for purpose of depicting disposition scenarios; 0.3 Review of EY Q&A document (a follow up to the EY financial vendor Due Diligence report which we reviewed for relevant tax information) with entity listing with focus on the IAC listing tab (which I compared to our information on entities in the Mundipharma group) to ensure a complete listing of IAC entities so that we can accurately gain insight regarding which entities may potentially be sold / where the assets are located. | 2.7          | \$ 695      | \$ 1,876.50   |
| Arpit Kakar        | 01/31/20    | Analyzed audited financial statements (Financial Year 2016-2018) of Modi-Mundipharma Private Limited to determine Tax reserves, Open tax audits or controversies as well as tax attribute carryforwards and concurrently drafted information summary of such details as appearing in the audited financials.  | 2.8          | \$ 640      | \$ 1,792.00   |
| Naman Gupta        | 01/31/20    | Analyzed audited financial statements (Financial Year 2016-2018) of Modi-Mundipharma Healthcare Private Limited and Win-Medicare Private Limited to determine Tax reserves, Open tax audits or controversies and Tax attribute carryforwards while concurrently preparing an information summary of same as appearing in the audited financials.  | 3.1          | \$ 640      | \$ 1,984.00   |
| Dawn Krishnamurthy | 01/31/20    | Performed Manager review of Mundipharma draft disposition scenarios deck (Canada).  | 3.1          | \$ 695      | \$ 2,154.50   |
| Pete DiMatteo      | 01/31/20    | Draft structuring deck depicting transactions related to Mundipharma Deutschland GmbH & Co. KG (Germany) stock/asset sales and tax consequences   | 3.3          | \$ 650      | \$ 2,145.00   |
| Frank Caratzola    | 01/31/20    | Performed research regarding foreign tax credits - as they relate to Purdue Pharma (client) structure   | 3.4          | \$ 534      | \$ 1,815.60   |
| Nidhi Jain         | 01/31/20    | Analyzed audited financial statements (Financial Year 2016-2018) of Modi-Mundipharma Beauty Products Private Limited to determine Tax reserves, Open tax audits or controversies and Tax attribute carryforwards; and prepared information summary of such details as appearing in the audited financials.  | 3.5          | \$ 640      | \$ 2,240.00   |
| Ashley Armfield    | 01/31/20    | 2.9 Performed research related to differential tax rate relating to foreign tax credit calculation pursuant to Purdue Pharma cash tax model; 0.9 Updating cash tax model to incorporate rate differential concept per results of research.  | 3.8          | \$ 534      | \$ 2,029.20   |

**EXHIBIT C1**

**Purdue Pharma L.P.**

**Case No. 19-23649**

Bankruptcy Tax Consulting Services  
December 23, 2019 through January 31, 2020

| <b>Name</b>                             | <b>Date</b> | <b>Description</b>   | <b>Hours</b>          | <b>Rate</b> | <b>Amount</b>               |
|---|-------------|--|-----------------------|-------------|-----------------------------|
| Thomas Giordano                         | 01/31/20    | Additional updates to the Purdue Pharma structure deck disposition scenarios related to Mundipharma Medical Company Limited and Mundibiopharma Limited   | 3.8                   | \$ 350      | \$ 1,330.00                 |
| Jess Commisso                           | 01/31/20    | Continued, from 1/30, to create assigned portion of illustrative structure deck based on Norton Rose sale computations of Mundipharma entities pursuant to sharing with our member firms for sale and tax analysis purposes. | 3.9                   | \$ 350      | \$ 1,365.00                 |
| Howard Steinberg                        | 01/31/20    | Performed Partner review of tax summary for purposes of determining high priority jurisdictions  | 1.7                   | \$ 856      | \$ 1,455.20                 |
| Nick Morgan                             | 01/31/20    | Reviewed bankruptcy trust documentation with focus on types of distributing entities for tax posture purposes.   | 1.0                   | \$ 350      | \$ 350.00                   |
| Nick Morgan                             | 01/31/20    | Created UK structure deck for the client deliverable for entity #2   | 1.4                   | \$ 350      | \$ 490.00                   |
| Nick Morgan                             | 01/31/20    | Created UK structure deck for the client deliverable for entity #1   | 1.6                   | \$ 350      | \$ 560.00                   |
| Nick Morgan                             | 01/31/20    | Continued (same day) creation of structure deck formation for UK entities with focus on providing provided additional structuring steps for each entity.   | 2.5                   | \$ 350      | \$ 875.00                   |
| <b>Subtotal Tax Consulting Services</b> |             |  | <b><u>1,311.1</u></b> |             | <b><u>\$ 702,712.00</u></b> |
| Less KPMG Voluntary Reduction           |             |  |                       |             | \$ (130,000.00)             |
| <b>Total Tax Consulting Services</b>    |             |  |                       |             | <b><u>\$ 572,712.00</u></b> |

**EXHIBIT C2**

**Purdue Pharma L.P.**

**Case No. 19-23649**

Non -Working Travel Time

December 23, 2019 through January 31, 2020

| <b>Name</b>                             | <b>Date</b> | <b>Description</b>  | <b>Hours</b>      | <b>Rate</b> | <b>Amount</b>                |
|---|-------------|---|-------------------|-------------|------------------------------|
| Isaac Hirsch                            | 01/16/20    | Non-working travel time (roundtrip) from home in Livingston, NJ and KPMG NYC office (560 Lexington Ave) to attend meeting related to Purdue Pharma bankruptcy matter. | 3.0               | \$ 819      | \$ 2,457.00                  |
| Isaac Hirsch                            | 01/27/20    | Non-working travel time (roundtrip) from home in Livingston, NJ and KPMG NYC office (560 Lexington Ave) to attend meeting related to Purdue Pharma bankruptcy matter. | 3.0               | \$ 819      | \$ 2,457.00                  |
| <b>Subtotal Non-Working Travel Time</b> |             |   | <b><u>6.0</u></b> |             | <b><u>\$ 4,914.00</u></b>    |
| Less 50% Rate Reduction                 |             |   |                   |             | \$ (2,457.00)                |
| Less KPMG Voluntary Reduction           |             |   |                   |             | \$ (2,457.00) <sup>(1)</sup> |
| <b>Total Non-Working Travel Time</b>    |             |   |                   |             | <b><u>\$ -</u></b>           |

<sup>(1)</sup> KPMG is taking a voluntary reduction of non-working travel time.

**EXHIBIT C3**

**Purdue Pharma L.P.**

**Case No. 19-23649**

Retention Services

December 23, 2019 through January 31, 2020

| <b>Name</b>                     | <b>Date</b> | <b>Description</b>  | <b>Hours</b> | <b>Rate</b> | <b>Amount</b>    |
|---------------------------------|-------------|---|--------------|-------------|------------------|
| Monica Plangman                 | 01/03/20    | Call with S. Carlin (KPMG Office of General Counsel) regarding retention 0.2; Revise Declaration and Order and transmit to counsel 1.1  | 1.3          | \$ 264      | \$ 343.20        |
| Monica Plangman                 | 01/09/20    | Create schedule 1 and 2 referenced in KPMG Declaration (1.1); review email from counsel regarding retention (0.1); review revised retention documents and concurrently email E. Dalmanieras (Foley Hoag) and S Carlin (KPMG) to advise on same, providing a summary of revisions and pertinent details (0.5); review responses received regarding same from S. Carlin and E. Dalmanieras (0.2) Request confirmation from S. Carlin (KPMG) regarding revised language in the Order (0.1) | 2.0          | \$ 264      | \$ 528.00        |
| Monica Plangman                 | 01/09/20    | Transmit email to H Steinberg regarding retention (0.1); transmit Schedules 1 and 2 of Declaration to Debtors' counsel along with an update regarding review of retention documents (0.2).  | 0.3          | \$ 264      | \$ 79.20         |
| <b>Total Retention Services</b> |             |   | <b>3.6</b>   |             | <b>\$ 950.40</b> |

**EXHIBIT C4**

**Purdue Pharma L.P.**

**Case No. 19-23649**

Fee Application Preparation Services  
December 23, 2019 through January 31, 2020

| <b>Name</b>        | <b>Date</b> | <b>Description</b>  | <b>Hours</b> | <b>Rate</b> | <b>Amount</b> |
|--------------------|-------------|---|--------------|-------------|---------------|
| Wendy Shaffer      | 01/06/20    | 0.4 initial communication with A. Armfield (KPMG) regarding Purdue Pharma bankruptcy including information related to use of KPMG member firms and next steps; 0.1 follow-up communication with M. Plangman (KPMG) regarding same; 2.5 begin to draft multiple emails to KPMG foreign member firms including creation of Templates (by country) for inclusion in email to provide US bankruptcy time / expense detail requirements to facilitate filings in the bankruptcy court. | 2.9          | \$ 202      | \$ 585.80     |
| Wendy Shaffer      | 01/07/20    | 0.1 Call with P. Reer (KPMG) regarding German KPMG professionals currently working in the US performing services for Purdue Pharma in order to provide correct time/expense timekeeping guidelines and 0.1 forward US SYNC instructions as requested to appropriate team members  | 0.2          | \$ 202      | \$ 40.40      |
| Wendy Shaffer      | 01/08/20    | Drafted additional emails to new Purdue team members (US and Foreign member firms) including updates to templates to facilitate billings in the bankruptcy court.   | 0.5          | \$ 202      | \$ 101.00     |
| Wendy Shaffer      | 01/10/20    | Draft email to new team members for Purdue as of 1/10/2020 to facilitate billing in the bankruptcy court.   | 0.2          | \$ 202      | \$ 40.40      |
| Dawn Krishnamurthy | 01/13/20    | 0.1 Discussion with W. Shaffer (KPMG) regarding services to be billed in KPMG 1st monthly fee application performed by KPMG foreign member firms.   | 0.1          | \$ 695      | \$ 69.50      |
| Wendy Shaffer      | 01/13/20    | Discussion with D. Krishnamurthy (KPMG) regarding services to be billed in KPMG 1st monthly fee application performed by KPMG foreign member firms.   | 0.1          | \$ 202      | \$ 20.20      |
| Wendy Shaffer      | 01/13/20    | 0.2 Updated exhibit C1 of Purdue 1st monthly fee application to include data from KPMG member firms - China and Germany; 0.1 review court docket to extract copy of Purdue ICO, 0.2 Updated exhibit A of Purdue 1st monthly fee application to include additional KPMG team members.  | 0.5          | \$ 202      | \$ 101.00     |
| Wendy Shaffer      | 01/14/20    | 0.4 begin initial review of documentation email communication to date related to Purdue Pharma bankruptcy; 0.9 begin to create Purdue Pharma 1st monthly fee application exhibits; 0.5 Updated exhibit C1 of Purdue 1st monthly to include data received from KPMG foreign member firms as of 1/14/20.  | 1.8          | \$ 202      | \$ 363.60     |
| Wendy Shaffer      | 01/15/20    | Continued, same day, to update exhibit C1 of Purdue Pharma to include data received from professionals as of 1/15/2021.   | 1.9          | \$ 202      | \$ 383.80     |
| Wendy Shaffer      | 01/15/20    | Updated exhibit C1 of Purdue Pharma to include data received from professionals as of 1/15/2020   | 3.8          | \$ 202      | \$ 767.60     |



**EXHIBIT C4**

**Purdue Pharma L.P.**

**Case No. 19-23649**

Fee Application Preparation Services  
December 23, 2019 through January 31, 2020

| <b>Name</b>   | <b>Date</b> | <b>Description</b>  | <b>Hours</b> | <b>Rate</b> | <b>Amount</b> |
|---------------|-------------|---|--------------|-------------|---------------|
| Wendy Shaffer | 01/17/20    | 0.1 Review of Purdue Pharma engagement letter with regards to rates to included in 1st monthly fee application- send communication to M. Plangman (KPMG) related to same; 1.6 Updates to exhibit C1 of Purdue Pharma to include data received from professionals as of 1/17/2020; 1.0 Call with M. Plangman (KPMG) regarding initial questions related to Purdue engagement including questions regarding rates, services to be performed by KPMG foreign member firms and related templates to be utilized to capture time and expense detail to be submitted in the bankruptcy court. | 2.7          | \$ 202      | \$ 545.40     |
| Wendy Shaffer | 01/22/20    | 3.2 Updated exhibit C1 of Purdue Pharma 1st monthly fee application to include data received from professionals as of 1/22/20; 0.1 drafted email to G. Flasser and D. Brogan (both Bayard law) re KPMG introduction and questions regarding assistance with filing / service of monthly and interim applications.   | 3.3          | \$ 202      | \$ 666.60     |
| Wendy Shaffer | 01/27/20    | 0.3 Review of Purdue Pharma Interim Compensation Order to facilitate billings in the bankruptcy court; 0.3 Draft email to KPMG Partners/team leads to provide copy of ICO and summary of timeline process related to same; 1.8 Updated exhibit C1 of Purdue Pharma 1st monthly fee application to include data received from KPMG professionals as of 1/27/2020   | 2.4          | \$ 202      | \$ 484.80     |
| Wendy Shaffer | 01/27/20    | 0.2 Updated exhibit C1 of Purdue Pharma 1st monthly fee application to include data received from KPMG member firm in South Korea as of 1/27/2020; 0.1 email to B. Defliese (KPMG) regarding time detail received for foreign member firms and next steps; 0.2 Reviewed KPMG work in progress reports to confirm billable hours for KPMG through 1/26/2020; 0.1 email to C. Nunez (KPMG) regarding rates to be used in Exhibit A of Purdue Pharma monthly fee applications.   | 0.6          | \$ 202      | \$ 121.20     |
| Wendy Shaffer | 01/28/20    | 3.5 Updated to exhibit C1 of Purdue Pharma 1st monthly fee application to include data received from professionals as of 1/22/20; 0.1 call with C. Nunez (KPMG) regarding rates to be included in Purdue Pharma 1st monthly fee application.  | 3.6          | \$ 202      | \$ 727.20     |
| Wendy Shaffer | 01/28/20    | 0.1 Follow-up communication via email with C. Nunez (KPMG) regarding rates to be included in Purdue Pharma 1st monthly fee application; 0.2 noted results of discussions with C. Nunez (KPMG) for future reference and go forward; 1.2 Begin to populate rates in Exhibit A of Purdue Pharma 1st monthly fee application per direction from C. Nunez (KPMG)   | 1.5          | \$ 202      | \$ 303.00     |

**EXHIBIT C4**

**Purdue Pharma L.P.**

**Case No. 19-23649**

Fee Application Preparation Services  
December 23, 2019 through January 31, 2020

| <b>Name</b>                                       | <b>Date</b> | <b>Description</b>  | <b>Hours</b> | <b>Rate</b> | <b>Amount</b>      |
|---|-------------|---|--------------|-------------|--------------------|
| Wendy Shaffer                                     | 01/29/20    | Continue, same day, to update exhibit C1 of Purdue Pharma 1st monthly fee application to include data received from KPMG professionals as of 1/29/2020.   | 0.3          | \$ 202      | \$ 60.60           |
| Wendy Shaffer                                     | 01/29/20    | 0.1 created exhibit for Non-working travel time (C3) in Purdue Pharma 1st monthly fee application; 0.3 communication and forwarding of emails to B. Defliese (KPMG) of foreign member firm emails and items requiring follow-up regarding summary of fees; 1.9 Updated exhibit C1 of Purdue Pharma 1st monthly fee application to include data received from KPMG foreign member firms as of 1/29/2020. | 2.3          | \$ 202      | \$ 464.60          |
| Wendy Shaffer                                     | 01/29/20    | Updated exhibit C1 of Purdue Pharma 1st monthly fee application to include data received from KPMG professionals as of 1/29/2020.   | 3.9          | \$ 202      | \$ 787.80          |
| Wendy Shaffer                                     | 01/30/20    | Updated exhibit A of Purdue Pharma 1st fee application to include rates / titles for South Korea  | 0.1          | \$ 202      | \$ 20.20           |
| Wendy Shaffer                                     | 01/31/20    | Updated exhibit C1 of Purdue Pharma 1st monthly fee application to include data received from KPMG professionals as of 1/31/2020  | 1.1          | \$ 202      | \$ 222.20          |
| <b>Total Fee Application Preparation Services</b> |             |   | <b>33.8</b>  |             | <b>\$ 6,876.90</b> |

**EXHIBIT D**

**Purdue Pharma L.P.**

**Case No. 19-23649**

Summary of Out of Pocket Expenses  
December 23, 2019 through January 31, 2020

| <b>Category</b>                                      | <b>Amount</b>    |
|--|------------------|
| Airfare  | \$ 170.28        |
| Lodging  | \$ 335.95        |
| Meals  | \$ 148.68        |
| Ground Transportation                                | \$ 334.13        |
| Miscellaneous  | \$ -             |
| <b>Expense Subtotal</b>                              | <b>\$ 989.04</b> |
| Less KPMG Voluntary Reduction as noted on Exhibit D1 | \$ (374.11)      |
| <b>Total</b>   | <b>\$ 614.93</b> |

EXHIBIT D1

Purdue Pharma L.P.

Case No. 19-23649

Detail of Out of Pocket Expenses

December 23, 2019 through January 31, 2020

| Name                                   | Date     | Description  | Amount                     |
|--|----------|--|----------------------------|
| Mark Hoffenberg                        | 01/16/20 | One way coach class airfare for travel from Washington, DC to New York to attend Purdue client meeting.                              | \$ 170.28                  |
| <b>Air Fare Subtotal</b>               |          |  | <b>\$ 170.28</b>           |
| Mark Hoffenberg                        | 01/17/20 | Hotel fee incurred on night of 1/16 with check out on 1/17 while traveling to attend Purdue Pharma meeting.                          | \$ 335.95                  |
| <b>Lodging Subtotal</b>                |          |  | <b>\$ 335.95</b>           |
| Michael Land                           | 01/10/20 | Business Meals: KPMG Participants: A. Armfield, D. Rowles, M. Land   | \$ 9.15 <sup>(1)</sup>     |
| Ashley Armfield                        | 01/13/20 | Overtime meals while performing services for Purdue. KPMG Participants: A. Armfield, D. Rowles, J. Commisso, M. Land                 | \$ 49.97 <sup>(1)</sup>    |
| Ashley Armfield                        | 01/14/20 | Business meals working late team coffee A. Armfield, M. Land, J. Commisso, D. Rowles   | \$ 32.56 <sup>(1)</sup>    |
| Jess Commisso                          | 01/15/20 | Overtime meals incurred while performing services for Purdue Pharma. KPMG Participants: A. Armfield, D. Rowles, J. Commisso, M. Land | \$ 57.00                   |
| <b>Meals Subtotal</b>                  |          |  | <b>\$ 148.68</b>           |
| Devon Rowles                           | 01/05/20 | Uber fees incurred for travel from office to home while working late on Purdue engagement.   | \$ 24.13 <sup>(1)</sup>    |
| Isaac Hirsch                           | 01/10/20 | Parking fee incurred while attending meeting to discuss client business  | \$ 30.00 <sup>(1)</sup>    |
| Michael Land                           | 01/10/20 | Uber fee for travel while performing services for Purdue   | \$ 34.79 <sup>(1)</sup>    |
| Ashley Armfield                        | 01/14/20 | Uber fee for late night travel from office to home working on client engagement.   | \$ 21.65 <sup>(1)</sup>    |
| Devon Rowles                           | 01/14/20 | Uber fees incurred for travel from office to home while working late on Purdue engagement.   | \$ 26.01 <sup>(1)</sup>    |
| Ashley Armfield                        | 01/15/20 | Uber fee for late night travel from office to home working on client engagement.   | \$ 20.96 <sup>(1)</sup>    |
| Michael Land                           | 01/15/20 | Uber fee for travel while performing services for Purdue   | \$ 33.62 <sup>(1)</sup>    |
| Ashley Armfield                        | 01/16/20 | Uber fee for late night travel from office to home working on client engagement.   | \$ 18.26 <sup>(1)</sup>    |
| Isaac Hirsch                           | 01/16/20 | Mileage for meeting to discuss client business (14 miles at \$0.575/mile)  | \$ 8.05 <sup>(1)</sup>     |
| Mark Hoffenberg                        | 01/16/20 | Uber fee for travel from NYC LaGuardia to hotel in New York City while traveling to attend Purdue client meetings.                   | \$ 51.70                   |
| Mark Hoffenberg                        | 01/17/20 | Cab fare incurred in New York City to attend client meeting  | \$ 39.96 <sup>(1)</sup>    |
| Mark Hoffenberg                        | 01/17/20 | Parking fees for personal car at airport while traveling to perform services for Purdue.   | \$ 25.00 <sup>(1)</sup>    |
| <b>Total Ground Transportation</b>     |          |  | <b>\$ 334.13</b>           |
| <b>Miscellaneous Subtotal</b>          |          |  | <b>\$ -</b>                |
| <b>Subtotal Out of Pocket Expenses</b> |          |  | <b>\$ 989.04</b>           |
| Less KPMG Voluntary Reduction          |          |  | \$ (374.11) <sup>(1)</sup> |
| <b>Total Out of Pocket Expenses</b>    |          |  | <b>\$ 614.93</b>           |

<sup>(1)</sup> KPMG is taking a voluntary reduction of expenses under \$50.00.